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List of abbreviations 
CF                                                  carboxyfluorescein 
TEM                                               transmission electron microscopy 
TSL                                                thermosensitive liposomes 
CTSL                                             cationic thermosensitive liposomes  
DMEM                                          Dulbecco modified eagle medium 
Tm                                                 phase transition temperature 
SD                                                 standard deviation 
DPPC                                            1,2-dipalmitoyl-sn-glycero-3-phosphatidylcholine 
DSPC                                            1,2-distearoyl-sn-glycero-3- phosphatidylcholine 
DSPE-PEG2000                           1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N 
                                                      PEG2000 
PDI                                                polydisperisty index 
GFP                                               green fluorescence protein 
FCS                                               fetal calf serum 
PBS                                               phosphate buffered saline 
Em.                                                Emission 
Ex.                                                 Excitation 
MRI                                               magnetic resonance imaging 
HIFU                                             high intensity focused ultrasound 
HT                                                 hyperthermia 
HPLC                                            high performance liquid chromatography 
H&E                                              hematoxylin and eosin 
LTSL                                             lysolipid-based thermosensitive liposomes 
LLC                                               Lewis lung carcinoma 
NT                                                 normothermia 
MSPC                                            monostearoylphosphatidylcholine 
Dox                                               Doxorubicin 
PEG                                               polyethyleneglycol 
MPS                                              Mononuclear phagocytic system  
EPR                                               Enhanced permeability and retention effect 
AUC                                              Concentration-time curve  
t ½                                                 Plasma or circulation half-life 
Vd                                                 Volume of distribution  
Cl                                                   Clearance  
RES                                               Reticuloendothelial system 
PLD                                               Pegylated liposomal doxorubicin 
IC50                                              Half maximal inhibitory concentration 
NaCl                                              Sodium chloride 
HEPES                                          4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid 
pdI                                                 Polydispersity index 
SEM                                              Standard error 
DNA                                             Deoxyribinucleic acid 
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Cancer chemotherapy 
Cancer chemotherapy is an important treatment option for primary (non-
resectable) or metastatic tumors. Chemotherapy involves the use of cytotoxic drugs to 
destroy rapidly dividing cells such as cancer cells. Although an ideal drug would 
destroy cancer cells without harming normal cells, most drugs are not that selective. 
Since chemotherapeutic drugs target all cells having high proliferation rate such as hair 
follicles, intestinal cells and bone marrow cells, finding a unique target against which 
chemotherapy has selectivity is very difficult. Because chemotherapy is associated with 
side effects only sub-optimal doses can be administered, which can lead not only to 
relapse of the tumor, but also to development of drug resistance. The antracyclin 
doxorubicin has been in clinical use for several decades and is still among the most 
widely used chemotherapeutic drugs for treatment of cancer 1. It is commonly used to 
treat different types of cancer, such as some leukemia’s, Hodgkin’s lymphoma as well 
as cancer of the bladder, breast, prostate, lung, ovaries, melanomas, carcinoma and 
sarcoma. Due to its intercalation with DNA to inhibit cell proliferation, doxorubicin can 
effectively kill cancer cells. However, Doxorubicin as a free drug has many side effects 
and its clinical use is hampered by cardiotoxicity, myelosuppression and the occurrence 
of drug resistance 2, 3. The medical community has searched for alternative therapies 
that improve selective toxicities against cancer cells leading to an increase of the 
therapeutic indexes of the anticancer drugs 4. To achieve this goal, nanoparticles such as 
liposomes were developed as a vector for therapeutic drug delivery in oncology and are 
supposed to break some of the physiologic and pharmacologic barriers to effective 
cancer drug treatment. 
Liposomes 
 Liposomes are one of the best studied drug delivery systems used in cancer 
treatment. Nowadays several liposomal products are commercially available. Some of 
them are approved for clinical application and many more are in various stages of 
clinical trials 5. Liposomes are closed vesicular structures consisting of one or more 
lipid bilayers enclosing an aqueous phase. In the aqueous phase of the liposomes water 
soluble drugs can be entrapped, whereas the lipid bilayer entraps lipid soluble drugs 6.  
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Fig 1. Schematic representation of a liposome. Loaded hydrophilic drugs into 
the aqueous phase (1). Polyethylene glycol coating (2). Lipophilic molecules embedded 
in liposomal bilayer (3). Lysolipids enabling drug release into liposomal bilayer (4). 
Surface modification with antibodies, antibody fragments or ligands for active targeting 
(5). Cationic lipids like DPTAP (6). Cholesterol for liposome stabilization (7). Figure is 
used from Hossann et al 7. 
 Amphiphilic drugs that are weak bases or weak acids can also be loaded into the 
liposome interior using remote loading methods like ammonium sulfate method for 
doxorubicin 8 or the pH gradient method for vincristine 9. 
The use of liposomes has several advantages over the use of free drugs. They are 
non-toxic, biodegradable and non-immunogenic 10. Another advantage of liposomes is 
that they have a long circulation time when equipped with a polyethyleneglycol (PEG) 
coating. These liposomes are also called Stealth liposomes 11. Without this coating 
liposomes are rapidly cleared from the blood due to absorption of plasma proteins 
(opsonins) to the phospholipid membranes, triggering recognition and uptake of the 
liposomes by the reticuloendothelial system (RES).  
Small 100 nm liposomes coated with PEG have half-lives of 12-30 hours in 
animal models and 21-54 hours in humans 12. These circulation properties result in an 
increased accumulation of liposomal drug in the tumor area. This process of liposome 
accumulation is called passive targeting and it is due to the enhanced permeability and 
retention (EPR) of tumor tissue 13. For efficient localization at the tumor site, the 
liposomes must have a diameter around 100 nm, which also depends on the tumor type.  
A pegylated liposomal formulation of doxorubicin used clinically is called 
Doxil/Caellyx 14-16. Doxorubicin is loaded into liposomes to a very high concentration 
by an ammonium sulfate gradient-based remote loading technique 8. The loading 
efficiency is high (>90%). Loading is the result of the base exchange with the 
ammonium ions. Most of the intraliposomal doxorubicin is present in an aggregated 
state. The stability of the ammonium ion gradient is related to the low permeability of 
its counter ion, the sulfate, which stabilize anthracycline accumulation for prolonged 
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storage periods (>6 months) due to the aggregation and gelation of anthracycline sulfate 
salt 8. Doxorubicin that is encapsulated in pegylated liposomes has a greatly altered 
pharmacokinetic profile, including the area under the plasma concentration-time curve 
(AUC), the half-life (t1/2), the volume of distribution (Vd) and the clearance (CL). The 
purpose of this alteration is to limit doxorubicin distribution into healthy tissue while 
increasing its concentration at the tumor site 10. 
If pegylated liposomes are small enough they can pass through capillaries that 
have increased permeability, such as capillaries in the tumors 13, 17, 18. This leakiness in 
the tumor vessels is due to basement membrane abnormalities and to decreased numbers 
of pericytes lining rapidly proliferating endothelial cells. The gaps size range from 100 
to 1200 nm depending on the tumor type and even within the tumor 13, 19, 20. This is in 
contradiction to the tight endothelial junctions of normal vessels of 5 to 10 nm size. 
Therefore, a proportion of tumor vessels is believed to be permeable and may allow 
extravasation of liposomes from them into interstitial space between the tumor cells.  
 Because doxorubicin is very slowly released from pegylated liposomes nearly 
all of the administered doxorubicin dose remains encapsulated in the carrier while in 
plasma 21, 22. This together with the non-tumor specific nature of the liposomes leads to 
limiting steps in the delivery process and subsequently low therapeutic efficacy 16. In 
this project we aim at developing new approaches to improve drug delivery into tumor 
cells. Liposomal drug delivery to tumors can be improved by using thermosensitive 
liposomes for triggering drug release upon hyperthermia (HT), by using cell-specific 
receptors for internalization into tumor cells or combining both targeted and triggered 
functions of liposomes in one carrier. 
 
Hyperthermia 
 
 Mild hyperthermia (40-44 °C) has been used in the clinic as an adjuvant to 
radio- or chemotherapy and has been proven successful in treatment of various tumors- 
melanoma, sarcoma, head and neck cancer, breast cancer and cervix cancer 23-31. The 
first large phase III clinical trial on combination of chemotherapy and HT has proven to 
be an effective treatment option for patients with localized soft-tissue sarcoma 24. This 
effect of HT can be explained not only by causing cellular sensitization and immune 
effect but also by its influence on tumor microenvironment. HT is known to increase 
blood circulation, tissue oxygenation, tumor perfusion and vessel permeability 32, 33. HT 
increases the gaps between endothelial cells causing extravasation of liposomes, thus 
increasing intratumoral liposomal drug accumulation 34-36. Dewhirst 35 and Li 36 have 
shown that when tumors were heated to 42 or 41 °C respectively, liposomes 
extravasation increased as compared to tumors subjected to normothermia (NT). HT is 
also shown to trigger drug release from temperature-sensitive liposomes. 
 
Thermosensitive liposomes 
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 Another effect of hyperthermia besides the above mentioned is triggering drug 
release from thermosensitive liposomes (TSL). In this thesis, thermosensitive liposomes 
and HT are used as means to improve drug delivery to tumors. TSL consist of a 
thermosensitive phospholipid bilayer undergoing gel-to-liquid transition at its 
membrane melting temperature (Tm) 37. The mobility of phospholipids is increased at 
Tm creating areas with increased permeability towards entrapped water soluble drugs 38. 
In the past decade, TSL underwent several modifications in order to improve their 
stability 39, 40, blood circulation 41, 42 and release kinetics 42, 43. Lindner et al. have used 
phosphatidyl-oligoglycerols in replacement of DSPE-PEG2000 for prolonged 
circulation and increased drug release at Tm 42. Low temperature sensitive liposomes 
(LTSL) are used in intravascular release approach relying on fast drug release from 
liposomes subjected to HT while in circulation 44.  Kong et al. demonstrated in their 
study that doxorubicin concentration in the tumor was 3.6-fold higher when LTSL were 
used compared to traditional thermosensitive liposomes 45. Recently, Al Jamal et al. 
compared the two formulations and showed that 1h after injection, LTSL delivered 
more doxorubicin to  the tumor. However, 24h after injection, the amount of 
doxorubicin in the tumor was higher for the traditional thermosensitive liposome 46. 
Tagami et al. developed similar LTSL using Brij surfactants replacing MSPC and 
DSPE-PEG2000. This formulation achieved faster drug release kinetics and higher 
doxorubicin levels in the tumor than LTSL 47-49. Li et al. optimized the concentration of 
PEG in TSL giving an optimal content release upon mild HT 41 and showed that a 
thermal dose of 41 °C for 1h causes long-lasting permeable tumor vasculature to induce 
liposome extravasation and penetration into the tumor 36. 
 
Targeted liposomes 
 
 Besides using an external trigger such as heat, increased drug delivery to tumors can be 
achieved by an active targeting of liposomes to tumors. Targeting of liposomes can be 
possible by decorating them with specific ligands recognizing receptors on tumor 
vessels or tumor cells. This specific recognition will yield increased liposome retention 
in tumors, liposome binding, liposome internalization into cells and subsequently 
increased drug delivery 10, 50. Tumor vascular targeting has a great role in suppressing 
tumor development as blocking tumor vasculature growth will decrease nutrients and 
oxygen to  tumor cells 51. Amongst the most specific targets on endothelial cell 
membranes are αvβ3 integrins 52, receptors for angiogenic growth factors (such as 
VEGFR, EGFR) 53, aminopeptidase N (e.g CD13) 54 and the overexpression of 
negatively charged molecules 55. Tumor vascular targeting is a promising way of killing 
tumors as tumor endothelial cells are easy to access and high interstitial fluid pressure 
does not play a role. Anti-VEGFR2 immunoliposomes developed by Wicki et al. 53, 
NGR-targeted 54 and RGD-targeted liposomes 52, 56, 57 have proven successful in 
diminishing tumor progression. Additionally, overexpressed anionic molecules on 
endothelial cell membranes can be target for cationic liposomes based on electrostatic 
interaction 58, 59. Various studies have shown that cationic liposomes were able to inhibit 
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tumor growth when compared to non-cationic formulations 60, 61. Besides vasculature 
targeting, taking the advantage of their small size and prolonged blood circulation, 
liposomes can extravasate and reach tumor cells. Once in close proximity with tumor 
cells, liposomes can bind and be internalized into tumor cells due to receptor-mediated 
endocytosis. Liposomes decorated with antibodies or peptides have been developed to 
successfully target tumor cells. For example, liposomes anchored with HER2 antibody 
are used to target HER2 overexpressing breast cancer cells 62, 63. EGF receptor 
overexpressed on tumor cells is another potent receptor for targeted liposomes and these 
liposomes have demonstrated higher tumor suppression when compared to non-targeted 
liposomes 64. Targeted liposomes bring the drug close to tumor vasculature or cells but 
the drug is usually released very slowly which hampers its bioavailability. In order to 
improve drug bioavailability, targeted thermosensitive liposomes appear as  promising 
drug carriers in the fight against cancer. 
 
Targeted thermosensitive liposomes 
 
  Combining targeting and thermosensitive characteristics of liposomes in 
creation of targeted thermosensitive liposomes (TTSL) can contribute to enhanced drug 
bioavailability by increasing liposomal drug retention in tumors, binding and triggering 
drug release locally in the tumor. TTSL may be developed by attaching to their outer 
surface specific peptides or antibodies or incorporating cationic lipids in their bilayer.   
The first TTSL were developed by Gaber et al. and were targeted to a folate 
receptor on tumor cells 65. The recently developed affibody-conjugated HER2 
thermosensitive liposomes were 10-fold more specific in HER2 positive tumor cells 
than non-targeted liposomes 66, 67. The studies by Kullberg et al. have shown that the 
incorporation of lysteriolysin 0 in the liposomes can form pores in the endosomal 
membrane and thus enable transition of released liposomal drug into the cytosol. It also 
showed that TTSL to HER2 positive cells delivered 22-fold higher amount of liposomal 
calcein to HER2 positive cells compared to HER2 negative 68, 69. Dreher et al. 70 has 
created TTSL to tumor vasculature by using NGR peptides on the liposomal surface. 
This emerging field in liposomal drug delivery shows promising results but still more in 
vivo work is needed in order to prove the efficiency of TTSL. 
 
AIM OF THE THESIS 
 
 The aim of the work described in this thesis is to improve liposomal drug 
delivery to solid tumors by using the combination of targeted thermosensitive liposomes 
and mild HT. The designed liposomes contained targeting moieties specific not only for 
tumor cells but also for tumor vascular endothelial cells. Targeting of liposomes is used 
to increase their retention in tumors, therefore contributing to increased drug delivery. 
In this thesis, two different targeted thermosensitive liposomal formulations are used - 
cationic TSL specific for overexpressed anionic molecules on tumor vascular 
endothelial cells and tumor cells; and RGD-TSL having affinity for αvβ3 integrins on 
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tumor vasculature and tumor cells. Local mild HT is used to increase permeability in 
tumor vasculature for liposomal extravasation and to enhance fluid flow thus enabling 
liposomal drug penetration in the tumor. When a maximum liposome accumulation 
occurs, a second heat treatment is applied to trigger drug release from liposomes. 
Liposomes with melting temperature at Tm are used as drug carriers to achieve 
triggered drug release. Choosing the best concentration of targeting ligands in order to 
achieve maximum targeting and drug loading efficiency are a matter of this thesis. 
  
Topics of the thesis 
 
Chapter 2 describes the development of cationic thermosensitive liposomes 
(CTSL) containing the hydrophilic marker carboxyfluorescein (CF) in the aqueous 
phase. CTSL were tested in vitro for stability at physiological temperatures and their 
drug release kinetics were investigated. In vitro, CTSL were compared to non-cationic 
thermosensitive liposomes (NCTSL) regarding their binding capacities to tumor cells 
and endothelial cells. In vivo, using advanced intravital microscopy techniques, we 
investigated the stability, binding and drug release of CTSL.  
Chapter 3 focuses on optimization of CTSL containing the chemotherapeutic 
drug doxorubicin with regards to their stability in serum, drug encapsulation and 
targeting functions. CTSL containing 7.5 mol % of the cationic lipid DPTAP was 
chosen for further experiments. The optimized Dox-CTSL are compared in vitro and in 
vivo to NCTSL loaded with doxorubicin with regards to cytotoxicity, drug release and 
uptake by endothelial and tumor cells and subsequently caused vessel damage.  
Chapter 4 studies the design of RGD-targeted thermosensitive liposomes 
incorporating doxorubicin. These liposomes were compared to their non-targeted 
formulation in vitro and in vivo aiming at increased drug delivery to tumors.  
Chapter 5 describes pharmacokinetics, biodistribution and therapeutic effect of 
TSL and CTSL.  
Chapter  6 reviews the literature on TSL, targeted liposomes and their 
combination in the creation of targeted thermosensitive liposome (TTSL), which are the 
topic of this thesis. 
Chapter 7 discusses the results of the different chapters. 
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Abstract  Developing selectively targeted and heat-responsive nanocarriers holds paramount promises in chemotherapy. We showed that this can be achieved by designing liposomes combining cationic charged and thermosensitive lipids in the bilayer.  We demonstrated, using flow cytometry, life cell imaging and intravital optical imaging, that cationic thermosensitive liposomes (CTSL) specifically target angiogenic endothelial and tumor cells. Application of mild hyperthermia led to a rapid content release extra-and intracellularly in two crucial cell types in a solid tumor.  
Keywords: cationic thermosensitive liposomes, hyperthermia, triggered release, drug delivery, targeted nanomedicine 
 
Nanoparticles, such as liposomes can preferentially deliver chemotherapeutics to 
tumors due to their small size and long circulation half-life in combination with the 
leakiness of tumor blood vessels.1,2,3 The increased permeability of tumor blood vessels 
is due to angiogenesis related endothelial cell proliferation, basement membrane 
abnormalities and irregular perycite lining. In contrast to normal vascular endothelium, 
which is continuous, tumor endothelial gap sizes can range from 100 to 400 nm.4  In 
addition to increased permeability, tumor blood vessels have a chaotic architecture and 
irregular branching.5 Small liposomal nanoparticles of around 100 nm were proven 
optimal for extravasation at sites with increased permeability.6 This in combination with 
decreased clearance and enhanced blood-residence time of the liposome-entrapped drug, 
will decrease drug exposure to normal tissue and increase drug concentrations in the 
tumor.7 In spite of the advantage of reduced toxicity to normal tissue demonstrated by 
clinically applied liposomal chemotherapy, a significant enhancement of therapeutic 
efficacy was not observed.8,9 The two main reasons for this are the low levels of 
retention of the liposomes in the tumor area as well as the slow and inefficient drug 
release from liposomes. The aim of this study is to develop a liposomal formulation 
which deals with both drawbacks and thereby improves intratumoral drug levels. In 
order to achieve improved retention we aim for cell-specific targeting and carrier 
internalization by introducing cationic charges on the particle surface. In addition, a 
thermally sensitive bilayer is used to render liposomal drug delivery heat responsive. 
Campbell et al.10 demonstrated that cationic liposomes have higher affinity for 
angiogenic endothelial cells and tumor cells, compared to normal tissue, while PEG 
coating ensured long circulation time. The increased binding of PEGylated cationic 
liposomes to tumor vessels is due to the overexpression of negatively charged functional 
groups on the angiogenic endothelial cell membrane.11,12 Moreover, the sluggish and 
irregular blood flow in tumor blood vessels further facilitates the interaction between 
cationic liposomes and angiogenic endothelial cells.10 Additionally, Bally et al.13 have 
shown that cationic liposomes might be opsonized by a yet unidentified plasma protein, 
causing specific binding of these liposomes to angiogenic endothelial cells.  Drugs 
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delivered to tumor endothelial cells in this way can induce damage to tumor 
microvasculature and eventual loss of tumor vessel function. As a result, a large number 
of tumor cells may die because of severe oxygen and nutrient deprivation.14 In addition, 
cationic PEG-liposomes may also bind to tumor cells upon extravasation through leaky 
tumor vasculature15,18,19, a process which can be further enhanced by applying 
hyperthermia (HT).16, 17 
Despite localization of liposomal drugs in tumors, drug bioavailability is not 
guaranteed. Seynhaeve et al. observed in vivo that after extravasation of clinically 
applied PEG-liposomal doxorubicin (Doxil/Caelyx) into the interstitial space, 
intracellular drug delivery is rather slow and inefficient, resulting in suboptimal 
bioavailable drug concentrations.18 Mild HT (40 - 43 °C) can trigger drug release 
locally from thermosensitive liposomes (TSL).20,21 Thermally sensitive bilayers can be 
obtained by selecting lipid compositions that undergo a gel-to-liquid phase transition at 
the desired temperature, causing release of entrapped water soluble compounds. TSL 
deposit their contents in heated tumors in the extracellular space after extravasation or 
intravascularly when still in circulation. However, TSL retention in tumors is low due to 
PEG coating and a lack of specific targeting, limiting drug delivery to the tumor. In 
order to improve this liposomal chemotherapy we propose to combine cationic charge 
mediated targeting with thermally triggered content release.  
This study reports on the development and application of PEGylated cationic 
thermosensitive liposomes (CTSL). These liposomes were used in combination with 
hyperthermia for a dual-targeting approach to address both angiogenic endothelial cells 
and tumor cells. After targeting, these nanoparticles can be triggered to release their 
contents upon heat. This novel approach combines for the first time the dual targeting 
by cationic lipids with temperature-triggered release and holds promise to improve 
chemotherapeutic drug delivery.  
CTSL and NCTSL (noncationic thermosensitive liposomes) were composed of 
the same phospholipids DPPC: DSPC: DSPE-PEG2000. In addition to the phospholipids, 
CTSL contained 10 mol % of the cationic lipid DPTAP in their bilayer in replacement 
of a similar amount of DPPC. Both formulations were prepared by the lipid film 
hydration and extrusion method. 22 Prepared nanoparticles were characterized by 
measuring size, polydispersity index (PDI), zeta potential (ζ), stability in serum, Tm 
(melting temperature) and encapsulation ratio (table 1). Sizes of NCTSL and CTSL 
were slightly less than 100 nm and both TSL had a polydispersity index (PDI) < 0.1, 
representing a high level of particle homogeneity. CTSL had a positive zetapotential, 
whereas NCTSL displayed a negative zeta potential, which is common for PEG-DSPE 
containing liposomes due to its shielded negatively charged phosphate group. NCTSL 
encapsulated two times more carboxyfluorescein (CF) than CTSL and both formulations 
retained > 90% of their contents at physiological conditions, during incubation for 1h at 
37 °C in 90% of serum. Dynamic scanning calorimetry (DSC) revealed for NCTSL a 
relatively narrow peak in the phase diagram with a Tm of 44,3 °C and  δT1/2 (half-
height width of the transition peak) of 3,1 °C. For CTSL a broader peak was observed 
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with a Tm of 47,4 °C and δT1/2 of 7,3 °C. The onset in the transition diagram was at 
approximately 40 °C for both formulations (see Supporting information fig1).  
 
 
Table 1. Characterization of NCTSL and CTSL. Mean of three independent 
experiments. PDI: polydispersity index. 
 
 
In order to test thermosensitivity of the developed CTSL and kinetics of content 
release upon hyperthermia, temperature- and time-dependent release profiles were 
determined. CTSL displayed a clear temperature dependent CF release profile upon 
exposure for 5 min in 90% FCS to temperatures varying between 37 and 45 °C (fig 1A). 
CF release from CTSL increased with increasing temperature up to 45 °C, reaching 
80% release in 5 minutes. Between 40 and 43 °C, release from CTSL and NCTSL were 
virtually identical. However, maximum CF release from NCTSL of 60% was observed 
at 43 °C, after which release levels decreased at higher temperatures. By contrast, 
release from CTSL continued to increase between 43 and 45 °C, which is in agreement 
with the increased Tm for CTSL represented in Table 1. Importantly, CF release from 
both formulations remained low (< 15%) at physiological temperatures of up to 39°C.   
Rapid content release from CTSL at 42 °C was demonstrated during a 1h time-
dependent CF release assay in 99.7% FCS (fig 1B). CTSL released up to 50% of their 
content in the first minute, similar to NCTSL. CF release continued to increase in time 
reaching approximately 100% release of entrapped CF in 1h from both formulations. By 
contrast, using similar conditions, but now at a temperature of 37 °C, hardly caused any 
content release from CTSL (Table 1).   
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Fig 1. Temperature- and time-dependent CF release from CTSL and NCTSL. 
Temperature-dependent release of CF (A) was measured upon exposure to temperatures 
varying from 37 - 45 °C for 5 min in 90% FCS. Whereas NCTSL displayed maximum 
release around 43 °C, CTSL showed increasing CF release up to a maximum level at 45 
°C. Time-dependant CF release (B) was measured at constant temperature of 42 °C for 
up to 1h in 99.7% serum. Both TSL displayed rapid CF release in the first five minutes 
and were emptied completely in 1h. Mean of three independent experiments with three 
independent batches of liposomes.  
 
  To compare binding of CTSL and NCTSL to BLM tumor cells and HUVEC, 
flow cytometric cell association studies were performed (fig 2). For these studies, trace 
amounts of the fluorescently labeled phospholipid, NBD-PE, were incorporated in the 
TSL bilayer. CTSL showed up to 50-fold higher level of association with BLM cells at 
37 °C (fig 2A) and up to 25-fold increase at 4 °C (see Supporting information fig 2A). 
The same tendency for increased binding of CTSL was observed in HUVEC as it was 
up to 7-fold higher than NCTSL at 37 °C (fig 2B) and 4-fold higher at 4 °C (see 
Supporting information fig 2B). Levels of binding of CTSL to both BLM cells and 
HUVEC were higher at 37 °C than at 4 °C. These differences are suggestive of CTSL 
internalization occurring at 37 °C.  
In order to further prove CTSL binding and internalization, living cell confocal 
microscopy was performed (fig 2C and D). Incubation for 1h at 37 °C led to abundant 
internalization of CTSL by BLM cells (fig 2C) and HUVEC (fig 2D), compared to 
NCTSL. Liposomes were observed in the cytosol of both BLM and HUVEC in 
punctuate red fluorescent spots of Rho-PE (rhodamine-PE) located perinuclearly, 
proving internalization. Fluorescent CTSL incubated for 1h at 4°C with BLM showed a 
high level of membrane bound fluorescence, in contrast to NCTSL (see Supporting 
information fig 2C). A similar experiment with HUVEC revealed minimal differences 
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between the two formulations at 4° C, and confirm the FACS results on liposome 
binding (see Supporting information fig 2B).  
 
 
 
Fig 2. Binding of CTSL or NCTSL to BLM melanoma cells (A) and endothelial cells 
(HUVEC) (B) measured by flow cytometry and confocal microscopy images proving 
binding and internalization of CTSL or NCTSL by BLM cells (C) and HUVEC (D). A 
and B. Cells in suspension were incubated for 1h with NBD-PE labeled CTSL or 
NCTSL at 37 °C. After washing, the cell-associated NBD-PE fluorescence was 
determined by flow cytometry. Values depicted in the figure represent the mean 
fluorescent intensity calculated as a percentage of the maximum mean fluorescent 
intensity from three experiments with three different batches of liposomes. C and D. 
BLM or HUVEC cells were incubated with Rho-PE labeled liposomes for 1h at 37 °C. 
After incubation, cells were washed and visualized by confocal microscopy. Scale bar 
apply for all images, 10 µm. 
 
  Upon binding and subsequent internalization of CTSL, release of content from 
the nanoparticles can be triggered by increasing temperature and may occur both extra- 
and intracellularly.  
Extracellular content release was studied by incubating BLM cells at 4 °C for 1h 
with CF-loaded CTSL, which had Rho-PE as a membrane marker, followed by a 
hyperthermia treatment of 1h at 43 °C. CF dequenching upon release from the CTSL 
was visualized by its green fluorescence and used as a marker for content release. After 
the binding phase and removal of unbound liposomes, hyperthermia at 43 °C caused a 
rapid content release from the cell-bound CTSL represented by a strong increase in 
10 µm 10 µm 
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green fluorescence in the medium surrounding the cells in contrast to cells that were 
kept at 37 °C (Fig 3A and  see Supporting information video 1).  
During the binding phase (1h at 4 °C) to BLM cells and the heating phase up to 
37 °C, no premature extracelular CF leakage was observed. Only upon HT, liposomes 
opened up and started to release their CF content extracellularly. Extracellular CF 
fluorescence continued to increase in time up to 1h of hyperthermia. In this 
experimental setup occasionally intracellular content release was observed (fig 3A white 
arrows) from liposomes internalized after raising the temperature. 
Intracellular content release in BLM cells was demonstrated by incubating the 
cells at 37 °C for 1h, allowing internalization, followed by a 1h heating at 43 °C (fig 
3B). Minimal CF release was observed during the incubation at 37 °C, whereas HT 
caused a strong increase in intracellular CF release as demonstrated by the increase in 
yellow fluorescence which represents colocalization of hyperthermia-released CF with 
the liposomes in the cytosol (see Supporting information video 2).  
 The experimental set up was adapted for HUVEC cells to a shorter incubation 
time due to their fast uptake and processing of CTSL compared to BLM cells. 
Extracellular and intracellular content release from CTSL were observed simultaneously 
in HUVEC incubated for 15 min at 4 °C, followed by removal of unbound liposomes, 
heating to 37 °C and a 1h HT at 43 °C (Fig 3C). Images taken at 37 °C before heating 
showed minimal CF release. Increasing the temperature to 43 °C caused immediate CF 
release, which increased gradually during the 1h heating period. In addition to 
extracellular release, significant intracellular release was also visible in HUVEC from 
the appearing green fluorescent hotspots with increasing intensity inside the cells or the 
increased yellow fluorescent signal inside the cells representing colocalization of the 
released CF with the liposomes (Fig 3C indicated by white arrows).  
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Fig 3. Content release from CTSL in BLM cells and HUVEC upon heat. Extracellular 
CF release in BLM cells (A) incubated for 1h at 4 °C with 1000 nmol/ml dual labeled 
Rho-PE CTSL (red color), encapsulating CF (green color) and intracellular release in 
BLM cells (B) incubated for 1h at 37 °C with 1000 nmol/ml dual labeled CTSL. In both 
conditions content release was triggered by a one hour hyperthermia treatment at 43 °C. 
Extra- and intracellular release in HUVEC (C) pre-incubated for 15 min at 4 °C with 
1000 nmol/ml Rho-PE CTSL, containing CF followed by HT at 43 °C. After CTSL 
incubation, cells were washed 3 times with medium containing FCS. Images were taken 
by confocal microscope. Scale bar apply for all images, 10 µm. 
 
Further proof of the validity of the dual targeting approach to angiogenic 
endothelial cells and tumor cells in vivo, was obtained by intravital microscopy. Dorsal 
skin-fold window chamber bearing mice were implanted with murine B16 melanoma or 
murine LLC lung carcinoma.15 In these mice tumor vasculature is visualized by the 
constitutive expression of a GFP-Enos-tag fusion protein in endothelial cells. 
Circulating liposomes in the blood stream were visualized by incorporation of Rho-PE 
in the bilayer of TSL (red). Fluorescence from labeled CTSL was diffusely distributed 
in the lumen of blood vessels in the first 15 minutes after injection. At later time points 
CTSL started to appear closely associated with the endothelial cells predominantly of 
blood vessels with a slow and irregular blood flow in both B16 (fig 4A,B,C,D) and LLC 
tumors (see Supporting information fig 3A), as represented by the appearance of patchy 
clusters of high intensity immobile red fluorescence in the blood vessels. This is in 
contrast to the NCTSL, which remained diffusely distributed without obvious binding to 
the vasculature even in tumor vessels with irregular blood flow (fig 4F and Supporting 
information fig 3B). Images in B16 melanoma taken 24h after injection of CTSL 
demonstrated considerable levels of remaining liposomes either associated with the 
tumor vasculature of functional blood vessels or extravasated from the vasculature and 
accumulated perivascularly (fig 4E white arrows).  
In order to prove direct binding of CTSL to angiogenic endothelial cells, we 
excluded possible binding of CTSL to circulating blood cells. Blood cells isolated from 
mice 2h after i.v. administration of Rho-PE labeled CTSL encapsulating CF did not 
show associated fluorescence (see Supporting information fig 4). Therefore, the specific 
binding of CTSL to angiogenic endothelial cells or the extravasation of the liposomes 
did not involve prior binding or interaction with circulating cells. 
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Fig 4. Intravital evaluation of binding of CTSL (A, B, C, D and E) or NCTSL (F) to 
angiogenic endothelial cells in B16 tumor model using the dorsal skin-fold chamber. 
Mice were injected with 5 µmol of lipid. Appearance of vasculature bound cationic 
liposomes started 20 min after injection and remained visible at least up to 24h. At that 
time point CTSL were found associated with tumor vasculature or extravasated 
perivascularly (E white arrows). NCTSL hardly bound to the endothelial lining of tumor 
associated blood vessels (F). Scale bar apply for all images, 20 µm. 
 
 
 
Fig 5. Binding of CTSL to melanoma cells in B16BL6 tumor model extravasated from 
tumor vessels (green) 3h after injection of CTSL. CTSL (in red) associated with 
melanoma cells (black, melanin-positive) are pointed with white arrows. A-bright field 
image, B-merged image of bright field, green and red fluorescence. Scale bar 50 µm. 
 
Upon arrival in the tumor tissue CTSL should release their content upon heat. 
Therefore, triggered content release from CTSL was studied by intravital microscopy. 
After CTSL had been allowed to bind to tumor vasculature and tumor cells during a 
period of 3h at 37 °C, the effect of HT on CF release in vivo was examined. For this 
purpose, images of different positions in the tumor area were first recorded at 37 °C (fig 
6 upper panel, tumor vasculature lining is represented in green from GFP-expressing 
endothelial cells). At this temperature no CF release (additional green fluorescence) 
could be detected in the tissue or vasculature, yet CF-containing liposomes were still in 
circulation as is apparent from the red fluorescence in the tumor microvessels. Upon 
applying HT at 43 °C, a massive CF release occurred (fig 6 lower panel). HT was 
applied for 1h and images taken at the end of the HT treatment were compared to those 
taken at 37 °C. Strong increases in the green fluorescence demonstrate massive heat 
triggered CF release from CTSL followed by its diffusion into the tumor tissue. The CF 
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fluorescence increased by 3-fold upon HT (see Supporting information fig 5A). HT also 
led to further increase of the binding and the extravasation of CTSL as evidenced by the 
increased level of yellow fluorescence appearing in patchy patterns on the tumor blood 
vessels and extravascularly. Rhodamine fluorescence increased 2-fold after 1 h of HT 
(see Supporting information fig 5B). All together, these results demonstrate HT-
triggered content release from CTSL 3h after administration and a further increased 
tumor retention of CTSL. 
 
 
 
Fig 6. CF release after HT triggering in B16 tumor bearing mouse, injected with 5 µmol 
of lipid. Images of circulating liposomes in blood stream at 37 °C were taken 2h after 
injection. Then, tumor was heated up to 43 °C for 1h and representative images from 
different positions in tumor area were recorded in the end of the hyperthermia (HT) 
treatment. Scale bar apply for all images, 50 µm. 
 
Liposomal chemotherapy has become an attractive clinical option in the 
treatment of various types of cancer, mainly because of their capacity to diminish side 
effects. 1, 8, 30, 31 However, the anticipated increase in therapeutic efficacy did not yet 
come to its full potential.8,9 The reasons for this are the limited tumor accumulation, 
drug bioavailability and lack of control of content release. In this study we addressed 
these issues by developing tumor targeted thermosensitive liposomes. For this we 
combined the approach of cationic charge mediated targeting of PEG-liposomes with 
heat triggered content release and successfully developed cationic thermosensitive 
liposomes (CTSL). These CTSL demonstrated content release kinetics similar to 
NCTSL that were proven successful for in vitro and in vivo heat triggered content 
release recently 21, i.e. they were stable at physiological temperatures of 37 °C and 
showed rapid content release at 41 °C or higher, temperatures which can be applied in 
clinical mild hyperthermia (41-43 °C). In addition to the triggered release, CTSL 
showed increased binding to endothelial and tumor cells in vitro and in vivo. Upon 
binding, CTSL were internalized and their release could, in addition to extracellularly, 
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also be triggered intracellularly. Most importantly, in vivo we were able to prove the 
dual targeting strategy by demonstrating binding of CTSL to tumor vasculature in 
combination with extravasation and subsequent tumor cell binding, and temperature-
triggered content release only upon heat.  
CTSL displayed high stability (< 10% release of their content) upon exposure to 
physiological conditions during 1h of incubation at 37 °C in 90% serum. The 
temperature dependent release assay showed that initial CF release mainly occurred in 
the first 5 min after which the liposomes apparently are stable. This small fraction 
released, may well represent anionic CF that has been electrostatically associated with 
DPTAP at the liposome surface and is released upon exposure to the biological 
environment with 90% of serum. 
The release kinetics of both formulations are consistent with their Tm. NCTSL 
have a Tm of 44,3 °C and show maximal release before reaching this temperature. Most 
likely NCTSL membranes that reach a homogeneous liquid crystalline phase at their Tm 
have less permeability at higher temperatures. Apparently, at temperatures just under 
their Tm maximal bilayer defects occur, allowing maximal CF release. CTSL displayed a 
higher Tm of 47,4 °C and a broader phase diagram, which explains the observation that 
release continued to increase up to 45 °C. The higher Tm of CTSL can be explained by 
the addition of DPTAP in the bilayer, which has a Tm of 49,3 °C. In addition, cationic 
lipids are known to cause an increased Tm of phospholipids 23, an effect which can be 
explained by the electrostatic interactions between the cationic DPTAP and the 
zwitterionic phospholipids, which changes the thermotropic behavior of the latter.24 
Importantly, in good correlation with the onset temperature of the phase diagram, 
significant content release from CTSL already occurred between 40 °C and 43 °C, 
temperatures that are feasible in clinical hyperthermia.  
Additionally, CTSL have a positive zeta potential (table 1), which increased 
their binding to tumor and endothelial cells compared to NCTSL. The level of cell 
association of CTSL to both BLM and HUVEC cells was higher at 37 °C than at 4 °C, a 
temperature at which internalization processes are blocked, indicating that at 37 °C 
liposomes are internalized after cell surface binding, a finding that was confirmed by 
confocal laser scanning microscopy.  
Besides CTSL binding and internalization, we also demonstrated HT-triggered 
liposomal content release both in vitro and in vivo. In vitro, using living cell 
microscopy we showed both extra- and intracellular CF release upon applying HT on 
BLM and HUVEC cells.  
In consistence with the in vitro results, the results from intravital microscopy 
also demonstrate a preferential binding of CTSL to tumor vascular endothelial cells. In 
accordance with Thurston et al. who studied non thermosensitive cationic nanoparticles 
25, our CTSL associated with endothelial cells already 20 min after injection and showed 
a patchy appearance at multiple locations lasting for several hours in both B16 and LLC 
tumor models (fig 4A,B,C,D,E and Supporting information fig 3A). In contrast, NCTSL 
remained in circulation and did not bind to the vasculature and appeared diffusely 
present in the vessel lumen (fig 4F and Supporting information fig 3B). In accordance 
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with Krasnici et al.26 who showed long term presence of cationic liposome in tumors up 
to 6h after administration, we were able to demonstrate long-term retention of CTSL, 
associated with tumor blood vessels, up to 24h after injection. Additionally, our CTSL 
did not show binding to blood cells, which indicates that their specific binding is most 
likely directly to angiogenic endothelial cells. Binding of CTSL to tumor vasculature 
most likely involves similar mechanisms as described by Campbell et al.10 showing that 
the sluggish and irregular blood flow in combination with increased anionic charges on 
the endothelial cell membranes enhanced binding of cationic liposomes to angiogenic 
endothelial cells. Binding events that we observed with CTSL were multiple in tumors 
and usually in areas with slow and chaotic blood flow. Remarkably, HT strongly 
enhanced binding of CTSL to tumor vessels and promoted further extravasaton and 
therefore could, besides triggering content release, also further enhance tumor retention 
of these nanoparticles.27, 6 This effect can be related to an increase in the exposure of 
negative charges on endothelial cell membranes as a response to the HT, leading to 
increased binding of CTSL. 
Besides binding to the tumor vasculature, our CTSL, due to their small size and 
prolonged presence in circulation, extravasated from the leaky tumor vasculature and 
bound to tumor cells, thus achieving dual targeting properties.   
In vitro stability of our CTSL at 37 °C was also confirmed in vivo. Intravital 
optical imaging at body temperature displayed minimal CF release over a period of 2h 
before HT was applied. HT at 43 °C 2 hours after liposome injection however, caused 
massive CF release, which was observed in numerous positions throughout the tumor 
area (fig 6). In our in vitro and in vivo studies we did not observe (cellular) toxicity of 
our cationic liposomes, which is in line with earlier findings.28,29 Future studies, in 
which CTSL will be loaded with chemotherapeutic drugs will address biocompatibility 
of our novel nanoparticles in more detail.   
In conclusion, thermosensitive cationic liposomes have been developed that are 
stable at physiological temperatures and release their contents extra or intracellularly 
upon application of mild hyperthermia both in vitro and in vivo. These new CTSL bind 
to tumor vascular endothelial and tumor cells both in vitro and in vivo. PEGylated 
CTSL in combination with mild HT can increase drug delivery to tumors because of 
their selective targeting properties together with heat triggered content release. With the 
use of CTSL, a dual targeting and internalization strategy for both tumor vascular 
endothelial cells and tumor cells can thus be achieved. Further studies will focus on 
developing CTSL, encapsulating a chemotherapeutic drug for targeting tumor 
vasculature, as well as tumor cells. 
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Supporting information 
 
Materials and methods 
 
Chemicals 
 
The phospholipids 1,2-dipalmitoyl-sn-glycero-3-phosphocholine (DPPC), 1,2-
distearoyl-sn-glycero-3-phosphocholine (DSPC), 1,2-distearoyl-sn-glycero-3-
phosphoethanolamine-N-PEG2000 (DSPE-PEG2000) were purchased from Lipoid 
(Ludwigshafen, Germany). Phosphatidylethanolamine-dioleoyl-sulforhodamine B (Rho-
PE),1,2-dipalmitoyl-sn-glycero-3-phosphoethanolamine-N-(7-nitro-2-1,3 
benzoxadiazol-4-yl) (NBD-PE) and the cationic lipid 1,2-dipalmitoyl-3-
trimethylammonium-propane (DPTAP Chloride salt) were provided by Avanti Polar 
Lipid Inc. Carboxyfluorescein was purified by recrystalization. 32 
 
Preparation of TSL 
 
CTSL contained DPPC: DSPC: DPTAP: DSPE-PEG2000 in a molar ratio 60:25:10:5. 
NCTSL were composed of DPPC: DSPC: DSPE-PEG2000 in a molar ratio 70:25:5. 
Small TSL were prepared by lipid film hydration and extrusion method.22 All lipids 
were dissolved in chlorophorm and methanol (9:1 vol/vol).Rho-PE was added at 0.1 
mol % for fluorescent labelling of lipid bilayer. TSL used for flow cytometry contained 
0.1% of NBD-PE in the lipid bilayer. The solvent was subsequently evaporated under 
vacuum in rotary evaporator until homogeneous lipid film was formed. The lipid film 
was hydrated in 100 mM CF solution, pH 7.2 at 60 °C for 30 min. The newly formed 
multilammelar vesicles were extruded subsequently 5 times through 200 nm, 100 nm, 
80 nm and 50 nm polycarbonate filter (thermo barrel extruder at 60 °C) and resulted in 
small sized TSL. Nonentrapped CF was removed from liposomal CF by gel permeation 
chromatography using a PD-10 Sephadex column (GE Healthcare, Buckinghamshire, 
UK), eluted with HEPES buffer, pH 7.4 (10 mM HEPES, 135 mM NaCl). Size, 
polydispersity index (PDI) and zeta potential (ζ) were measured by dynamic light 
scattering using Zetasizer Nano ZS (Malvern Instruments, Worcestershire, UK).For the 
size and PDI measurements TSL were diluted in HEPES, pH 7.4, while the zeta 
potential was obtained in HEPES, pH 7. Lipid concentration was determined by 
phosphate assay.33 
 
Differential scanning calorimetry 
 
Tm of TSL was measured by differential scanning calorimetry (DSC) 34 using Capillary 
Cell MicroCalorimeter (MicroCal VP-DSC). Samples were scanned from 20-60 °C and 
then cooled to 20 °C with a heating and cooling rate of 1 °C/min. The data were 
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normalized to the maximum Cp (heat capacity) and the average of three independent 
batches of liposomes was plotted.  
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Stability of TSL was tested by incubating samples of TSL suspension (1mM [lipid]) in 
pre-heated 90% fetal calf serum (FCS) (1:9 v/v) for 1h at 37 °C using a thermal-shaker 
(Eppendorf Thermomixer) at 300 rpm. Samples without incubation were considered as a 
blank (Io). Maximum CF fluorescence (positive control - I∞) was achieved when 
incubating TSL suspension (1mM [lipid]) in 2% Triton X-100 in H2O for 30 min in a 
thermoshaker at 55 °C and 1400 rpm. All samples were diluted in 10 mM Tris/NaCl 
0.9%, pH 8.0 at 1:50 (v/v) (It) after incubation and CF fluorescence was measured by 
fluorimetry at Ex. 493 nm / Em. 513 nm (Hitachi F-4500 Fluorescence 
Spectrophotometer). Encapsulated CF was quantified as encapsulation ratio 
(CF/lipid)=[CF]/[lipid]. CF release was determined as CF (%) = (It−Io) / (I∞−Io) × 100. 
Stability of TSL was calculated as 100 – CF (%). 
 
Temperature-dependent CF release 
 
Temperature-dependent release profile of CF from NCTSL and CTSL was established 
by fluorometry upon incubating the TSL samples (section 2.4) at various temperatures 
between 37- 45 °C for 5 min. The CF release (%) was calculated as in section 2.4. 
 
Time-dependent CF release 
 
Time-dependent release profile of CF from NCTSL and CTSL was performed at 42 °C. 
TSL suspension (1mM [lipid]) was mixed with pre-heated FCS (1:149 v/v) under 
stirring and CF release was measured over time (at 1, 2, 3, 4, 5, 30, 60 min). TSL 
samples without heating were considered as a blank. TSL were destroyed by adding 
10% Triton X-100 (150:1 v/v) and considered as a positive control. The CF release (%) 
was calculated as in 2.4. 
 
Cell culture 
 
Tumor cell line BLM (human melanoma) was cultured in a Dulbecco’s Modified 
Eagles’ medium (Lonza, Belgium) containing 10% FCS. Human umbilical vein 
endothelial cells (HUVECs) were isolated from umbilical cords and cultured in Human 
Endothelial SFM medium (Gibco, Invitrogen) enriched with 30% FCS. Cells were 
subcultured once a week using Trypsin (Sigma, Aldrich) and maintained at 37 °C, 5% 
CO2 in a humidified incubator. All experiments were performed at a confluence of 80-
90%. 
 
Flow cytometry 
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Binding of TSL to BLM and HUVEC cells was assessed by flow cytometry (FACS) 
analysis. 1x105 cells in suspension were incubated for 1h either at 4 °C or at 37 °C with 
various concentrations (100, 200, 500, 1000, 2000, 5000 nmol/ml) of NBD-PE labeled 
TSL. After incubation, cells were washed three times with medium with FCS to remove 
unbound liposomes. Liposomal NBD-PE fluorescence was determined at excitation and 
emission wavelengths of 470 and 530 nm by a BD FACScan (Becton Dickinson, San 
Jose, CA, USA). Data were analyzed with FlowJo software. From the mean fluorescent 
intensity data, the maximum, which was achieved at the highest liposome concentration, 
was set at 100% and further data were calculated as percentage of maximum mean 
fluorescent intensity (% of MFI). Ten thousand gated events were acquired per sample 
and samples were prepared in duplicate. Experiments were repeated at least three times 
with different batches of liposomes. 
 
Living cell confocal microscopy 
 
BLM or HUVEC cells were seeded at a concentration of 60000 cells/ml in cell culture 
chambers containing a cover glass insert coated with 0.1% gelatine or fibronectin, 
respectively. Cells were allowed to grow for 24 hours in the incubator. After 24h, BLM 
were incubated with 1000 nmol/ml CTSL for 1h at 4 °C or 37 °C and HUVEC for 15 
min at 4 °C. After incubation, cells were washed 3 times with either DMEM (for BLM) 
or HUVEC medium (for HUVEC) with FCS. Cells were analyzed on a Zeiss LSM 510 
META confocal laser scanning microscope. CF release was detected by 513 nm argon 
laser and Rho-PE was monitored by a 543 nm Helium –Neon laser. Images were taken 
from 37 °C to 43 °C for 1h (40 x objective lens 5 µm pinhole). Images of 1024 x 1024 
pixels were analyzed using Zeiss LSM image software (Zeiss, Germany). 
 
Animal models 
 
B16BL6 (murine melanoma) and LLC (Lewis-lung carcinoma) cells were cultured in 
DMEM medium with 10% FCS. Ten million tumor cells were injected subcutaneously 
in the flanks of C57Bl6 mice and bulk tumors of 10 mm in diameter were used for 
transplantation into C57Bl6, expressing an eNos-tag-GFP fusion protein constitutively 
in their vascular endothelium. Tumor pieces were implanted in a dorsal skin flap 
window chamber for intravital imaging.18, 35 Bulk mice were housed at 20-22 °C, 
humidity of 50-60%.  Window chamber-bearing mice were used for experiments after 
8-12 days of tumor implantation when tumor size reached 4-6 mm in diameter. These 
mice were housed in an incubator room with a humidity of 70% and temperature of 30-
32 °C. NMRI nu/nu mice were used for observing possibility of CTSL binding to blood 
cells. They were housed at 20-22 °C and humidity of 50-60%. All mice were fed a 
standard laboratory diet ad libitum (Hope Farms Woerden, the Netherlands). Mice 
weighing 20-25 g were used for experiments. All animal experiments were performed in 
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compliance with protocols approved by the committee on Animal Research of the 
Erasmus MC, Rotterdam, The Netherlands. 
 
In vivo binding to angiogenic endothelial cells and tumor cells  
 
In vivo binding of CTSL and NCTSL to tumor and endothelial cells was observed by 
intravital confocal microscopy on dorsal skin-fold window chamber-bearing mice 
implanted with B16BL6 or LLC tumors. The mice were anesthetized with isoflurane 
(Nicholas Piramal, London, UK) and placed on a heated stage (37 °C) under the 
confocal microscope. Thermocouples (point-welded thin manganese and constantane 
wires, H. Drijfhout & Zoon's edelmetaalbedrijven, Amsterdam) were inserted in the 
window chamber for online monitoring of tissue temperature. A circular resistive 
heating coil, attached to the glass at the back of the chamber was used to provide 
homogeneous temperature distribution in the tissue. CTSL or NCTSL were injected i.v. 
through the penile or tail vein at a dose of 5 µmol. Binding of CTSL or NCTSL to 
vascular angiogenic endothelial cells or tumor cells was observed by confocal 
microscopy (Zeiss LSM 510 META) during 3h. Imaging started right after the injection 
and Rho-PE labeled liposomes were detected as described above (section 2.9). Mice 
were observed up to 24h after injection of TSL in order to visualize remaining bound 
liposomes to the endothelial and tumor cells. Images were analyzed as described in 2.9. 
 
In vivo CF release upon hyperthermia 
 
After 2h of binding and liposome extravasation, tumor was heated at 43 °C for 1h and 
CF release was detected as above (20x objective lens). Regions of interest were selected 
before and in the end of the hyperthermia treatment. Images were analyzed as described 
in 2.9. 
 
Binding of CTSL to blood cells 
 
Ten µmol of CTSL were injected through the tail veins of nude mice. After 2h, blood 
was withdrawn by heart puncture. Blood was spun down two times for 5 min at 400 g 
and blood cells were washed with medium containing FCS. After washing, the blood 
cells were placed on glass slides and covered with glass coverslips. Images were taken 
with Zeiss 100 M microscope, 63x objective lens. 
 
Image inalysis 
 
The mean fluorescent intensity (AU) from the green and the red channels at 37 °C and 
43 °C was quantified for 14 positions obtained from 3 mice. The data are presented as 
average of the mean fluorescent intensity from the all positions with SEM. The data 
were analyzed by Image J software. 
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Fig 1. DSC analysis of NCTSL (A) and CTSL (B) in HEPES buffer, pH 7,4. The heat 
flow is 1 °C/min. Values represented in the figure show the normalized Cp as average 
from three independent batches of liposomes. 
 
 
 
Fig 2. Binding of CTSL or NCTSL at 4 °C to BLM melanoma cells (A) and endothelial 
cells (HUVEC) (B) and confocal microscopy of BLM cells (C) and HUVEC (D). Cells 
in suspension were incubated for 1h with NBD-PE labeled CTSL or NCTSL at 4 °C. 
After washing, the NBD-PE fluorescent intensity was determined by flow cytometry. 
Values depicted in the figure represent the mean fluorescent intensity calculated as a 
percentage of the maximum mean fluorescent intensity from three experiments with 
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three different batches of liposomes. C and D. BLM or HUVEC cells were incubated 
with Rho-PE labeled liposomes (red color) for 1h at 4°C. After incubation, cells were 
washed and visualized by confocal microscopy. Scale bar applies for all images, 10 µm. 
 
 
 
Fig 3. Intravital evaluation of binding of CTSL (A) or NCTSL (B) to angiogenic 
endothelial cells in LLC tumor model using the dorsal skin-fold chamber. Mice were 
injected with 5 µmol of lipid. Appearance of vasculature bound cationic liposomes 
started 20 min after injection and remained visible at least up to 2h. NCTSL hardly 
bound to the endothelial lining of tumor associated blood vessels. Scale bar applies for 
all images, 20 µm. 
 
 
 
 
 
 
 
 
 
 
 
Fig 4. Binding of CTSL to blood cells in circulation. Ten µmol liposomes were injected 
in nude mice and blood was withdrawn 2h after injection. Images showing absence of 
CTSL binding to blood cells were taken by fluorescence microscopy.  
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Fig 5. Effect of hyperthermia on CF release (A) and liposome binding to and 
extravasation from tumor vasculature (B). Columns, mean; bars, SEM. 
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Abstract   
Liposomal nanoparticles can circumvent toxicity of encapsulated 
chemotherapeutic drugs, but fall short in tumor-specific and efficient intracellular drug 
delivery. To overcome these shortcomings, we designed a multifunctional dual targeted, 
heat-responsive nanocarrier encapsulating doxorubicin (Dox) as a chemotherapeutic 
content. Dox-loaded cationic thermosensitive liposomes (Dox-CTSL) carry targeting 
functions addressing tumor cells and tumor vasculature and have a heat-responsive lipid 
bilayer. Targeted Dox-CTSL demonstrated superior uptake by and toxicity to different 
tumor cell lines and endothelial cells compared to non-targeted TSL. Heat-triggered 
intracellular Dox release in acidic cell compartments was visualized as fluorescent Dox 
nanobursts by live cell confocal microscopy. In vivo, using high resolution intravital 
microscopy, we demonstrated that Dox-CTSL upon an external heat-trigger delivered 3-
fold higher Dox quantity to tumors than TSL. Dox-CTSL bound specifically to tumor 
vasculature, which in combination with the heat-triggered drug release caused 
significant tumor vessel damage, which was not observed when non-targeted TSL were 
administered. Therefore, Dox-CTSL have strong potency to increase drug efficacy due 
to targeted delivery and heat-triggered drug release in tumors. 
 
Keywords: Cationic thermosensitive liposomes, hyperthermia, triggered drug release, 
cytotoxicity, cancer chemotherapy 
 
1. Introduction 
Liposomes currently represent one of the best studied nanoparticle-based drug 
delivery systems used for treatment of cancer and have several advantages over free 
drug administration. 1-3 Their small size (< 100nm) and prolonged presence in systemic 
circulation allow them to preferentially deliver chemotherapeutics to tumors by altering 
their biodistribution. 4 Due to these advantages, liposomal encapsulation has 
significantly decreased toxicity of various chemotherapeutic drugs. 5-7 Yet, mainly 
limited improvements in therapeutic efficacy were demonstrated. 6, 8 The latter is due to 
a low retention of liposomes in tumors and their high intrinsic stability causing low 
concentrations of drug becoming bioavailable in tumor tissue at a slow pace. 9-11 The 
aim of this study is to develop a drug delivery strategy that deals with these short-
comings in current clinical liposomal chemotherapy. Our strategy employs a 
combination of tumor targeting of drug loaded nanoparticles with an externally 
triggerable controlled release function. To achieve this we encapsulate drugs into 
targeted cationic liposomes with a thermosensitive bilayer. This novel nanoparticle 
makes use of shielded cationic charged lipids to induce specificity for tumor vasculature 
and tumor cells thereby increasing nanoparticle tumor retention, in combination with a 
thermosensitive liposomal bilayer for heat-triggered drug release. 
Tumor angiogenesis is an important mechanism for supply of nutrients and 
oxygen to tumor cells. Therefore, attacking tumor vasculature is a promising way of 
treating cancer. For nanoparticle-based drug delivery, tumor pathophysiological barriers 
such as the vascular endothelial barrier and high interstitial fluid pressure 12 appear as 
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obstacles for effective drug delivery. 13 Vasculature targeting of nanoparticles may 
overcome these barriers through preferential delivery of chemotherapeutics to 
angiogenic endothelial cells and may provide a promising alternative strategy. 
14, 15
 Next to vascular targeting, such nanoparticles may benefit from the somewhat more 
leaky tumor vasculature allowing for their extravasation into tumor interstitium and 
targeting of tumor cells. 16 
Cationic liposomes have been described to selectively target angiogenic 
endothelial cells and tumor cells based on electrostatic interactions between their 
cationic surface and overexpressed anionic molecules on angiogenic endothelial and 
tumor cell membranes. 17,14, 18, 19 In addition, coating cationic liposomes with PEG will 
prolong their circulation half-life, while preserving their targeting capacity. 12 Slow and 
irregular blood flow in tumors further contributes to strong binding of cationic 
liposomes to tumor vasculature 17, whereas extravasation allows tumor cell targeting. 20 
Upon binding to either tumor endothelial or tumor cells, the cationic charge can 
promote nanoparticle internalization, bringing the drug closer to its active site 
intracellularly. The use of thermosensitive bilayers and hyperthermia is known to trigger 
rapid drug release from nanoparticles locally in heated tumor areas. 20-24 Combining the 
dual targeting functionality and internalization properties of cationic liposomes with a 
heat-triggerable release function can ensure controlled release of drug contents at the 
tumor site either extra- or intracellularly. Next to triggering release, HT also plays a key 
role in modifying tumor microenvironment to increase liposomal drug delivery to 
tumors. 22 Temperature of 41-43 °C is known to increase tumor blood flow, oxygenation 
and vascular permeability 22, 25 and specifically increases permeability to liposomes. 25-27 
Solid efforts have been made to design liposomes which are either 
thermosensitive or targeted. 28-31 Thermosensitive liposomes can be obtained by 
incorporating lipids in the bilayer that undergo a gel-to-liquid phase transition at 
elevated temperatures causing release of the encapsulated drug. 32, 33 We have recently 
developed a cationic thermosensitive liposome (CTSL) formulation, which promoted 
binding and internalization into tumor and angiogenic endothelial cells in comparison to 
thermosensitive liposomes (TSL) and proved to be thermosensitive in vitro and in vivo 
by releasing a liposome- encapsulated fluorescent marker upon heat. 20 Based on this 
novel dual targeted thermosensitive nanoparticle we designed a variant containing the 
widely used anti-cancer drug doxorubicin. 
In this study we report on the development, characterization and application of 
doxorubicin loaded targeted thermosensitive liposomes. CTSL were applied in 
combination with mild hyperthermia to different tumor cells and endothelial cells in 
order to test their cytotoxic potential. In addition, we studied the intracellular fate of the 
nanocarrier and its drug content by live cell imaging. Finally, we investigated the effect 
of mild hyperthermia on intratumoral fate, endothelial targeting and extravasation of 
CTSL, its drug delivery potential and its subsequent damaging effects on tumor 
vasculature using high resolution intravital microscopy on dorsal skin-fold window 
chamber bearing mice implanted with tumors. 
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2. Materials and methods. 
 
2.1. Chemicals.  The phospholipids 1,2-dipalmitoyl-sn-glycero-3-phosphocholine 
(DPPC), 1,2-distearoyl-sn-glycero-3-phosphocholine (DSPC), 1,2-distearoyl-sn-
glycero-3-phosphoethanolamine-N-PEG2000 (DSPE-PEG2000) were purchased from 
Lipoid (Ludwigshafen, Germany). 1,2-dipalmitoyl-sn-glycero-3-phosphoethanolamine-
N-(7-nitro-2-1,3 benzoxadiazol-4-yl) (NBD-PE), phosphatidylethanolamine-dioleoyl-
sulforhodamine B (Rho-PE) and the cationic lipid 1,2-dipalmitoyl-3-
trimethylammonium-propane (DPTAP Chloride salt) were from Avanti Polar Lipid Inc. 
Doxorubicin-HCl was purchased from Pharmachemie (Haarlem, The Netherlands). 
Sodium 3’-[(1-phenylaminocarbonyl)-3,4-tetrazolium]-bis(4-methoxy-6-nitro)benzene 
sulfonic acid hydrate (XTT) was provided by Sigma- Aldrich (Zwijndrecht, The 
Netherlands). LysoTracker Red DND-99 and Dioctadecyl 
tetramethylindotricarbocyanine perchlorate (DiD-C18(3)) were provided by Invitrogen. 
 
2.2. Preparation of TSL. CTSL were composed of DPPC: DSPC: DPTAP: DSPE-
PEG2000 in a molar ratio 60:25:10:5 (CTSL-10) or 62.5:25:7.5:5 (CTSL-7.5). NCTSL 
consisted of DPPC: DSPC: DSPE-PEG2000 in a molar ratio 70:25:5. All the liposomes 
were prepared by lipid film hydration and extrusion method.34 The lipids were dissolved 
in chloroform and methanol (9:1 vol/vol). TSL used for confocal microscopy contained 
0.3 mol% of NBD-PE in the lipid bilayer and TSL used for intravital microscopy 
contained 0.1 mol% of Rho-PE or 0.3 mol% of DiD. The solvent was subsequently 
evaporated under vacuum in rotary evaporator until homogeneous lipid film was 
formed. The lipid film was hydrated in 250 mM (NH4)2SO4 solution at 60 °C for 30 
min. The newly formed multilammelar vesicles were extruded subsequently 5 times 
through 100 nm and 10 times through 50 nm polycarbonate filter (thermo barrel 
extruder at 60 °C) and resulted in small sized TSL. Extraliposomal (NH4)2SO4 was 
removed from liposomal suspension by gel permeation chromatography using a PD-10 
Sephadex column (GE Healthcare, Buckinghamshire, UK), eluted with HEPES buffer, 
pH 7.4 (10 mM HEPES, 135 mM NaCl). Size, polydispersity index (PDI) and zeta 
potential (ζ) were measured by dynamic light scattering using Zetasizer Nano ZS 
(Malvern Instruments, Worcestershire, UK). For size and PDI measurements, TSL were 
diluted in HEPES, pH 7.4, while the zeta potential was obtained in HEPES, pH 7 
without NaCl. Lipid concentration was determined by phosphate assay. 35 After the 
phosphate concentration was determined, doxorubicin was loaded into the liposomes 
(5mM lipid) in 0.05:1 drug:lipid ratio (mol:mol) at 38 °C for 1h. The liposomes were 
concentrated by ultracentrifugation for 2h, 4°C, 49000 rpm for control and 29000 rpm 
for cationic liposomes. The pellet was resuspended in HEPES buffer, pH 7.4 and left 
overnight on slow rotation at 4 °C. Then the liposomes were passed through PD 10 
column eluted with HEPES buffer, pH 7.4 to remove residual nonentrapped 
doxorubicin. Doxorubicin concentration was measured by spectrophotometer at Ex. 479 
nm / Em. 590 nm. 
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2.3. TEM cryo imaging. Samples for imaging were prepared by applying a 2 µl droplet 
of liposome suspension to a lacy carbon film and subsequently plunge-freezing this 
sample into liquid ethane using a Vitrobot. An amorphous (‘vitrified’) ice film which 
contains the particles of interest was created. Cryo-TEM studies were performed using a 
FEI TECNAI F30ST (300kV, using a cryo-holder, keeping the sample at –174 ºC 
during the studies). Imaging was done in low-dose mode on a CCD camera (1 k x 1k). 
Due to the negatively charged grid used for sample holding, cationic liposomes were 
attracted by the grid to some extent. Therefore, a lower number of cationic liposomes as 
compared to the noncationic ones was visualized in positions between the grids. 
Observations on both locations indicated no morphological differences between the 
liposomes. 
2.4. Stability at physiological conditions and prolonged storage at 4 °C. Stability of 
TSL was established by incubating 10mM [lipid]) in pre-heated FCS (1:149 v/v) under 
stirring and Dox release was measured for 1h at 37 °C. Samples without incubation 
were considered as a blank (Io). TSL were destroyed by adding 10% Triton X-100 
(150:1 v/v) and considered as a positive control (I∞). Fluorescence was measured by 
fluorometry at Ex. 479 nm / Em. 590 nm (Hitachi F-4500 Fluorescence 
Spectrophotometer). Dox release was determined as Dox (%) = (It−Io) / (I∞−Io) × 100. 
Stability of TSL was calculated as 100 – Dox (%). Liposomes were also tested for 
prolonged storage over 4 weeks at 4 °C by measuring size, pdi and dox release. Dox 
release measurements were performed by mixing 1mM [lipid]) with 10 mM Tris/NaCl 
0.9%, pH 8.0 at 1:149 (v/v) and dox fluorescence was measured at Ex. 479 nm / Em. 
590 nm. TSL were destroyed by adding 10% Triton X-100 (150:1 v/v) and considered 
as a positive control and dox release measured as mentioned above. 
  
2.5. Temperature-dependent dox release. Temperature-dependent dox release profile 
from NCTSL and CTSL was performed by fluorometry upon incubating the TSL 
samples (10mM [lipid]) in pre-heated 90% fetal calf serum (FCS) at various 
temperatures between 37- 45 °C for 5 min in a thermal-shaker (Eppendorf 
Thermomixer) at 300 rpm. Maximum dox fluorescence (positive control) was achieved 
when incubating TSL suspension (10mM [lipid]) in 2% Triton X-100 in H2O for 30 min 
in a thermal shaker at 55 °C and 1400 rpm. All samples were diluted in 10 mM 
Tris/NaCl 0.9%, pH 8.0 at 1:50 (v/v) after incubation and dox fluorescence was 
measured by fluorometry at Ex. 479 nm / Em. 590 nm. The dox release (%) was 
calculated as in section 4. 
 
2.6. Time-dependent dox release. Time-dependent dox release from NCTSL and 
CTSL was established at 42 °C. TSL suspension (10mM [lipid]) was mixed with pre-
heated FCS (1:149 v/v) under stirring and dox release was measured over time (at 1, 2, 
3, 4, 5, 30, 60 min). TSL samples without heating (RT) were considered as a blank. TSL 
were destroyed by adding 10% Triton X-100 (150:1 v/v) and considered as a positive 
control. The dox release (%) was calculated as in 4. 
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2.7. Cell culture. Tumor cell lines BLM (human melanoma), B16 (murine melanoma) 
and LLC (Lewis lung carcinoma) were cultured in a Dulbecco’s Modified Eagles’ 
medium (Invitrogen) containing 10% FCS. Tumor cell line BFS 1 (murine sarcoma) 
was cultured in RPMI medium containing 10% FCS. Human umbilical vein endothelial 
cells (HUVEC) were isolated from umbilical cords and cultured in Human Endothelial 
SFM medium (Gibco, Invitrogen) enriched with 30% FCS. Cells were subcultured once 
a week using Trypsin (Sigma, Aldrich) and maintained at 37 °C, 5% CO2 in a 
humidified incubator. All experiments were performed at a confluence of 80-90%, 
except for cytotoxicity experiments where the confluence was reched after 72h. 
 
2.8. Cell toxicity. BLM, B16, BFS 1, LLC and HUVEC cells were plated in 96 well 
plates at concentration 10000cells/well for BLM, BFS 1 and LLC, 12000cells/well for 
B16 and 6000/well for HUVEC. The cells were allowed to adhere to the bottom of the 
wells for 24h and after that incubated with various concentrations of free Dox or Dox 
incorporated in either TSL or CTSL for 1h at 37 °C. After 1h, liposomes were removed 
and cells washed 3 times with DMEM (for BLM, B16 and LLC) or RPMI (for BFS 1) 
or HUVEC medium (for HUVEC) without FCS. Plates were placed at either 37 °C or 
42 °C for 1h and then left in the incubator at 37 °C for 72h. Cell survival was 
determined by XTT assay. Electron coupling reagent N-methyl dibenzopyrazine 
methylsulfate (1.25 mM in PBS; Sigma) (100 µl) was mixed with 5ml of XTT solution 
(1 mg/ml in RPMI 1640) and cells were incubated with the mixture for 1h at 37 °C. 
Afterwards, XTT conversion was measured at 490 nm in a PerkinElmer Victor Wallac 
plate reader (Perkin Elmer, Groningen, The Netherlands). IC50 (the concentration of 
drug causing 50% reduction of the survival of the control) was calculated from the 
survival growth curves by fitting using GraphPad Prism software (GraphPad, San 
Diego, CA, USA). 
 
2.9. Fluorescence microscopy. BLM, BFS 1, LLC, B16 or HUVEC cells were seeded 
at a concentration of 100000 cells/ml in cell culture chambers containing a cover glass 
insert coated with 0.1% gelatine. Cells were allowed to grow for 24 hours in the 
incubator. After 24h, cells were incubated with Dox-TSL or Dox-CTSL at 50 µM Dox 
for 1h at 37 °C. After 1h of incubation, liposomes were removed, cells washed 3 times 
with medium without FCS and then substituted with fresh medium with FCS. Images 
were taken with a fluorescence microscope (Zeiss Axiovert 100M equipped with 
Hamamatsu C 4742-98 camera) after 1h at 37 °C or 42 °C (63x/NA1.40  objective lens). 
 
2.10. Live cell confocal microscopy. BLM, BFS 1, LLC, B16BL6 or HUVEC cells 
were seeded at a concentration of 100000 cells/ml in cell culture chambers containing a 
cover glass insert coated with 0.1% gelatine. Cells were allowed to grow for 24 hours in 
the incubator. After 24h, cells were incubated with 1000 nmol/ml NBD-PE labelled 
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CTSL for 1h at 37 °C and for 30min with lysotracker (LysoTracker® Red DND-99, 
Molecular Probes). After incubation, cells were washed 3 times with medium without 
FCS. Cells were analysed on a Zeiss LSM 510 META confocal laser scanning 
microscope. NBD-PE fluorescence was detected by 488 nm argon laser and lysotracker 
was monitored by a 543 nm Helium –Neon laser. Images were taken at 37 °C for 1h. 
For Dox release experiments, cells were also incubated with NBD-PE labelled Dox-
CTSL-7.5 for 1h at 37 °C and after that washed 3 times with medium without FCS. Dox 
release was followed in time for 1h at 42 °C and its fluorescence was detected by a 543 
nm Helium –Neon laser, pinhole 2,5 µm. Images of 1024 x 1024 pixels were analysed 
using Zeiss LSM image software (Zeiss, Germany) (40x/NA1.30 objective lens 2,5 µm 
pinhole). 
 
2.11. Doxorubicin extraction from tumor and endothelial cells. BLM, BFS 1, LLC, 
B16 or HUVEC cells were seeded at a concentration of 4.10x5 cells/well in 6 well 
plates. The cells were allowed to adhere to the bottom of the wells for 24h and 
afterwards incubated with 100 µM Dox-CTSL or Dox-TSL for 1h at 37 °C. After 
incubation, cells were washed three times with medium without FCS to remove 
unbound liposomes and then incubated at either 37 °C or 42 °C for 1h. Cells were then 
trypsinized and cell suspensions containing the same amount of cells prepared. 
Afterwards, cells were centrifuged at 1400g for 10 min. Supernatant was discarded and 
the pellet was resuspended in premixed Acidic isopropanol with 4% Triton X-100 (1:1 
v/v). The samples were sonicated in a bath sonicator for 45 min. The concentration of 
dox was measured by fluorometer at Ex. 479 nm / Em. 590 nm. 
 
2.12. Animal models. B16 (murine melanoma) cells were cultured in DMEM medium 
with 10% FCS. Ten million tumor cells were injected subcutaneously in the flanks of 
C57Bl6 mice and bulk tumors of 10 mm in diameter were used for transplantation into 
C57Bl6, expressing an eNos-tag-GFP fusion protein constitutively in their vascular 
endothelium. Tumor pieces were implanted in a dorsal skin flap window chamber for 
intravital imaging. Bulk mice were housed at 20-22 °C, humidity of 50-60%. Window 
chamber-bearing mice were used for experiments after 8-12 days of tumor implantation 
when tumor size reached 4-6 mm in diameter. These mice were housed in an incubator 
room with a humidity of 70% and temperature of 30-32 °C. All mice were fed a 
standard laboratory diet ad libitum (Hope Farms Woerden, the Netherlands). Mice 
weighing 20-25 g were used for experiments. All animal experiments were performed in 
compliance with protocols approved by the committee on Animal Research of the 
Erasmus MC, Rotterdam, The Netherlands. 
 
2.13. In vivo extravasation of CTSL. In order to determine the effect of hyperthermia 
on liposome extravasation, intravital microscopy on dorsal skin-fold window chamber-
bearing mice implanted with B16 tumor was performed. The mice were anesthetized 
with isoflurane (Nicholas Piramal, London, UK) and placed on a heated stage (37 °C) 
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under the confocal microscope. Thermocouples (point-welded thin manganese and 
constantane wires, H. Drijfhout & Zoon's edelmetaalbedrijven, Amsterdam) were 
inserted in the window chamber for online monitoring of tissue temperature. A circular 
resistive heating coil, attached to the glass at the back of the chamber was used to 
provide homogeneous temperature distribution in the tissue. Rho-PE or DiD- labelled 
CTSL liposomes were injected through the penile or tail vein and left to circulate in the 
blood stream for 2 or 5h respectively. After 2 or 5h, the tumor tissue of B16 window 
chamber-bearing mice was heated at 42 °C for 1h. Images were recorded during the 1h 
of heat triggering in order to detect its effect on extravasation, which may promote 
higher delivery of liposomes to tumor cells. Representative images of 1024 x 1024 
pixels were analysed using Zeiss LSM image software (Zeiss, Germany) (10x/NA0.30 
objective lens). 
 
2.14. In vivo dox release upon hyperthermia and uptake by tumor and angiogenic 
endothelial cells. In order to evaluate Dox release during hyperthermia and its uptake 
by tumor vascular endothelial cells and tumor cells, Dox-CTSL or Dox-TSL were 
injected i.v. through the penile vein at a dose of 5mg/kg doxorubicin. CTSL or TSL 
were allowed to circulate for 5h at body temperature in order to be able to bind to 
vascular angiogenic endothelial cells or tumor cells and observed by confocal 
microscopy (Zeiss LSM 510 META). After 5h of circulation, tumor was heated at 42 °C 
for 1h and release and uptake was detected as above (10x/NA0.30  objective lens). 
Regions of interest were selected before, during and at the end of the hyperthermia 
treatment. Mice were observed up to 72h after injection of liposomes in order to 
visualize Dox and liposome retention in the tumor and observe possible vessel 
destruction. Images of 1024 x 1024 pixels were analysed using Zeiss LSM image 
software (Zeiss, Germany). 
 
2.15. In vivo Dox and liposome quantification. The integrated density (IntDen) from 
either the red (Dox) or the purple (DiD) channel (obtained after setting a threshold) 
representing released doxorubicin at 42 °C and liposomes respectively, was quantified 
by Image J software. Mice were injected with either CTSL or TSL and Dox was 
quantified from 11 positions from  each group, which were obtained from 3 mice. When 
DiD quantified, 5 or 6 positions were used per mouse obtained from  either 5 mice 
(cationic) or 3 mice (control). The data are presented as an average of IntDen of all the 
positions of each mouse.  
 
3. Results.  
 
3.1. Liposome characterization 
 
CTSL and TSL were composed of the same phospholipids and PEG-lipid; 
DPPC:DSPC and DSPE-PEG2000. CTSL contained an additional amount of the cationic 
lipid DPTAP in replacement of a similar quantity of DPPC. All formulations were prepared 
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by lipid film hydration and extrusion method. 34 Dox was loaded after extrusion by 
(NH4)2SO4 loading method. 36 Initially, CTSL were prepared with 10 mol % of DPTAP.20 
Empty CTSL-10 showed size below 100 nm and monodispersity (supporting information, 
table 1) similar to previous carboxyfluorescein-loaded CTSL. 20 However, after Dox loading 
these liposomes displayed inhomogeneous size distribution and appearance of a small 
second peak in the dynamic laser light scattering analysis, which indicates some aggregate 
formation (supplemental information, Fig 1A). As we thought the observed instability to be 
related to the cationic lipid, we lowered its amount to 7.5%. This resulted in disappearance 
of the second peak in DLS measurements and a homogeneous liposome formulation after 
Dox-loading (supplemental information, Fig 1B). After decreasing the amount of cationic 
lipid, we analysed particle characteristics and redefined the cellular binding capacity of the 
novel formulation in comparison to Dox-CTSL-10.  
Liposomes were characterized by measuring size, polydispersity index (pdi), zeta 
potential (ζ) and Dox encapsulation efficiency. Moreover, the three formulations were 
tested for stability at storage conditions (4 °C) during 4 weeks. In order to mimic and 
evaluate liposome stability in circulation, Dox retention was analysed at 37 °C in full serum 
for 1h (Table 1). Dox-CTSL-7.5 and TSL represented smaller hydrodynamic diameter than 
Dox-CTSL-10, and also displayed a pdi <0,1, representing homogeneity. All formulations 
demonstrated optimal remote loading of doxorubicin (>90% encapsulation efficiency). 
When incubated in serum at 37 °C for 1 h, all liposome formulations retained >70% of the 
encapsulated Dox, with the highest level of Dox release from CTSL-10. Storage of 
liposomes at 4°C for 4 weeks proved both Dox-TSL and Dox-CTSL-7.5 were stable with 
regard to particle size, pdI and Dox retention. By contrast, Dox-CTSL-10 were less stable 
showing increased size and pdi after 4 weeks storage at 4 °C. All three liposome 
formulations released a minimal amount (10% or less) of Dox in 4 weeks at 4 °C (Table 1). 
 
Table 1. *Characterisation of TSL, CTSL-7.5 and CTSL-10. Mean of three independent  
experiments. pdI:polydispersity index. 
 
 
 
3.2. Temperature- and Time-dependent Dox release kinetics 
Active loading of Dox by ammonium sulphate gradient method resulted in 
mostly spherical liposomal structures with intraliposomal Dox crystals, which were well 
visualized in TSL and CTSL-7.5 (Fig 1A, B). CTSL-10 displayed more aberrant 
structures next to spherical liposomes including elongated rod-shaped Dox-precipitate 
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containing particles, bilayer sheets and disc shaped micelles (DSM), confirming 
inhomogeneity observed by DLS (Fig 1C). A few DSMs were also observed in the 
images of CTSL-7.5, but not in TSL preparations (Fig 1A and B). These structures were 
not related to Dox loading as they were also observed before loading (Fig 2 
supplemental).  
In order to test thermosensitivity of all liposome formulations, temperature- and 
time-dependent release kinetics of Dox in presence of serum were measured. All three 
liposome formulations showed a clear temperature-dependent Dox release, which 
increased with temperature during a 5 min heating period (Fig 1D). All formulations 
were stable at 37-38 °C showing no Dox release in 5 min. All three liposome 
formulations showed initiation of Dox release at temperature of 39 °C, but their further 
temperature release profiles deviated. TSL and CTSL-7.5 displayed similar release 
kinetics up to 42 °C, after which Dox release from TSL declined similar to earlier 
observations 24 and Dox release from CTSL-7.5 remained high up to 45 °C with 90% 
release in 5 min. Dox release from CTSL-10 increased with increasing temperature until 
45 °C, but was lower at all temperatures than the other formulations reaching maximally 
60% release in 5 min at 45 °C.  
 Release kinetics in time at a constant temperature of 42 °C in 99% serum 
showed that all liposome formulations released increasing Dox levels in time (Fig 1E). 
The release kinetics for TSL and CTSL-7.5 were nearly similar, demonstrating fast 
release of 80% and 65%, respectively in the first minute. Dox release from both 
formulations continued to increase in time approaching maximal release after 
approximately 10 min. By contrast, CTSL-10 displayed slower release rate with 20% 
Dox release after 1 min reaching ~ 87% in 1h. 
 
 
 
 
Fig 1. TEM cryo imaging of Dox-TSL (A), Dox-CTSL-7.5 (B) and Dox-CTSL-10 (C). 
Bar, 200nm. Temperature- (D) and time-dependent (E) Dox release from CTSL and 
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TSL. (D) Temperature-dependent release of Dox was measured upon a 5 min. exposure 
of TSL in 90% of serum to temperatures varying between 37−45 °C. (E) Time-
dependent Dox release from TSL in 99% serum was measured at constant temperature 
of 42 °C at various time points up to 1 h. Mean ± SEM of three independent 
experiments with three independent batches of liposomes. 
 
3.3.  Dox uptake and release in tumor and endothelial cells 
 
Triggered Dox release from CTSL at the cellular level was studied by live cell 
fluorescent microscopy on 4 different tumor cell lines (BLM, B16, BFS 1 and LLC) and 
human endothelial cells (HUVEC) (Fig 2A). Cells were incubated for 1h at 37 °C to allow 
binding and internalization of liposomes. After removing unbound liposomes, continued 
control incubation at 37 °C for 1h caused only minimal Dox release from the three different 
formulations in all cell lines proving significant liposome stability at physiological 
conditions. However, upon heating cells to 42 °C for 1 h increased intracellular Dox 
fluorescence was observed from cells incubated with CTSL compared to cells treated with 
TSL, representing cellular targeting of the CTSL and triggered intracellular Dox release. No 
differences were observed between CTSL-7.5 and CTSL-10. Dox delivery to HUVEC was 
less abundant compared to tumor cells, which is in accordance with earlier observations that 
cationic liposomes bind to a lesser extent to HUVEC cells than to tumor cells in vitro. 20  
Dox targeting was confirmed by measuring cellular Dox levels in tumor cells 
(BLM, B16, BFS 1, LLC) and HUVEC after a 1h incubation with liposomal Dox 
formulations followed by 1h HT at 42 °C or normothermia (NT) at 37 °C (Fig 2B). Cellular 
Dox delivery by CTSL was higher than TSL, confirming microscopy data. No significant 
differences between both CTSL were observed. Application of HT for 1h at 42 °C, which 
triggered Dox release from the nanoparticles, did not affect total cellular Dox levels in any 
of the cell lines showing that heat-released Dox remains intracellular. 
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Fig 2. A, Targeted and triggered Dox delivery studied by live cell fluorescent 
microscopy on melanoma (murine B16 and human BLM), sarcoma (murine BFS1), 
Lewis lung carcinoma (murine LLC) and HUVECs. Cells were incubated for 1h at 37 
°C with Dox-TSL, Dox-CTSL-7.5 or Dox-CTSL-10 at 50 µM Dox in order to allow 
binding and internalization of liposomes. After 1h, cells were washed 3x with wash 
medium to remove unbound liposomes. HT at 42 °C for 1h was applied to trigger 
doxorubicin release and compared to NT at 37 °C. B, Quantification of cellular 
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doxorubicin levels in BLM, B16, BFS 1, LLC tumor cells and HUVECs by Dox 
extraction method at 37 °C (black bars) and 42 °C (white bars). Cells were incubated 
with 100 µM liposomal Dox, after which they were washed to remove unbound 
liposomes and treated either at 37 °C or 42 °C for 1h. Cellular doxorubicin was 
extracted from cell lysates and measured fluorometrically. Mean ± SEM of three 
independent experiments with three independent batches of liposomes. 
 
3.4. Cytotoxicity of Dox encapsulated in TSL, CTSL-7.5 or CTSL-10 upon NT and 
HT 
 
A short (1h) treatment of BLM, B16, BFS 1, LLC tumor cells and HUVEC with 
Dox-CTSL and Dox-TSL demonstrated superior toxicity of Dox-CTSL to all cell lines 
as determined 72h later (table 2). Inhibitory concentrations of Dox killing 50% of the 
cells (IC50) were similar for both Dox-CTSL and 2-10 fold lower than Dox-TSL in the 
various cell lines, confirming that decreasing the amount of cationic lipid in the 
liposomal bilayer from 10 to 7.5 mol% did not interfere with cellular CTSL mediated 
Dox targeting and subsequent induction of cytotoxicity. Application of a 1h HT at 42 °C 
following CTSL incubation and removal could not further  impact cytotoxicity outcome 
72 h later.  
As cellular Dox delivery and cytotoxicity displayed no differences between both 
Dox-CTSL formulations, CTSL-7.5 (from now on abbreviated as CTSL), which proved 
a pharmaceutically more stable formulation with faster drug release kinetics, was 
chosen for further experimentation.  
 
                Table 2. *IC 50 values in µM Dox of BLM human melanoma, B16 murine 
melanoma, BFS 1 murine sarcoma, LLC murine lung carcinoma and endothelial cell 
(HUVEC) treated with Dox formulated in TSL CTSL-7.5 or CTSL-10 for 1h at 37 °C. 
After removal of unbound liposomes, cells were subjected to HT at 42 °C for another 1h 
(grey rows) or NT (white rows) as control. 
 
 
 
3.5. Uptake of CTSL in lysosomes 
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Next we investigated internalization and intracellular fate of CTSL labelled with 
a fluorescent NBD-PE phospholipid bilayer marker in all cell lines by live cell confocal 
microscopy. After 1h incubation, NBD-CTSL (green fluorescence) were observed at the 
cell surface and internalized in all 5 studied cell lines and appeared to colocalize to 
considerable extent with lysosomes stained with lysotracker (red fluorescence) (Fig 3). 
Besides lysosomal colocalization (yellow in merged images) also punctuate liposomal 
fluorescence (green) was observed in the cytoplasm in non-acidic cell organelles 
(magnified images in supporting information, Fig 3). 
 
 
 
Fig 3. Confocal microscopy on tumor cells (BLM, B16, BFS1, LLC) and endothelial 
cells (HUVEC) incubated with NBD-PE labelled CTSL (green) for 1h  at 37 °C and 
lysotracker (red). After 1h, unbound liposomes were removed by 3x washing with 
medium without FCS and live cell imaging was performed immediately at 37 °C. 
Liposomes were found cell-bound and internalized into the cytoplasm (green) and 
colocalized to some extent with the lysotracker (red) as visualized in yellow in the 
merged images. Images were taken by confocal microscope (40x, 2,5µm pinhole, 2x 
zoom). Scale bar applies for all images, 10 µm. 
 
3.6. Intracellular, HT-triggered Dox release from CTSL in tumor and endothelial 
cells 
 
To prove that CTSL deliver their drug payload intracellularly, live cell confocal 
microscopy was performed on tumor and endothelial cells incubated for 1h at 37 °C 
with Dox-NBD-CTSL (Fig 4).  Dox is quenched inside CTSL and its red fluorescence 
appears only upon release. After removal of unbound liposomes, at 37 °C CTSL (green) 
were internalized and displayed minimal Dox release (red) in BLM, BFS1 and LLC. In 
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B16 and HUVEC, a higher intracellular and mostly nuclear doxorubicin fluorescence 
was observed upon Dox-CTSL incubation, likely representing faster cellular processing 
of the nanoparticles. A subsequent heat trigger at 42 °C immediately induced Dox 
release in all cell lines as is evident from appearance of cytoplasmic colocalization of 
released Dox from CTSL (yellow) and increases in nuclear Dox fluorescence (red) (Fig 
4 and higher magnification images in supporting information Fig 4).The increasing 
number of cytoplasmic nanoscale fluorescent burst release processes (represented in 
yellow), which is typically seen in cells with a more stretched morphology such as BLM 
and HUVEC, and the increasing nuclear Dox fluorescence (red) in most other cell types 
indicates that the heat-triggered Dox release continued to increase up to 1h.  
 
 
 
Fig 4. Doxorubicin release (red) from NBD-PE labelled CTSL (green) in BLM, B16, 
BFS1, LLC and HUVEC upon heat. Cells were incubated with Dox-CTSL (50 µM) for 
1h at 37 °C, after which the cells were washed 3x with medium without FCS. Dox 
release was triggered at 42 °C for 1h. Images were taken by confocal microscope. Scale 
bar applies for all images, 20 µm. 
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3.7. Binding to and extravasation from tumor vasculature of TSL and CTSL 
 
To evaluate the in vivo potential of the CTSL targeted and triggered Dox delivery 
approach, intravital confocal microscopic imaging in B16-tumor bearing mice 
expressing eNOStag-GFP (green) in their endothelial cells was performed. Using this 
advanced optical imaging technology we studied the intratumoral fate of CTSL, in vivo 
triggered Dox release during 1h of HT and the intratumoral fate of Dox. Dox-CTSL or 
TSL carrying a fluorescent bilayer probe DiD (purple) were administered i.v. and 
allowed to circulate for 300 min to study CTSL tumor targeting. During this 
normothermic targeting phase tumor vascular levels of TSL decreased due to 
nanoparticle clearance (Fig 5B left panel and C). By contrast, total CTSL fluorescence 
in vasculature remained relatively constant due to CTSL (purple) binding to tumor 
vasculature (green) represented as immobile fluorescence concentrated in patchy spots 
associated with endothelial cells, which increased over time (Fig 5A left panel) Next to 
bound CTSL, circulating CTSL levels (mobile fluorescence) decreased due to clearance 
and tumor vasculature binding (Fig 5B and C). This targeting event was not observed 
with TSL, which fluorescence appeared homogeneously distributed and mobile in the 
lumen of tumor vessels (Fig 5B left panel). Quantification of DiD-labelled liposomes in 
multiple images from ≥ 3 mice per treatment group showed that both TSL and CTSL 
fluorescence decreased similarly slow with time, representing comparable clearance 
from circulation in the period up to 300 min after injection (Fig 5C). This is remarkable, 
in view of the charge differences between both types of liposomes which did not seem 
to affect clearance. A HT treatment of 60 min at 42 °C following the targeting phase 
induced extravasation of both CTSL and TSL represented as diffused extravascular DiD 
fluorescence (fig 5A and B right panels marked with white arrows). Extravasation, 
which can promote nanoparticle delivery in the tumor interstitial space and subsequent 
binding to tumor cells started about 30 min after HT was initiated and increased in time 
up to 60 min confirming earlier observations with non-targeted TSL 27. Extravasation of 
CTSL during 60 min of HT at 42 °C was confirmed using Rho-PE labelled CTSL 
(supplemental Fig 6). However, extravasation of both DiD and Rho-labelled liposomes 
was heterogeneous throughout the tumor and was not observed in every position and to 
the same extent. Remarkably, HT seemed to further promote binding of CTSL to tumor 
vasculature represented by increasing DiD fluorescence colocalizing with tumor vessels 
in the merged images, confirming earlier findings. 20 Interestingly, quantification of the 
liposomal DiD-fluorescence in intravital images indicates that the decline in 
intratumoral liposome fluorescence observed during the 5h targeting phase is halted and 
increases during hyperthermia. This increase may represent enhanced liposome 
extravasation of both formulations and increased CTSL binding. 
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Fig 5. CTSL (A) and TSL (B) appearance (DiD, in purple) in tumor vasculature (green) 
during 300 min at NT in B16 window bearing mice (Fig 6 and B left panels) and upon 
subsequent HT at 42 °C for 60 min (Fig 6A and B right panels). DiD-labelled CTSL or 
TSL were injected through the penile vein, after which they were allowed to circulate in 
blood stream at NT for 300 min in order to allow binding of CTSL to angiogenic 
endothelial cells. Thereafter, HT at 42 °C for 60 min was applied to promote 
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extravasation of CTSL (A) and TSL (B). Scale bar applies to all images 50 µm. C. In 
vivo quantification of DiD liposomal fluorescence before and during 60 min of HT, 
presented as integrated density (IntDen) in time, see materials and methods for details. 
 
3.8. In vivo Dox release, Dox uptake by tumor and endothelial cells and vessel 
destruction from Dox-CTSL 
 
During 5h of circulation of Dox-TSL and Dox-CTSL, Dox tumor accumulation 
was low, and seemed slightly higher for TSL than CTSL, indicating some premature 
Dox release during the targeting phase from both formulations (Supplemental Fig 5). A 
HT of 42 °C applied at this 5 h time point however, triggered massive Dox release from 
both CTSL and TSL (Fig 6A). Dox release started when tissue temperature reached 42 
°C and continued to increase with time. CTSL delivered higher levels of Dox to the 
tumor compared to TSL. Quantification of Dox fluorescence from the images 
demonstrated 2.7 fold higher Dox fluorescence delivered to the tumor by CTSL than by 
TSL (Fig 6B). Remarkably, Dox fluorescence appearance from TSL seemed to arise 
mainly from the vasculature (Fig 6A lower panel), whereas CTSL triggered Dox release 
appeared more homogeneous. High magnification intravital imaging demonstrated 
tumor vasculature (green) bound CTSL (purple) and Dox (red) delivered to endothelial 
cell and tumor cell nuclei (Fig 6C and supplementary video 1). CTSL delivered Dox 
was massively taken up by endothelial cells and tumor cells surrounding the blood 
vessels 24h after injection (Fig 6D). CTSL induced massive tumor vessel damage, 
which was heterogeneous in the tumor (Fig 6D). In contrast, no tumor vasculature 
damage was observed when TSL were applied (supporting information, Fig 7).  
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Fig 6. Dox release upon HT from CTSL (A upper panel) and TSL (A lower panel) in 
B16 window bearing mice. Temperature of 42 °C for 1 h was applied to the mice 
injected 5 h earlier with either Dox-CTSL or Dox-TSL. The i.v. injected Dox 
concentration was 5mg/kg. Images from mice injected with either Dox-CTSL or Dox-
TSL were taken during 1 h of HT treatment. Scale bar applies for all images, 50 µm. B. 
In vivo quantification of Dox released from CTSL or TSL 1 h after HT treatment, 
 
 
59 
 
presented as integrated density (IntDen), see materials and methods. C. DiD labelled 
Dox-CTSL (purple) binding to and nuclear Dox uptake (red) by angiogenic endothelial 
cells (green) and tumor cells in a B16 tumor model. D. destruction of tumor vasculature 
at 24, 48 and 72 h after treatment with Dox-CTSL and HT. Scale bar 20 µm. 
 
Discussion. 
Various types of liposomal nanoparticles encapsulating chemotherapeutic drugs 
have been successfully developed and are being used in the treatment of cancer. 37 
Although nanoparticle encapsulation can diminish drug side effects tremendously, their 
limited tumor accumulation 38, and intrinsic stability 9-11, hinder to increase therapeutic 
efficacy. 6, 8 Designing thermosensitive liposomes aids to control drug release locally in 
the tumor. 32, 33 The application of HT to thermosensitive liposomes allows their 
increased extravasation and accumulation in the tumor area. 22, 26, 27, 39 Dox encapsulated 
in lysolipid-thermosensitive liposomes (Dox-LTSL) has been developed for an 
intravascular drug release approach 40 and is used currently in clinical trials. 41 An 
alternative way of treating cancer with TSL involves an interstitial drug release, in 
which liposome extravasation from the tumor vasculature is promoted first. 42 Next to 
controlling drug release through an external heat trigger, cell-specific targeting of the 
nanoparticles may help to further improve therapeutic outcome. Recently we reported 
on combining the targeting and triggered release functions in one nanocarrier and 
developed CTSL, a triggered release device targeting both tumor and angiogenic 
endothelial cells. 20 In the present study we redesigned CTSL to accommodate the 
chemotherapeutic drug Dox for preferential targeting to angiogenic endothelial and 
tumor cells, to deliver high quantity of drug to tumors in an externally controlled, 
triggered manner. 
CTSL design was modified to create a pharmaceutically stable formulation upon 
Dox loading. A slight decrease in the amount of cationic lipid content of the CTSL 
bilayer to 7.5 mol % was required to achieve a homogeneous and stable formulation 
regarding size, pdI, encapsulation efficiency and drug release, while still retaining its 
cell-binding capacity through a positive surface charge. The resulting Dox-CTSL 
formulation showed drug release kinetics at various temperatures similar to TSL lacking 
the cationic lipids, which were proven successful in vitro and in vivo at 42 °C in a 
recent study. 23 Dox-CTSL demonstrated stability up to temperature of 39 °C and 
rapidly released the encapsulated drug at 42 °C showing almost 100% release in 10 min 
(Fig 1), characteristics favourable for use in clinical settings. Fluorescence microscopy 
confirmed stability of TSL and CTSL at physiological temperatures (37 °C) for 1h, 
showing only minimal intracellular drug delivery (Fig 2). In contrast, HT at 42 °C 
triggered massive intracellular drug release in several tumor cell types and primary 
cultured endothelial cells being more abundant for CTSL than TSL, which is in 
accordance with the increased binding of CTSL to tumor and angiogenic endothelial 
cells. 20 The increased Dox delivery to all the cell lines by CTSL compared to TSL 
induced by the targeting function, was confirmed in a quantitative fluorometric assay 
(Fig 2). The induced specific cellular targeting and uptake of CTSL compared to TSL 
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leading to enhanced drug delivery resulted in increased cytotoxicity (Table 2). A HT 
trigger could not further increase the cytotoxicity of Dox-CTSL in any of the cell lines. 
This is likely due to the nature of the assay in which cytotoxicity is measured 72 h after 
nanoparticle incubation and heat treatment. During the remaining 72 h also non-heat 
triggered CTSL will release their Dox contents intracellularly due to cellular 
nanoparticle processing, causing cellular cytotoxicity. A possibly contributing factor 
may relate to the intracellular localization of CTSL in acidic compartments in the 
cytosol. Co-staining of acidic organelles (lysosomes) demonstrated that despite not all 
liposomes were yet associated with lysosomes, an important part of them did end up in 
this acidic cell compartment (Fig 4 and supporting information, Fig 3). This may hinder 
release of Dox, which in protonated form has more difficulty to pass membrane barriers 
43, preventing its rapid nuclear accumulation. It may be interesting to further promote 
Dox release from acidic cell compartments by virtue of pH-sensitive functions that 
affect endo-lysosomal membrane stability at low pH. This approach caused faster 
nuclear Dox accumulation compared to non-pH sensitive liposomes 44-46. Triggered 
intracellular Dox release in vitro from CTSL entrapped in cytoplasmic vesicles was 
visualized by live cell confocal microscopy as intracytoplasmic fluorescent nanobursts 
(Fig 4 and supporting information, Fig 4). This HT-triggered drug release resulted in an 
increased nuclear Dox uptake in studied tumor cell lines, but was less clear for 
endothelial cells, which showed a high number of cytoplasmic Dox nanobursts. This is 
likely due to slower endo-lysosomal Dox release in endothelial cells compared to tumor 
cells. 43 
During a 5 h circulation of CTSL in the blood stream (targeting phase) minimal 
Dox accumulation in tumor was observed suggesting minimal premature Dox release 
(Supporting information, Fig 5), which correlates nicely to their stability in vitro when 
exposed to 37 °C in serum. (table 1). Targeting of Dox-CTSL to tumor vasculature was 
demonstrated during the 5 h targeting phase (Fig 5) confirming that adaption of particle 
design and Dox loading did not affect the targeting potential of CTSL that we observed 
earlier 20. Application of HT at 42 °C for 1h seemed to further promote the binding of 
Dox-CTSL to tumor vasculature, which may be due to increased negatively charged 
molecules on the endothelial cell membranes. In accordance with Li et al 27, HT also 
induced extravasation of CTSL and TSL, which appeared heterogeneous within the 
tumor area. Extravasation started around 30 min after application of HT and increased 
up to 1h (Fig 5). Remarkably, quantification of liposomal fluorescence at various 
positions in the tumor in multiple animals indicated that CTSL were not cleared faster 
from circulation than TSL (Fig 5C). Interestingly, the levels of liposomal fluorescence 
of both CTSL and TSL increased upon HT for 1h, which may represent enhanced 
extravasation as well as possible binding of CTSL. Importantly HT triggered abundant 
Dox release especially from CTSL and to a lesser extent from TSL (Fig 6). 
Quantification of numerous position in the tumors showed that Dox-CTSL delivered 
nearly 3-fold higher Dox quantities than TSL. This indicates that due to the positive 
charge Dox-CTSL have improved capacity to increase Dox delivery to tumors 
compared to TSL. Since both formulations had similarly low levels of serum induced 
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Dox leakage (Table 1), increased intratumoral retention and cellular uptake by tumor 
and endothelial cells (Fig 2 and Fig 6C) are likely responsible for the enhanced drug 
delivery using Dox-CTSL. Specificity of cationic liposomes for angiogenic endothelial 
cells has been previously reported by several groups. 47 Campbell et al 17 have shown in 
their study in a DSC mouse model that only 4% of the injected cationic liposomes 
associated with the normal vasculature whereas 25-28% were delivered to tumor 
vessels. In addition, the specific binding of cationic liposomes to tumor vasculature 
appeared not dependent on tumor type. They speculated that the reason for this 
preferential delivery was the sluggish and irregular blood flow in tumor vasculature that 
facilitated the binding between positively charged cationic liposomes and anionic sites 
on tumor vasculature. A study by Thurston et al 14 showed that angiogenic blood vessels 
in RIP-Tag2 and K14-HPV16 mice took up 15-33 fold more cationic liposomes than 
normal vessels. Additionally, this study showed that angiogenic endothelial cells in 
tumors and chronically inflamed tracheas took up cationic liposome-DNA complexes, 
but not anionic, neutral or sterically stabilized neutral liposomes. In accordance with our 
findings and Thurston et al 14, Krasnici et al 18 also proved the specific uptake of 
cationic liposomes by tumor endothelium compared to anionic and neutral liposomes in 
a melanoma window chamber model in Syrian hamsters. Finally, a study by Dellian et 
al 48 in ortotopically grown pancreatic cancer revealed that in both early and late 
tumorigenesis cationic liposomes bound preferentially to tumor microvessels compared 
to normal pancreatic microvessels. Moreover, the same study showed that the delivery 
of fluorescent paclitaxel-containing cationic liposomes was increased in tumors 
compared to normal surrounding tissue. In our previous study 49 in window chamber 
bearing mice implanted with either melanoma B16 or Lewis lung carcinoma tumor 
models, we have shown that cationic thermosensitive liposomes bound specifically to 
tumor endothelial cells even 20 min after injection. By contrast, in neither of the tumor 
models neutral thermosensitive liposomes were found associated with angiogenic 
endothelial cells even at later time points. 
HT-triggered drug release resulted in massive drug uptake by both tumor and 
angiogenic endothelial cells, confirming the dual targeting approach. Additionally, only 
CTSL were able to cause massive tumor vasculature destruction, most probably due to 
their vascular targeting and drug delivery potential, which is in accordance with studies 
using non-triggerable cationic formulations by Abu-Lila et al. 19 using oxaliplatin loaded 
cationic liposomes and Kunstfeld et al 50 using paclitaxel loaded cationic liposomes.  
 
Conclusion.  
CTSL were successfully redesigned to accommodate Dox as a chemotherapeutic drug 
with remaining dual targeting and heat-triggered release functions. The novel Dox-
CTSL complied with all requirements for in vivo application, i.e. a homogeneous and 
stable nanoparticle formulation with targeting specificity towards angiogenic 
endothelial and tumor cells. With these advanced properties Dox-CTSL promoted 
delivery of high Dox quantities intracellularly into various tumor cell lines and 
endothelial cells in vitro and to tumors in vivo. HT-induced intracellular Dox nanoburst 
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events demonstrated that temperature triggered drug release within the cell is a feasible 
option. Massive CTSL association with tumor vasculature and hyperthermia promoted 
CTSL extravasation and tumor cell targeting delivered high quantities of Dox into the 
tumor. Next to direct tumor cell kill the observed tumor vessel damage can further 
contribute to an antitumor effect. Further studies will address the efficacy of our novel 
dual targeted and triggered doxorubicin delivery approach using Dox-CTSL. 
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Supplemental information 
 
 
Fig 1. Size distribution of Dox-CTSL-10 (A) and Dox-CTSL-7.5 (B). Decreasing the 
amount of the cationic lipid resulted in a more homogeneous liposome formulation. 
 
Table 1. Characterization of empty TSL, CTSL-7.5 and CTSL-10. Data are represented 
as mean ± standard error of the mean (SEM), N=4. 
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Fig 2. TEM cryo imaging of empty CTSL-7.5 (A) and CTSL-10 (B). CTSL 
formulations consisted of liposomes, and disc shaped micelles (DSMs) which were 
observedin the images of both formulations (black arrows), but more abundant for 
CTSL-10. Bar, 100nm. 
 
 
 
Fig 3. Colocalization of CTSL with lysosomes 1h after incubation and removal of 
unbound liposomes. Liposomes (green) were observed colocalized (yellow) with the 
lysotracker (red). Colocalization is indicated with blue arrows. Liposomes which were 
not colocalized with lysotracker were also observed in all cell lines (yellow arrows). 
Images were taken with a confocal microscope (40x/NA1.30, pinhole 2,5 µm). Scale 
bar applies to all images, 20 µm. 
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Fig 4. Release of Dox (red) upon HT at 42 °C for 1h in B16, BLM and HUVEC. The 
application of HT for 1h caused additional Dox release (red) in the cytoplasm of B16 
(Top panels, marked with white arrows). Magnifications of BLM and HUVEC treated 
with Dox-CTSL and HT clearly show released Dox in the cytoplasm from internalized 
liposomes (green), seen as yellow colocalization. Images were taken with a confocal 
microscope. Scale bar applies to all images 20 µm. 
 
 
 
Fig 5. Stability of Dox-CTSL (A) and Dox-TSL (B) in circulation. Liposomes were 
injected i.v. in penile vein of B16 window bearing mice at 5 mg/kg Dox, after which 
they were allowed to circulate for 5h. Images were taken right after injection at NT and 
5h later in order to observe possible accumulation of prematurely released Dox in the 
tumor. Scale bar applies for all images, 50 µm. 
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Fig 6. Extravasation of Rho-PE labelled CTSL (red) upon heat. CTSL (5 µmol) were 
injected into B16-tumor bearing mice and allowed to circulate for 2h. After 2h, 
hyperthermia at 42 °C for 1h was applied. Hyperthermia caused massive liposome 
extravasation observed by diffusely distributed red fluorescence outside blood vessels 
and the presence of less liposomes inside the blood vessel lumen.  Scale bar applies to 
all images 20 µm. 
 
 
 
Fig 7. Absence of tumor vasculature damage when B16-tumor bearing mice were 
treated with Dox-TSL in combination with 1h of HT. Representative images were taken 
for different time points (24, 48 and 72h) after the HT treatment. Dox (red) can be 
observed outside blood vessels (green) and is cleared from the tumor in time. Scale bar 
applies for all images 50µm. 
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Abstract 
Purpose: To develop RGD-targeted thermosensitive liposomes with increased tumor 
retention, improving drug release efficiency upon mild hyperthermia (HT) in both tumor 
and angiogenic endothelial cells.  
Methods: Standard termosensitive liposomes (TSL) and TSL containing a cyclic Arg-
Gly-Asp (cRGD) pentapeptide with the sequence Arg-Cys-D-Phe-Asp-Gly (RGDf[N-
Met]C) were synthetized, loaded with Dox and characterized. Temperature- and time-
dependent drug release profiles were assessed by fluorometry. Intracellular Dox 
delivery was studied by flow cytometry and confocal microscopy. Cytotoxic effect of 
TSL and RGD-TSL was studied on B16BL6 melanoma, B16F10 melanoma and 
HUVEC. Intravital microscopy was performed on B16BL6 tumors implanted in dorsal-
skin fold window-bearing mice. Pharmacokinetic and biodistribution of Dox-TSL and 
Dox-RGD-TSL were followed in B16BL6 tumor bearing mice upon normothermia or 
initial hyperthermia conditions. 
Results: DLS and cryo-TEM revealed particle homogeneity and size of around 85 nm. 
Doxorubicin loading efficiency was >95% as assessed by spectrofluorometry. Flow 
cytometry and confocal microscopy showed a specific uptake of RGD-TSL by 
melanoma and endothelial cells when compared to TSL and an increased doxorubicin 
delivery. High resolution intravital microscopy demonstrated specific accumulation of 
RGD-TSL to the tumor vasculature. Moreover, application of hyperthermia resulted in 
massive drug release from RGD-TSL. Biodistribution studies showed that initial 
hyperthermia increases Dox uptake in tumors from TSL and RGD-TSL. 
Conclusion: RGD-TSL have potency to increase drug efficacy due to higher uptake by 
tumor and angiogenic endothelial cells in combination with heat-triggered drug release. 
 
Keywords: doxorubicin, RGD, thermosensitive liposomes, hyperthermia, drug delivery 
 
Introduction. 
Nanoparticles, such as liposomes have passed different stages of modifications in 
their design and nowadays are commonly used in cancer chemotherapy [1]. Stealth 
liposomal nanoparticles of 100 nm are believed to accumulate passively in the tumor 
due to the leaky tumor vasculature and related enhanced permeability and retention 
effect [2, 3]. Liposomes have contributed significantly to decrease toxic side effects 
caused by free drug administration [4-6]. However, tumor accumulation of anticancer 
drugs using liposomes seemed far from optimal to guarantee improvement in 
therapeutic efficacy in clinical practice [4, 7]. Low specificity of liposomes and their 
high intrinsic stability limit therapeutic outcome. Selectivity and efficacy can be 
achieved by decorating liposomes with targeting ligands, while an external trigger, e.g. 
heat, can control liposomal drug release. In this study we aimed at developing RGD-
targeted thermosentitive liposomes, which combine active targeting of tumors together 
with a heat-triggered drug release function. These nanoparticles contain multiple RGD 
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peptides on their surface to achieve tumor specificity and increased retention in tumors 
and a thermosensitive bilayer for heat-triggered drug release.  
In order to efficiently target tumor cells, liposomes first need to extravasate from 
tumor vasculature and penetrate the tumor tissue. However, the extravasation process is 
usually heterogeneous and inefficient [3, 8]. Targeting of tumor vasculature rather than 
tumor cells has become a promising approach in cancer therapy [9]. In this case several 
tumor pathophysiological barriers do not play a role as endothelial cells are easily 
accessible to circulating chemotherapeutic drugs and deep penetration into tumor tissue 
is not necessary. Moreover, destruction of tumor vessels leads to indirect killing of 
tumor cells, which depend on their supply of oxygen and nutrients. Finally, endothelial 
cells are genetically stable and therefore less resistant to drug therapy [10]. Besides 
vascular targeting, those small liposomes may extravasate through the leaky tumor 
vasculature and target tumor cells in addition [11].  
Various vascular targets have been studied for anti-vascular therapy of which αvβ3 
integrins have been used most often [12, 13]. These integrins have been found to be 
overexpressed on tumor vasculature, but also on some metastatic melanoma cells [14, 
15]. The RGD (Arg-Gly-Asp) sequence is known to be a recognition motif for integrins 
such as αvβ3 [16]. Binding to either tumor or endothelial cells via specific receptors 
may lead to internalization of liposomal chemotherapy thereby bringing the drug closer 
to the nucleus. The combination of targeting properties of this nanoparticle with the 
heat-triggered release function might aid at releasing the drug locally in the tumor. 
Besides triggering drug release, hyperthermia (HT) is known to play a role in changing 
tumor environment by increasing tumor blood flow, oxygenation and vessel 
permeability [16-21].  
An abundant amount of literature is available on thermosensitive or targeted 
liposomes [22-25]. However, the combination of both strategies in one carrier is a 
promising approach. In the present study we describe the design, characterization and 
behavior of RGD-targeted thermosensitive liposomes containing the chemotherapeutic 
drug doxorubicin in vitro and in vivo. These liposomes were decorated with a novel and 
specific cyclic Arg-Gly-Asp (cRGD) pentapeptide containing the sequence Arg-Cys-D-
Phe-Asp-Gly (RGDf[N-Met]C) [26]. We tested the cytotoxic effect of those liposomes 
on melanoma cell lines and endothelial cells. Extensive live cell imaging was performed 
to study their intracellular fate in vitro. In vivo, their affinity for tumors, drug release 
kinetics and uptake were studied in dorsal skin fold window chamber models implanted 
with melanoma B16Bl6 tumors. Pharmacokinetics and biodistribution of Dox 
encapsulated in either TSL or RGD-TSL were investigated in mice implanted with 
B16Bl6 tumors. 
 
Materials and methods. 
 
Chemicals.  The phospholipids 1,2-dipalmitoyl-sn-glycero-3-phosphocholine (DPPC), 
1,2-distearoyl-sn-glycero-3-phosphocholine (DSPC), 1,2-distearoyl-sn-glycero-3-
 
 
73 
 
phosphoethanolamine-N-PEG2000 (DSPE-PEG2000) were ordered from Lipoid 
(Ludwigshafen, Germany). 1,2-dipalmitoyl-sn-glycero-3-phosphoethanolamine-N-(7-
nitro-2-1,3 benzoxadiazol-4-yl) (NBD-PE) and 1,2-Disteroyl-sn-Glycero-3-
Phosphoethanolamine-N-[Maleimide (Polyethylene Glycol)2000] (Ammonium Salt) 
were purchased from Avanti Polar Lipid Inc. Doxorubicin-HCl was from 
Pharmachemie (Haarlem, The Netherlands). The RGDf[N-Met]Cys was provided by 
Peptron, South Korea. Sodium 3’-[(1-phenylaminocarbonyl)-3,4-tetrazolium]-bis(4-
methoxy-6-nitro)benzene sulfonic acid hydrate (XTT) was purchased from Sigma-
Aldrich (Zwijndrecht, The Netherlands). LysoTracker Red DND-99 and Dioctadecyl 
tetramethylindotricarbocyanine perchlorate (DiD-C18(3)) were purchased from 
Invitrogen.  
Preparation of TSL. TSL and RGD-TSL were composed of DPPC:DSPC:DSPE-
PEG2000 in a molar ratio 70:25:5. RGD peptide was coupled to mPEG in  a molar ratio 
1.1:1 (peptide:lipid) and coupling efficiency was confirmed by MALDI analysis. For 
MALDI analysis, all peptide samples were prepared as 0.001 M in water. The matrix-
assisted laser desorption/ionization (MALDI) 2,5-dihyfroxy benzoic acid was prepared 
as 10 mg/mL in water. 10 uL of sample and 90 uL of matrix solution were mixed and 
0.5 uL of this mixture was spotted on an anchor chip plate and allowed to dry at ambient 
temperatures. MALDI-TOF mass spectra were recorded on a Bruker Ultraflex III mass 
spectrometer, Bremen, German. [27] Coupling of >95% was used for further liposome 
preparation. Liposomes were prepared by lipid film hydration and extrusion method 
[16]. The lipids were dissolved in chlorophorm and methanol (9:1 vol/vol). TSL used 
for confocal microscopy contained 0.3 mol% of NBD-PE or 0.3 mol% DiD in the lipid 
bilayer. TSL used for intravital microscopy contained 0.3 mol% of DiD. The solvent 
was subsequently evaporated in a rotary evaporator until homogeneous lipid film was 
formed. The lipid film was hydrated in 250 mM (NH4)2SO4 solution with a pH 5,0 at 60 
°C for 30 min. The spontaneously formed liposomes were extruded subsequently 5 
times through 100 nm, 5 times through 80 nm and 5 times through 50 nm polycarbonate 
filter (thermo barrel extruder at 60 °C) and resulted in < 100 nm TSL. (NH4)2SO4 
outside of liposomes was removed from liposomal (NH4)2SO4 by a PD-10 Sephadex 
column (GE Healthcare, Buckinghamshire, UK), eluted with HEPES buffer, pH 7.4 (10 
mM HEPES, 135 mM NaCl). Size and polydispersity index (PDI) were measured by 
dynamic light scattering using Zetasizer Nano ZS (Malvern Instruments, 
Worcestershire, UK). Lipid concentration was analysed by phosphate assay [27]. After 
the phosphate concentration was determined, doxorubicin was loaded into the liposomes  
in 0.05:1 drug:lipid ratio (mol:mol) at 38 °C for 1h. The liposomes were concentrated 
by ultracentrifugation for 2h, 4°C, 106.000 xg (Ti50.2 rotor). The pellet was 
resuspended in HEPES buffer, pH 7.4 and left overnight on slow rotation at 4 °C. Then 
the liposomes were passed through PD 10 column eluted with HEPES buffer, pH 7.4 to 
remove free doxorubicin. Doxorubicin concentration was measured by 
spectrophotometer at Ex 480 nm and loading efficiency (%) determined as [Dox/Lipid] 
after loading/[Dox/Lipid] before loading x100. 
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TEM cryo imaging. Samples were prepared by adding a 2 µl droplet of liposome 
suspension to a lacy carbon film and subsequently plunge-freezing this sample into 
liquid ethane using a Vitrobot. An amorphous (‘vitrified’) ice film which contains the 
particles of interest was created. Cryo-TEM studies were performed using a FEI 
TECNAI F30ST (300kV, using a cryo-holder, keeping the sample at –174 ºC during the 
studies). Imaging was done in low-dose mode on a CCD camera (image size 1k x 1k).  
Stability at physiological conditions. Stability of TSL and RGD-TSL was established 
by incubating 10mM [lipid]) in pre-heated FCS (1:149 v/v) under stirring and Dox 
release was measured for 1h at 37 °C. Samples without incubation were considered as a 
blank (Io). TSL were destroyed by adding 10% Triton X-100 (150:1 v/v) and considered 
as a positive control (I∞). Fluorescence was measured by fluorometry at Ex. 479 nm / 
Em. 590 nm (Hitachi F-4500 Fluorescence Spectrophotometer). Dox release was 
determined as Dox (%) = (It−Io) / (I∞−Io) × 100. Stability of liposomes was calculated 
as 100 – Dox (%). 
In vitro Dox release. Temperature-dependent Dox release kinetics from TSL and RGD-
TSL were performed by fluorometry upon incubating the TSL samples (10mM [lipid]) 
in pre-heated 90% fetal calf serum (FCS) (1:9 v/v) at temperatures ranging between 37- 
45 °C for 5 min in a thermal-shaker (Eppendorf Thermomixer) at 300 rpm. Samples 
without incubation were considered as a blank (Io). After incubation, the samples were 
diluted in 10 mM Tris/NaCl 0.9%, pH 8.0 at 1:50 (v/v) and Dox fluorescence was 
measured by fluorimetry at Ex. 479 nm / Em. 590 nm. Maximum Dox fluorescence 
(positive control) (I∞) was achieved when incubating TSL suspension (10mM [lipid]) in 
2% Triton X-100 in H2O for 30 min in a thermal shaker at 55 °C and 1400 rpm. The 
Dox release (%) was calculated as Dox (%) = (It−Io) / (I∞−Io) × 100. In vitro time-
dependent Dox release from TSL and RGD-TSL was measured at 42 °C. TSL 
suspension (10 mM [lipid]) was mixed with pre-heated FCS (1:149 v/v) under stirring 
and Dox release was measured over time (at 1, 2, 3, 4, 5, 30, 60 min). TSL samples 
without heating were considered as a blank. TSL were destroyed by adding 10% Triton 
X-100 (150:1 v/v) and considered as a positive control. The Dox release (%) was 
calculated as described above. 
 
Cell culture. Tumor cell lines B16Bl6 (murine melanoma) and B16F10 (metastatic 
murine melanoma) were cultured in a Dulbecco’s Modified Eagles’ medium (Lonza, 
Belgium) containing 10% FCS. Human umbilical vein endothelial cells (HUVECs) 
were isolated in-house and cultured in Human Endothelial SFM medium (Gibco, 
Invitrogen) enriched with 30% FCS. Cells were passaged once a week using Trypsin 
(Sigma, Aldrich) and maintained at 37 °C, 5% CO2 in a humidified incubator. All 
experiments were performed at a confluence of 80-90%. 
 
In vitro Dox-TSL toxicity. B16Bl6, B16F10 and HUVEC cells were plated in 96 well 
plates at concentration 12000 cells/well for B16Bl6 and B16F10 and 6000/well for 
HUVEC. The cells were allowed to attach for 24h at 37 °C and after that incubated with 
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various concentrations of free Dox, Dox-TSL or RGD-Dox-TSL for 3h at 37 °C. After 
3h, liposomes were removed and cells washed 3 times with medium with FCS. Plates 
were placed at either normothermia (NT; 37 °C) or hyperthermia (HT; water bath at 42 
°C for 1h) and then left in the incubator at 37 °C for additional 72h. Cell survival was 
determined by XTT assay. Electron coupling reagent N-methyl dibenzopyrazine 
methylsulfate (1.25 mM in PBS; Sigma) (100 µl) was mixed with 5ml of XTT solution 
(1 mg/ml in RPMI 1640) and each well was incubated with 50µl of this mixture for 1h 
at 37 °C. Afterwards, XTT conversion was measured at 490 nm in a PerkinElmer Victor 
Wallac plate reader (Perkin Elmer, Groningen, The Netherlands).  
Flow cytometry. Binding of TSL or RGD-TSL to B16Bl6, B16F10 and HUVEC cells 
was assessed by flow cytometry (FACS) analysis. 1x105 cells in suspension were 
incubated for 3h at 37 °C with 400 nmol/ml TSL or RGD-TSL labelled with 0.3 mol% 
NBD-PE. After incubation, cells were washed three times with medium with FCS to 
remove unbound liposomes. Liposomal NBD-PE fluorescence was determined at 
excitation and emission wavelengths of 470 and 530 nm by a BD FACScan (Becton 
Dickinson, San Jose, CA, USA). Dead cells were labelled with propidiumiodide (PI) 
(Sigma, Aldrich) and ten thousand gated events were acquired per sample and samples 
were prepared in triplicate. For Dox uptake FACS analysis, the same amount of cells 
was incubated with 100 µM Dox for 3h and subsequently washed 3x with medium with 
FCS. Cells in suspension were placed either at normothermia (37 °C) or hyperthermia 
(42 °C) for 1h. Dox fluorescence was determined at excitation and emission 
wavelengths of 488nm and 585nm, respectively. As a dead cell marker, Sytox Green 
(Invitrogen) was used. Data was analysed with FlowJo software. Experiments were 
performed three times with three different batches of liposomes. 
 
Live cell confocal microscopy. B16Bl6, B16F10 or HUVEC cells were seeded at the 
same  concentrations as for fluorescent microscopy in cell culture chambers containing 
a cover glass insert coated with 0.1% gelatine. Cells were allowed to recover for 24 
hours. After 24h, cells were incubated with 400 nmol/ml NBD-PE labelled TSL or 
RGD-TSL for 3h at 37 °C and for 30 min with lysotracker (LysoTracker® Red DND-
99). After incubation, cells were washed 3 times with DMEM (B16Bl6 and B16F10) or 
HUVEC medium (HUVEC). Cells were analyzed on a Zeiss LSM 510 META confocal 
laser scanning microscope. NBD-PE fluorescence was detected by 513 nm argon laser 
and lysotracker was monitored by a 543 nm Helium –Neon laser. For Dox release 
experiments, cells were incubated with NBD-PE or DiD labelled Dox-TSL or RGD-
Dox-TSL for 3h at 37 °C and after that washed 3 times with medium with FCS. Dox 
release was followed in time for 1h at 42 °C (40 x objective lens, 2.5 µm pinhole) and 
its fluorescence was detected by a 543 nm Helium –Neon laser. Images of 1024 x 1024 
pixels were analyzed using Zeiss LSM image software (Zeiss, Germany).   
 
Animal models. B16Bl6 (murine melanoma) cells were cultured in DMEM medium 
with 10% FCS. Ten million tumor cells were injected subcutaneously in the flanks of 
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C57Bl6 mice and bulk tumors of 10 mm in diameter were used for transplantation into 
C57Bl6, expressing an eNOS-tag-GFP fusion protein constitutively in their vascular 
endothelium. Tumor pieces were implanted in a dorsal skin flap window chamber for 
intravital imaging. Bulk mice were housed at 20-22 °C, humidity of 50-60%.  Window 
chamber-bearing mice were used for experiments after 8-12 days of tumor implantation 
when tumor size reached 4-6 mm in diameter. These mice were housed in an incubator 
room with a humidity of 70% and temperature of 30-32 °C. All mice were fed a 
standard laboratory diet ad libitum (Hope Farms Woerden, the Netherlands). Mice 
weighing 20-25 g were used for experiments. All animal experiments were performed in 
compliance with protocols approved by the committee on Animal Research of the 
Erasmus MC, Rotterdam, The Netherlands.  
 
Intravital microscopy for Dox release upon hyperthermia and uptake by tumor and 
angiogenic endothelial cells. Liposome binding to tumor vasculature and their 
clearance from circulation was analysed by intravital microscopy after injection of DiD-
labelled TSL or RGD-TSL and followed up to 24h or 5h respectively. In order to 
evaluate Dox release during hyperthermia and its uptake by tumor vascular endothelial 
cells and tumor cells, DiD-labelled Dox-TSL or RGD-Dox-TSL were injected i.v. 
through the penile or tail vein at a dose of 5mg/kg Dox. Both formulations were allowed 
to circulate for 5h at body temperature in order to be able to bind to vascular angiogenic 
endothelial cells or tumor cells and observed by confocal microscopy (Zeiss LSM 510 
META). After 5h of circulation, tumor was heated at 42 °C for 1h and Dox release and 
uptake was detected as above (20x objective lens). Regions of interest were selected 
before, during and in the end of the hyperthermia treatment. Images of 1024 x 1024 
pixels were analyzed using Zeiss LSM image software (Zeiss, Germany). 
 
In vivo dox quantification. The integrated density (IntDen) from the red channel 
(obtained after setting a threshold) representing released doxorubicin at 42 °C into mice 
injected with either RGD-Dox-TSL or Dox-TSL was quantified from 13 positions from 
each group, which were obtained from 3 mice. The data are presented as an average of 
IntDen of all the positions of each mouse. The data was analyzed by Image J software. 
When DiD quantified, 3-6 positions were used per mouse obtained from 3 mice from 
each group. The data are presented as an average of IntDen of all the positions of each 
mouse.  
 
Pharmacokinetic and biodistribution of Dox-TSL and Dox-RGD-TSL. 
Pharmacokinetic and biodistribution of Dox-TSL and Dox-RGD-TSL was followed in 
B16Bl6 tumor bearing mice upon NT or initial HT conditions. At NT condition, mice 
were injected with 3mg/kg Dox and blood sampling was performed at 0.1; 1; 2; 4; 6 and 
24h and organs were collected 24h after liposome injection. At HT condition, tumors 
were first preheated for 1h at 41 °C and then cooled down for 15 min, in order to 
facilitate liposome extravasation. Then, liposomes were injected at 3mg/kg Dox and 
blood samples were collected up to 24h (0.1; 1; 2; 6; 24h), after which the organs were 
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removed. The Dox concentration in the blood and organs was analyzed by HPLC and 
calculated as % injected dose/g tissue (%ID/g). 6 mice were used per each group. 
 
Statistics. In vivo drug release was analyzed  by Mann-Whitney test and results with p-
value ≤ 0.05 were considered statistically significant.  
 
Results. 
Liposome characterization 
RGD-TSL and TSL consisted of the phospholipids DPPC, DSPC, DSPE-
PEG2000 in a molar ratio (70:25:5). In the RGD-TSL formulation, RGD peptide was 
coupled to mPEG2000 and its coupling efficiency was analyzed by MALDI (Fig 1), after 
which it was mixed with all the lipids in a molar ratio (70:25:5). Both formulations were 
prepared by lipid film hydration and extrusion method [28]. Dox was loaded into the 
liposomes after extrusion by (NH4)2SO4 loading method [29]. Liposomes were 
characterized by measuring size, polydisperity index (pdI), encapsulation efficiency and 
stability. All liposomes were ~85 nm after extrusion and with a pdI < 0.1. After Dox 
loading, liposomes retained their small size and a low pdI. Encapsulation efficiency of 
both formulations was >95%. Liposomes were comparably stable after 1h of incubation 
at 37 °C in 99% FCS. TSL contained 92% ± 1.8 of the entrapped Dox after 1h at 37 °C 
whereas RGD-TSL contained 85% ± 2.3 (data not shown). 
 
 
 
Fig 1. MALDI-TOFF spectra of the free peptide RGD (A), the free lipid (B upper 
panel) and the coupled RGD to mPEG in lipopeptide (B lower panel). 
 
Temperature- and Time-dependent Dox release 
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In order to test whether liposomes are thermosensitive, their temperature- and 
time-dependent drug release profiles were determined (Fig 2A and B). According to the 
temperature-dependent release kinetics (A), which was performed at varying 
temperatures (37-45 °C), both formulations were thermosensitive showing an increasing 
drug release with increasing temperature. The formulations were stable at physiological 
temperatures (37-38 °C) in 5 min and started to release their drug payload slightly at 39 
°C. The maximum drug release from TSL in 5 min was observed at 42 °C (~85%), 
whereas for RGD-TSL it was at 43-44 °C (~80%), after which temperatures the drug 
release declined as seen before [21].  
Time-dependent release profile at a constant temperature of 42 °C for 1 h was 
similar for both formulations (Fig 2B). RGD-TSL and TSL rapidly released Dox in the 
first minute and released >90% of the encapsulated Dox in 1h.  
Active loading of Dox into RGD-TSL and TSL by ammonium sulphate gradient 
method resulted in an abundant amount of intraliposomal Dox crystals, which were well 
visualized by TEM cryo imaging in both formulations (Fig 2C).   
 
  
 
Fig 2. Temperature- (A) and time- (B) dependent Dox release kinetics from RGD-TSL 
and TSL. Temperature-dependent drug release profile was performed in temperatures 
between 37-45 °C for 5 min in 90 % FCS. Time-dependent release was carried for 1 h at 
42 °C in 99.7 % FCS. Mean of three independent experiments with three different 
batches of liposomes. TEM-cryo imaging  (C) of Dox-TSL and Dox-RGD-TSL. Bar, 
100nm.  
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RGD-TSL demonstrate higher uptake by tumor and endothelial cells than non-
targeted TSL 
 
In order to test whether RGD coupling to liposomes increases liposomal uptake 
into tumor and endothelial cells, confocal microscopy and FACS analysis on melanoma 
B16Bl6 and B16F10 cells and HUVEC with NBD-PE labelled TSL or RGD-TSL was 
performed. Confocal microscopy on B16Bl6, B16F10 and HUVEC demonstrated that 
RGD-TSL are more abundantly taken up by the tumor cells and HUVEC  compared to 
TSL (Fig 3A). The 3h incubation period at 37 °C followed by a washing step for 
removal of unbound liposomes revealed that the RGD modification of TSL led to a 
preferential binding and uptake by all the cell lines. This was confirmed also by FACS 
analysis ( Fig 3B). In order to measure Dox delivery, FACS analysis was performed in 
B16Bl6, B16F10 and HUVEC after 1h (C) or 3h (D) of incubation with Dox-TSL or 
Dox-RGD-TSL followed by 1h of HT at 42 °C. The amount of Dox delivered from 
RGD-TSL at NT was higher than TSL in all cell lines and this amount further increased 
after 3h of incubation. When HT was applied to the cells after 1h of incubation at 37 °C, 
there was an increase in Dox release and uptake in all cell lines. HT trigger did not 
further increase the delivered Dox to B16Bl6 and B16F10 cells after 3h of incubation. 
Only  in HUVECs there was an increased delivery of Dox upon HT after 3h of 
incubation.  
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Fig 3. Confocal live-cell imaging for preferential uptake of RGD-TSL compared to TSL 
into B16Bl6, B16F10 and HUVEC cells after 3h of incubation at 37 °C (A). Unbound 
liposomes were removed by washing. Scale bar applies for all images, 10µm. 
Intracellular NBD-PE fluorescent intensity represented as mean fluorescent intensity 
(MFI) in melanoma B16Bl6, B16F10 cells and HUVEC (B) treated with either TSL or 
RGD-TSL for 3h at 37 °C. Unbound liposomes were removed by washing. As unstained 
cells are used cells which were not incubated with liposomes. C and D. Intracellular 
Dox uptake represented as MFI in melanoma B16Bl6, B16F10 cells and HUVEC after 
1h (C) or 3h (D) of incubation at 37 °C, washing of unbound liposomes, followed by 1h 
of HT at 42 °C.  
 
Uptake of RGD-TSL in lysosomes and intracellular, HT-triggered Dox release from 
RGD-TSL in tumor and endothelial cells 
 
The intracellular localization of liposomes was studied by live cell imaging in 
B16Bl6, B16F10 and HUVEC (Fig 4A). Cells were incubated with NBD-PE labelled 
(green) RGD-TSL and lysotracker (red, to stain lysosomes) for 3h at 37 °C, after which 
the unbound liposomes were removed by washing. B16Bl6 and B16F10 were able to 
localize the RGD-TSL in the cytoplasm after 3h of incubation and those liposomes were 
colocalized with the red lysotracker, seen as yellow fluorescence signal (white arrows). 
Still, there were some RGD-TSL (green fluorescence spots), which were not 
concentrated in the acidic compartments (blue arrows). By contrast, in HUVEC 
sequestering of RGD-TSL in the lysosomes occurred at a slower pace. After 3h of 
incubation at 37 °C, liposomes and lysotracker were observed as green and red 
separated fluorescence signals, showing no entrapment of the liposomes in the 
lysosomes. However, when cells were followed for a prolonged period, colocalization 
(in yellow) started to be visible. After 7h of incubation, there was an abundant amount 
of RGD-TSL localized in the lysosomes but also some non-entrapped liposomes in 
lysosomes could be observed. 
To prove that Dox-RGD-TSL deliver the encapsulated drug intracellular, live 
cell imaging on B16Bl6, B16F10 and HUVEC was performed using DiD labelled Dox-
RGD-TSL and green lysotracker (Fig 4B). Removing the unbound liposomes 3h after 
incubation at 37 °C resulted in some doxorubicin release inside of all cell lines, most 
probably due to processing of liposomes by the cells in this time frame. The released 
Dox localized mainly in the cell nuclei but could also be observed in the cytoplasm. The 
application of HT for 1h triggered additional Dox release, seen as increased red 
fluorescence signal intracellularly. In B16Bl6 and B16F10, the Dox delivery upon HT 
treatment was predominantly nuclear, whereas in HUVEC it was cytoplasmic (Fig 4B 
and C). In accordance with Fig 4A, DiD-labeled RGD-TSL (purple) also localized in 
lysosomes (green) to some extent. Non-colocalized liposomes with lysosomes could 
also be observed. Interestingly, the released cytoplasmic Dox upon HT colocalized with 
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the green lysotracker, which indicates Dox release from RGD-TSL also occurs in acidic 
compartments in the cytosol (Fig 4B and C). 
 
 
 
Fig 4. A. Confocal microscopy on melanoma B16Bl6 and B16F10 cells and HUVEC 
incubated with NBD-PE (green) labelled RGD-TSL for 3h at 37°C and lysotracker 
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(red). Unbound liposomes were removed by washing 3x with medium without FCS. 
After washing, B16Bl6 and B16F10 were immediately imaged at 37°C, whereas 
HUVEC were followed up to 7h. Internalized liposomes in the cytosol can be observed 
in all the cell lines (white arrows). Non-internalized in the lysosomes liposomes were 
also visible (blue arrows). B16Bl6 and B16 internalized liposomes immediately in the 
lysosomes after the 3h of incubation period (yellow colocalization of green liposomes 
and red lysotracker), whereas this process happened in HUVEC after 7h. Images were 
taken by confocal microscope (40x, 2.5µm pinhole, 2x zoom). Scale bar applies for all 
images, 20µm. B. Doxorubicin release (red) from DiD-labelled RGD-TSL (purple) in 
B16Bl6, B16F10 and HUVEC upon HT trigger. Cells were incubated with 50µM Dox 
for 3h at 37 °C, after which cells were washed 3x with medium without FCS. Images 
were taken right after this incubation at 37 °C. Then, HT at 42 °C for 1h was applied 
and images in the end of the HT treatment were recorded. Images were taken by 
confocal microscope. Scale bar applies for all images, 50µm. C. Colocalization of 
RGD-TSL (purple) with lysotracker (green) and Dox release (red) in the lysosomes. 
Scale bar applies for all images, 10µm. 
 
Cytotoxicity of Dox encapsulated in TSL and RGD-TSL upon NT and HT 
 
Incubation of B16Bl6,B16F10 and HUVEC cells for 3h with Dox-TSL or Dox-
RGD-TSL showed no differences in cell toxicity determined 72h later as seen in Fig 5 
and table 1. Application of HT for 1h at 42 °C after 3h of liposomes incubation could 
not further improve cytotoxicity impact 72h later in B16F10 and HUVEC but only to 
some extent in B16Bl6 cells. Free Dox demonstrated the highest cytotoxicity on all the 
cell lines because it is rapidly taken up by the cells in its free form. 
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Fig 5. Cytotoxicity of Dox-TSL and Dox-RGD-TSL either at 37 °C or 42 °C in B16Bl6 
(A), B16F10 (B) and HUVEC (C) determined 72h after liposome incubation. 
 
Table 1. *IC 50 values in µM Dox of B16Bl6 murine melanoma, B16F10 murine 
melanoma and endothelial cell (HUVEC) treated with free Dox or Dox formulated in 
TSL or RGD-TSL for 1h at 37°C. After removal of unbound liposomes, cells were 
subjected to HT at 42 °C for another 1h (in blue) or NT (in black) as a control.  
 
 
 
Binding to- and extravasation from tumor vasculature of TSL and RGD-TSL 
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In order to proof that RGD-TSL target angiogenic endothelial cells in vivo, 
intravital microscopy in B16Bl6 window chamber bearing mice was performed. To 
visualize circulating liposomes in the blood stream, liposomes were labelled with DiD 
(purple). In these mice tumor vasculature is visualized by the constitutive expression of 
a GFP-eNOS-tag fusion protein in endothelial cells (Fig 6). Twenty minutes after 
injection of RGD-TSL, next to circulating liposomes in the lumen of the blood vessels, 
bound RGD-TSL could be observed (Fig 6A yellow arrows). These liposomes can be 
visualized as patchy fluorescent spots on the vessel walls. Besides bound liposomes to 
the angiogenic endothelial cells, extravasated liposomes from tumor vasculature are 
visible already 20 min after injection (white arrows). They are visible as diffuse purple 
fluorescence outside of the green blood vessels. Binding continued in time and was 
pronounced 24h after injection. In contrast, using DiD-labeled TSL, no binding to tumor 
vasculature was detected after 5h of circulation. In the last time point (24h), only 
extravasated TSL were visible (Fig 6A, right panel). 
Liposome clearance from circulation during the 5h targeting phase and Dox 
triggered release upon HT was further evaluated by intravital microscopy in B16Bl6 
window chamber bearing mice (Fig 6B). Liposome clearance was observed already 2h 
after injection by decrease in DiD fluorescence signal from both RGD-TSL and TSL. 
Clearance of liposomes continued in time up to 5h (Fig 6B and C). However, RGD-TSL 
bound to tumor vasculature was visible already 5min after injection, whereas this was 
not observed for TSL even after 5h of circulation, which is in accordance with Fig 6A. 
HT trigger at 42°C for 1h did not seem to cause any additional clearance neither of 
RGD-TSL or TSL. Upon HT, TSL could be observed extravasated from the tumor 
vasculature (white arrows) a process which is known to be heterogeneous within the 
tumor. This is in accordance with the quantification of the images, showing an increase 
of the TSL signal upon HT, which is most probably due to extravasation. However, 
there was no increase of the RGD-TSL levels upon HT (Fig 6C). 
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Fig 6. A. Binding of DiD-labeled RGD-TSL (purple) to tumor vasculature (green) of 
B16Bl6 window chamber bearing mice. Binding of liposomes to tumor endothelial cells 
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started 20min after injection and was followed in time up to 24h. Representative images 
from intravital microscopy were selected. Scale bar applies to all images, 50µm. B. 
RGD-TSL and TS appearance (DiD, in purple) in tumor vasculature (green) during 5h 
at NT in B16Bl6 window bearing mice (Fig  B left panels) and upon subsequent HT at 
42 °C for 1h (Fig 5B right panels). DiD-labelled RGD-TSL or TSL were injected i.v, 
after which they were allowed to circulate in blood stream at NT for 5h in order to allow 
binding of RGD-TSL to angiogenic endothelial cells. Thereafter, HT at 42 °C for 1h 
was applied to promote extravasation of RGD-TSL and TSL. Scale bar applies to all 
images 50µm. C. In vivo quantification of DiD liposomal fluorescence before and 
during 1h of HT, presented as integrated density (IntDen) in time, see materials and 
methods for details. 
 
In vivo Dox release upon HT and  Dox uptake by tumor and endothelial cells  
 
In order to understand whether RGD-TSL release Dox in vivo upon HT 
treatment and to follow Dox distribution in the tumor, intravital microscopy was 
performed. Circulation of TSL and RGD-TSL for 5h in the blood stream did not cause 
any premature release of Dox (data not shown). However, when HT at 42 °C was 
applied, immediate Dox release (red) was observed from TSL (Fig 7A) and RGD-TSL 
(Fig 7B). Dox from both formulations was released first intravascular from the 
circulating DiD-labelled liposomes (purple), after which it was gradually taken up by 
endothelial cells and tumor cells surrounding the blood vessels (Fig 7D and supporting 
information, video 1). The Dox uptake in the both treatment groups increased in time 
and was maximal after 1h of HT, when also the lumen of the blood vessels was cleared 
from Dox. Quantification of the images showed that the amount of delivered Dox to the 
tumor from RGD-TSL was 1.7 fold higher than from TSL (Fig 7C). However, this 
difference was not statistically significant (p-value = 0.8). 
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Fig 7. Dox release upon HT treatment from TSL (A) and RGD-TSL (B) in B16Bl6 
window chamber bearing mice. Mice were injected with 5 mg/kg Dox in DiD-labelled 
(purple) TSL or RGD-TSL. After 5h of liposome circulation, a temperature of 42 °C for 
1h was applied to trigger Dox release. Representative images were taken from the 
beginning of the HT treatment up to 1h. C. In vivo quantification of Dox released from 
RGD-TSL or TSL 1h after HT treatment, presented as integrated density (IntDen), see 
materials and methods. D. Dox uptake in endothelial cells (green) and tumor cells from 
RGD-TSL after 1h of HT treatment. Scale bar applies for all images, 50µm. 
 
Pharmacokinetics and biodistribution of Dox-TSL and Dox-RGD-TSL  
 
To follow up Dox clearance from circulation, its distribution in healthy organs 
and tumors and to be able to quantify Dox concentrations in tumors and organs, the 
pharmacokinetic and biodistribution profiles of Dox in TSL or RGD-TSL were studied 
(Fig 8) under NT or HT conditions. At NT condition (Fig 8A and C), Dox from both 
formulations seemed to clear from circulation quite fast in the first 1h, as it was faster 
for RGD-TSL than for TSL (27% v/s 52% remaining Dox respectively). After 2h of 
liposome circulation, the trend was the same showing lower remaining Dox from RGD-
TSL than from TSL (10% v/s 20% respectively). At later time points (4, 6, 24h) there 
was barely any Dox present in circulation from TSL and RGD-TSL. The application of 
initial HT (Fig 8B) seemed to increase the presence of Dox from RGD-TSL in 
circulation at 1h time point, after which its clearance was the same as at NT conditions. 
Besides, upon initial HT conditions, clearance of Dox from TSL and RGD-TSL was 
similar. Considering the biodistribution of Dox (Fig 8C and D), at both NT and HT 
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conditions, there was a significant uptake of Dox from both formulations in the spleen 
as it was higher for Dox from RGD-TSL than TSL (11.3 respectively v/s 8.3% ID/g at 
NT; and 11 v/s 6 % ID/g at HT). Similar high Dox accumulation in the kidney was 
observed from both formulations. Dox accumulated in the liver was similar for RGD-
TSL and TSL under NT (3.9 %ID/g respectively  v/s 2.7 %ID/g). The higher Dox 
uptake in spleen and liver from RGD-TSL is due to most probably opsonization of 
RGD-TSL by proteins in these organs. There was a minimal uptake of Dox from TSL 
and RGD-TSL in the heart, lungs and muscle upon NT and HT. No Dox was detected in 
the brain from neither of the formulations. At NT, the tumor uptake of Dox was similar 
for both formulations. Application of initial HT for 1h at 41 °C was able to cause ~ 3.7 
fold increase of Dox delivery to the tumor from RGD-TSL (1.6 v/s 6 % ID/g) and ~ 2.3 
fold increased Dox amount  to the tumor from TSL (1.7 v/s 4 % ID/g). The amount of 
Dox delivered to the tumor upon initial HT conditions from RGD-TSL was not 
significantly different from Dox delivered from TSL (p-value 0.1). 
 
 
 
Fig 8. Pharmacokinetics (A and B) and biodistribution (C and D) of Dox-TSL and 
Dox-RGD-TSL in B16BL6 tumor bearing mice upon NT or initial HT conditions. A,C. 
At NT condition, mice were injected with 3 mg/kg Dox and blood sampling was 
performed at the indicated time points and organs collected 24h after liposomes 
injection. At HT condition (B and D), tumors in mice were preheated for 1h at 41 °C 
and cooled down for 15min, in order to allow for liposome extravasation. Then, 
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liposomes were injected at 3 mg/kg Dox and blood samples were collected up to 24h, 
after which the organs were removed. The Dox concentration in the blood and organs 
was analyzed by HPLC. 
 
 
Discussion 
Nanoparticles, such as liposomes have been successfully designed and used in 
treatment of various types of cancer [30]. Although modifications to these nanocarriers 
contributed to decreased drug-related side effects, their high stability [31-33] and 
limited tumor localization [34] prevent the desired increase in therapeutic outcome [4, 
7]. Forcing encapsulated drug to leave the liposome, as is achieved with TSL exposed to 
hyperthermia, leads to an enhanced drug release locally in the tumor [35-37]. Also, 
application of an external trigger such as HT, can promote liposome extravasation from 
tumor vasculature and increase their accumulation locally in the tumor area [18-20, 38]. 
When combined, this interstitial release approach relies primarily on HT-augmented 
liposome extravasation followed by heat-triggered drug release [39]. More directly, 
improved drug accumulation is observed with the intravascular release approach, for 
instance with lysolipid-thermosensitive liposomes [40]. Next to the use of an external 
trigger for controlling drug release, decorating liposomes with targeting ligands specific 
for the tumor cells or vasculature can also increase the liposomal drug efficacy. We 
have recently developed cationic thermosensitive liposomes, a nanoparticle combining 
targeting and triggered release properties in one carrier [41,42] and redesigned it in 
ordered to achieve a pharmaceutically stable formulation. In the present study, we report 
on the development of TSL decorated with another targeting ligand, cRGD (RGDf[N-
Met]C, which is specific for integrins overexpressed on both tumor vasculature and 
tumor cells.  
Engrafting of TSL with cRGD did not cause significant changes in the 
pharmaceutical properties of the formulation. Dox-TSL and Dox-RGD-TSL were 
similar in size, pdI, Dox encapsulation and Dox release kinetics. This is in accordance 
with Al-Ahmady et al. using monoclonal antibody-targeted thermosensitive liposomes 
showing that traditional thermosensitive liposomes maintain their physicochemical and 
thermal properties when conjugated to the monoclonal antibody [43]. Both formulations 
showed to be stable at temperatures up to 38 °C, slightly released Dox at 39 °C and at 
42 °C released >90% of the encapsulated Dox in 1h,characteristics favorable for use in 
clinical settings. In accordance with Kim et al. [44] and Al-Ahmady et al. [43] there was 
a preferential uptake of RGD-TSL by both melanoma and endothelial cells, which was 
confirmed by FACS analysis and confocal microscopy (Fig 3A and B). The specificity 
of RGD-TSL for the tested cell lines contributed to an increased Dox delivery to all the 
cell lines at both NT and HT conditions (Fig 3C and D). After 1h of incubation at NT 
with either TSL or RGD-TSL, there was an increased Dox uptake by all the cell lines 
from RGD-TSL. HT additionally triggered the drug release and uptake from TSL and 
RGD-TSL, which was higher for RGD-TSL than TSL. In accordance with Al-Ahmady 
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et al. [43], the longer incubation period of 3h at 37 °C led to an increased Dox uptake in 
the cell lines and was higher again for RGD-TSL. However, the subsequent HT trigger 
did not change the drug uptake in the melanoma cell lines, which is most likely due to 
the fact that in the 3h period the cells are able to degrade the liposomes themselves 
preventing an additional release upon HT. Only an increase in drug uptake upon HT 
after 3h of incubation was observed with HUVECs, which might be due to the fact that 
these cells take longer time to entrap liposomes in acidic compartments in the cytosol 
(Fig 4A). In contrast, B16Bl6 and B16F10 were able to process endocytosed RGD-TSL 
in a faster manner.  
Using confocal microscopy, we demonstrated that HT was able to trigger drug 
release and uptake in vitro in melanoma and endothelial cells. After 3h of incubation of 
the cells at 37 °C with Dox-RGD-TSL, there was a premature drug release and uptake 
most likely due to cellular processing of the drug at this time point. However, HT 
additionally increased Dox delivery in all the cell lines and was mostly nuclear for 
melanoma cells and both nuclear and cytoplasmic for HUVEC (Fig 4B and C), which is 
in accordance with Kim et al. [44]. There was no difference in cytotoxicity of Dox-TSL 
and Dox-RGD-TSL to any of the cell lines at NT conditions.  
A HT trigger could not further increase the cytotoxicity of Dox-RGD-TSL in 
B16F10 and HUVEC but only in B16Bl6. This is likely due to the nature of the assay in 
which cytotoxicity is measured 72 h after nanoparticle incubation and heat treatment. 
During the remaining 72 h also non-heat triggered RGD-TSL will release their Dox 
contents intracellular due to nanoparticle processing, causing cellular cytotoxicity.  
The 5h targeting phase did not show any premature Dox release from neither 
RGD-TSL or TSL (data not shown), which is in accordance with other targeted TSL 
[42]. During this phase, RGD-TSL bound to tumor endothelial cells already 20min after 
liposome injection and were observed bound up to 24h. In contrast, TSL did not bind to 
tumor vasculature and were mostly extravasated 24h after injection (Fig 6A), which 
confirmed the targeting properties of RGD-TSL. Liposomes were cleared from 
circulation gradually in 5h, shown by intravital microscopy and image quantification. 
The application of HT could increase TSL extravasation starting at 30min of HT and 
increasing up to 1h, which is in accordance with Li et al. [20] and Dicheva et al. [42] 
(Fig 6B and C). 
HT at 42 °C could trigger a massive Dox release from both RGD-TSL and TSL. 
Release started already 5min after heat trigger and increased up to 1h (Fig 7A). Image 
quantification from numerous positions in the tumor in several mice demonstrated that 
due to the RGD-TSL specificity for the tumor, these liposomes delivered 1.7 fold higher 
amount of doxorubicin than TSL (Fig 7C). However, this difference was not statistically 
significant. Additionally, hyperthermia triggered release of doxorubicin and subsequent 
uptake by both tumor and angiogenic endothelial cells, which proves the dual targeting 
approach (Fig 7D).  
The pharmacokinetic behavior of Dox-TSL and Dox-RGD-TSL was 
investigated with or without initial HT. Initial HT was used to increase liposome 
extravasation. Dox from RGD-TSL was cleared faster from circulation than Dox from 
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TSL under NT. This observation might show that targeting influenced Dox clearance. 
However, upon HT conditions, Dox clearance from circulation from the two 
formulations was similar.  
Biodistribution studies showed that the highest uptake of Dox-TSL and Dox-
RGD-TSL was in the spleen and the kidneys followed by the liver (Fig 8C and D). The 
high spleen and liver uptake are due to the fact that these organs are part of the 
mononuclear phagocyte system (MPS), which is responsible for filtering out of 
liposomes from the blood circulation [45]. There was no explanation why kidneys had 
an increased Dox uptake at both NT and HT conditions. As expected, there was a little 
Dox uptake from the two formulations under NT and HT in heart and lungs and no 
uptake in brain and the leg muscle close to the heated tumor. The absence of Dox in the 
leg muscle shows that the heating was restricted only to the tumor. There was not a 
difference in tumor uptake of Dox under NT by any of the formulations showing that 
targeting do not contribute to increased drug uptake at this conditions. However, when 
initial HT for 1h at 41 °C was applied, there was an increased Dox uptake in the tumor 
from both formulations, which is likely due to increased extravasation of liposomes 
upon HT and therefore their higher accumulation at the tumor site.  
Future experiments will focus on improving the HT treatment protocols and will 
address the efficacy of our dual targeted and triggered drug delivery approach using 
cRGD thermosensitive liposomes. 
 
Conclusion 
 
RGD-TSL encapsulating Dox were successfully developed with both targeting and 
triggered properties. They demonstrated specificity to tumor and endothelial cells as 
compared to non-targeted TSL. RGD-TSL were taken up by acidic compartments in 
cytosol and  intracellularly released Dox upon HT. In vivo, RGD-TSL bound to 
angiogenic endothelial cells and massively released Dox when HT was applied. 
Biodistribution studies showed that initial HT treatment increases Dox delivery to the 
tumor from both formulations. Further studies will address the efficacy of our dual 
targeted and triggered Dox delivery approach using RGD-TSL. 
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Abstract  
 
Purpose: To evaluate pharmacokinetic profile, biodistribution and therapeutic effect of 
cationic thermosensitive liposomes (CTSL) encapsulating doxorubicin (Dox) upon mild 
hyperthermia (HT).  
Methods: Non-targeted thermosensitive liposomes (TSL) and CTSL were developed, 
loaded with Dox and characterized. Blood kinetics and biodistribution of Dox-TSL and 
Dox-CTSL were followed in B16BL6 tumor bearing mice upon normothermia (NT) or 
initial hyperthermia conditions. Efficacy study in B16BL6 tumor bearing mice was 
followed with Dox-TSL or Dox-CTSL upon NT or HT. Efficacy study in LLC tumor 
bearing mice was performed upon two HT conditions. Intravital microscopy was 
performed on B16BL6 tumors implanted in dorsal-skin fold window-bearing mice. 
Results: Targeting did not cause faster blood clearance of CTSL compared to TSL. 
Highest uptake of liposomes was observed in spleen, kidneys and liver. Applying HT 
prior to CTSL administration increased drug delivery to the tumor and CTSL delivered 
~1.7 fold higher Dox concentration compared to TSL. Efficacy in B16BL6 murine 
melanoma showed that HT had a significant effect on CTSL in tumor suppression and 
prolonged survival. Efficacy in LLC Lewis lung carcinoma tumor model demonstrates 
that two HT treatments hold promises for a successful treatment option. 
Conclusion: CTSL have potency to increase drug efficacy in tumors due to their 
targeted and drug release functions. 
 
Keywords: therapeutic efficacy, doxorubicin, cationic thermosensitive liposomes, 
hyperthermia 
 
 
Introduction. 
 
Liposomes as one of the best studied nanocarriers for treatment of cancer 
improve pharmacokinetics and biodistribution of the encapsulated chemotherapeutic 
drugs after systemic administration 1. Despite their prolonged blood circulation, in the 
clinic, pegylated limosomal doxorubicin has only limited therapeutic efficacy 2, 3 due to 
its low tumor retention and low drug bioavailability 4-6. An idea to improve this includes 
targeting of liposomes with specific ligands for increased tumor retention together with 
an external trigger, i.e heat, which can increase drug delivery locally in the tumor area 
while preventing the healthy tissues from side effects. The aim of this study was to use 
cationic thermosensitive liposomes (CTSL) 7 loaded with doxorubicin (Dox), which 
combine both targeted and triggered characteristics of liposomes in one carrier in order 
to deal with the drawbacks of the liposomal chemotherapy. The designed nanoparticles 
made use of shielded cationic lipids for specific recognition of tumor vasculature and 
tumor cells in combination with thermosensitive lipid bilayers for heat-triggered drug 
release. 
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In the clinic, mild hyperthermia (HT) is known to increase the effect of chemo- 
and radiotherapy leading to enhanced therapeutic efficacy in cancer patients 8,9. Mild 
hyperthermia can inhibit DNA repair, augment tissue oxygenation and sensitize cancer 
cells to cytotoxic drugs 10,11. Additionally, HT is able to increase blood flow and 
interstitial fluid flow helping an enhanced passive perfusion of small molecules. More 
importantly, HT can increase nanoparticle extravasation by increasing the gaps between 
the vascular endothelial cells 12-14. In addition, HT can trigger drug release locally in the 
tumor 13, 15-18. Previous studies have shown increased therapeutic effect from 
thermosensitive liposomes (TSL) triggered with mild HT. The effect was mostly due to 
extravasation and increased drug release locally in the tumor 18-22. 
Another approach for improved drug bioavailability comes from active targeting 
of liposomes to the tumor. Decorating liposomes with ligands specific for tumor 
vasculature or tumor cells may result in their higher retention in tumors and 
subsequently increased drug delivery. 
Cationic liposomes are known to specifically bind angiogenic endothelial and 
tumor cells due to the increased expression of negatively charged molecules on these 
cell membranes 23. The slower and irregular blood flow in tumors also promotes binding 
between passing cationic liposomes and tumor vasculature 24. The specific binding of 
CTSL to either endothelial or tumor cells may lead to receptor-mediated endocytosis of 
the carrier therefore bringing the drug closer to the nucleus. CTSL are also composed of 
thermosensitive lipids with a large capacity to encapsulate drugs and release them upon 
heat. When  HT is applied, CTSL lipid membrane undergoes gel-to-liquid crystalline 
phase transition and becomes more permeable towards water and solutes 25. In this way, 
the encapsulated hydrophilic drugs can be release intracellularly. 
Several TSL formulations have been studied 36  and Al-Jamal et al. 37 reported on 
a detailed study on pharmacokinetics and biodistribution of different TSL in presence or 
absence of HT. An optimum HT protocol requires knowledge on pharmacokinetics, 
biodistribution and tumor accumulation of the liposomal nanocarrier as HT may become 
a treatment option for many types of cancer. However, detailed understanding of the 
pharmacological behaviour of targeted thermosensitive liposomes is not available yet. 
In this study, the pharmacokinetics, biodistribution and therapeutic efficacy of 
doxorubicin encapsulated in cationic thermosensitive liposomes (CTSL) were 
investigated. For the efficacy studies, we tested the tumor growth of 2 different types of 
tumors - B16BL6 murine melanoma and LLC Lewis lung carcinoma over time. The 
tumor growth of 2 groups – TSL and CTSL was studied with or without HT in B16BL6 
or with two HT treatments in LLC . PBS was used as a control. 
 
Materials & Methods.  
 
Chemicals. The phospholipids 1,2-dipalmitoyl-sn-glycero-3-phosphocholine (DPPC), 
1,2-distearoyl-sn-glycero-3-phosphocholine (DSPC), 1,2-distearoyl-sn-glycero-3-
phosphoethanolamine-N-PEG2000 (DSPE-PEG2000) were purchased from Lipoid 
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(Ludwigshafen, Germany). The cationic lipid 1,2-dipalmitoyl-3-trimethylammonium-
propane (DPTAP Chloride salt) was from Avanti Polar Lipid Inc. Doxorubicin-HCl was 
purchased from Pharmachemie (Haarlem, The Netherlands). Sodium 3’-[(1-
phenylaminocarbonyl)-3,4-tetrazolium]-bis(4-methoxy-6-nitro)benzene sulfonic acid 
hydrate (XTT) was purchased from Sigma-Aldrich (Zwijndrecht, The Netherlands). 
Dioctadecyl tetramethylindotricarbocyanine perchlorate (DiD-C18(3)) was purchased 
from Invitrogen. 
 
Preparation of TSL. CTSL were composed of DPPC:DSPC:DPTAP:DSPE-PEG2000 in 
a molar ratio 62.5:25:7.5:5. TSL consisted of DPPC:DSPC:DSPE-PEG2000 in a molar 
ratio 70:25:5 All the liposomes were prepared by lipid film hydration and extrusion 
method.  The lipids were dissolved in chloroform and methanol (9:1 vol/vol). 
Liposomes used for intravital microscopy contained 0.3% of DiD. The solvent was 
subsequently evaporated under vacuum in rotary evaporator until homogeneous lipid 
film was formed. The lipid film was hydrated in 250 mM (NH4)2SO4 solution at 60 °C 
for 30 min. The newly formed multilammelar vesicles were extruded subsequently 5 
times through 100 nm, 5 times through 80 nm and 5 times through 50 nm polycarbonate 
filter (thermo barrel extruder at 60 °C) and resulted in small sized TSL. Extraliposomal 
(NH4)2SO4 was removed from liposomal (NH4)2SO4 by gel permeation chromatography 
using a PD-10 Sephadex column (GE Healthcare, Buckinghamshire, UK), eluted with 
HEPES buffer, pH 7.4 (10 mM HEPES, 135 mM NaCl). Size, polydispersity index 
(PDI) and zeta potential (ζ) were measured by dynamic light scattering using Zetasizer 
Nano ZS (Malvern Instruments, Worcestershire, UK). For size and PDI measurements, 
TSL were diluted in HEPES, pH 7.4, while the zeta potential was obtained in HEPES, 
pH 7 without NaCl. Lipid concentration was determined by phosphate assay. 35 After the 
phosphate concentration was determined, doxorubicin was loaded into the liposomes 
(5mM lipid) in 0.05:1 drug:lipid ratio (mol:mol) at 38 °C for 1h. The liposomes were 
concentrated by ultracentrifugation for 2h, 4°C. The pellet was resuspended in HEPES 
buffer, pH 7.4 and left overnight on slow rotation at 4 °C. Then the liposomes were 
passed through PD 10 column eluted with HEPES buffer, pH 7.4 to remove residual 
nonentrapped doxorubicin. Doxorubicin concentration was measured by 
spectrophotometer at Ex 480nm. 
 
Cell lines and culture. Tumor cell lines B16 (murine melanoma) and LLC (Lewis lung 
carcinoma) were cultured in a Dulbecco’s Modified Eagles’ medium (Lonza, Belgium) 
containing 10% FCS. Cells were subcultured once a week using Trypsin (Sigma, 
Aldrich) and maintained at 37 °C, 5% CO2 in a humidified incubator. All experiments 
were performed at a confluence of 80-90%. 
 
Animal models. The eNOStag-GFP mice line in which the endothelial cells are visible 
due to constitutive expression of a GFP eNOS-tag fusion protein was used for intravital 
imaging. Mice weighing about 25 grams were used and fed a standard laboratory diet ad 
libitum (Hope Farms Woerden, The Netherlands). All animal experiments were done in 
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accordance with the Dutch law and protocols were approved by the committee on 
animal experimentation of the Erasmus MC, Rotterdam, the Netherlands.  
Preparation of the dorsal skin-fold chamber with B16BL6 tumor is an adaptation 
from previously described procedures [13, 18, 19]. The mice were housed in an 
incubation room with an ambient temperature of 30°C and a humidity of 70%. 
Experiments started 8 to 12 days after tumor implantation, at which a functional 
vasculature is established in the tumor. For in vivo efficacy study, ~ a 3 mm3 tumor 
piece of either B16BL6 or LLC tumors was implanted in the hind limb of C57BL6 
mice. Mice were used for experiments when tumors reached ~ 5mm in diameter. 
 
Intravital microscopy for Dox and liposome retention in B16BL6 tumors. DiD-
labelled TSL or CTSL containing Dox were injected i.v. (5mg/kg Dox) and let to 
circulate in the blood stream for 5h in order to allow for liposome targeting to tumor 
vasculature. After the targeting phase, HT at 42 °C for 1h was applied to trigger drug 
release from the liposomes. Mice were observed by confocal microscopy (Zeiss LSM 
510 META) up to 120h after injection of Dox-TSL or Dox-CTSL in order to visualize 
Dox and liposome clearance from the tumor. Images of 1024 x 1024 pixels were 
analyzed using Zeiss LSM image software (Zeiss, Germany), 10x objective lens. 
Doxorubicin fluorescence was detected by a 543 nm Helium –Neon laser and DiD 
fluorescence by 613 nm nm Helium –Neon laser. 
 
Pharmacokinetic and biodistribution of Dox-TSL and Dox-CTSL. Pharmacokinetics 
and biodistribution of Dox-TSL and Dox-CTSL were followed in B16BL6 tumor 
bearing mice upon NT or initial HT conditions. At NT condition, mice were injected 
with 3mg/kg Dox and blood sampling was performed at 0.1;1;2;4;6 and 24h and organs 
were collected 24h after liposomes injection. At HT condition, tumors were first 
preheated for 1h at 41 °C and then cooled down for 15 min, in order to facilitate 
liposome extravasation. Then, liposomes were injected at 3mg/kg Dox and blood 
samples were collected up to 24h (0.1;1;2;6;24h), after which the organs were removed. 
The Dox concentration in the blood and organs was analyzed by HPLC and calculated 
as % injected dose/g tissue (%ID/g). 6 mice were used per each group. 
 
Therapeutic efficacy of Dox-TSL and Dox-CTSL in B16BL6 and LLC tumors. 
C57Bl6 mice were implanted s.c. with B16BL6 murine melanoma or murine LLC 
Lewis lung carcinoma in their hind limbs. When tumor size reached 5 mm in diameter, 
mice were anesthetized and the tumor bearing hind legs except the tumor were covered 
with vaseline to protect them from direct heat. The tumor was in direct contact with the 
water bath. The hind legs were fixed on a rack to ensure a steady position in a water 
bath during the HT treatment.  Thermocouples were attached to the tumor surface at 
multiple spots to monitor tumor temperature over time. The water bath temperature was 
set to 43 °C to reach tumor temperature at 42 °C. In B16BL6 bearing mice, mice were 
injected with PBS, Dox-TSL and Dox-CTSL (3mg/kg Dox) and 5h later HT at 42 °C 
for 1h was applied to trigger drug release. Mice with PBS, Dox-TSL and Dox-CTSL 
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under NT were used as control groups. In LLC bearing mice, there was an initial HT 
treatment for 1h at 41 °C followed by a cool down for 15 min. Then, liposomes were 
injected and allowed to circulate for 5h. A second HT for 1h at 42 °C was then applied 
to trigger drug release. After the treatment, the mice were returned back to the cages. 
The tumor size and the body weight were measured on the day of the experiment and 
every other day after the treatment. Mice were sacrificed if the tumor weight exceeded 
10% of the body mass, the mice lost 10% body weight, when the tumor reached a tumor 
size of 1350 mm3 or at the end of the experiment.  
 
Histology. Mice implanted s.c. with murine B16BL6 melanoma were injected with 
3mg/kg Dox-TSL or Dox-CTSL and liposomes were allowed to circulate for 5h. Then, 
HT for 1h at 42 °C was applied to trigger drug release. Organs and tumors were taken 
out 24h after liposome injection. PBS without HT was used as a control. 
 
Statistics. In vivo biodistribution study was analyzed  by Mann-Whitney test and results 
with p-value ≤ 0.05 were considered statistically significant.  
 
Results. 
 
Pharmacokinetics and biodistribution of Dox-TSL and  Dox-CTSL  
 
In order to understand Dox clearance from circulation and its distribution in 
healthy organs and tumors, pharmacokinetic and biodistribution profiles of Dox in TSL 
or CTSL were followed (Fig 1A and B) under NT or HT conditions. At both NT and 
HT conditions, the trend of Dox-TSL and Dox-CTSL clearance from circulation was 
similar. At NT condition (Fig 1A), Dox from TSL and CTSL seemed to clear from 
circulation fast in the first 1h (52% and 47% remaining Dox respectively). After 2h of 
liposome circulation, there were ~ 20% remaining Dox from both formulations. At later 
time points (4, 6, 24h) there was barely any Dox present in circulation from TSL 
whereas there were 11% Dox left from CTSL after 4h of circulation. Considering the 
biodistribution of Dox (Fig 1C and D), at both NT and HT conditions, there was a 
significant uptake of Dox from the two formulations in spleen as it was significantly 
higher for Dox from CTSL than TSL under HT conditions (19.7 v/s 6 % ID/g). Similar 
high Dox accumulation in the kidneys was observed from the two formulations, which 
was slightly increased upon HT conditions for TSL but significantly increased for CTSL 
(7.6 to 12.4 %ID/g). Dox accumulated in the liver was slightly higher for CTSL than for 
TSL under NT (4.7 %ID/g  v/s 2.7 %ID/g respectively). However, under HT conditions 
there was an increase in delivered Dox from CTSL to the liver than TSL (6.7 % ID/g v/s 
3.7 %ID/g respectively). The higher Dox uptake in spleen and liver from CTSL is due 
to most probably opsonization of CTSL by proteins in these organs. There was a 
minimal uptake of Dox from TSL and CTSL in the heart, lungs and muscle upon NT 
and HT. No Dox was detected in the brain from neither of the formulations. At NT, the 
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tumor uptake of Dox was similar for the two formulations. However, the application of 
initial HT for 1h at 41 °C was able to cause  ~ 2.3 fold increased Dox amount  to the 
tumor from TSL (1.7 v/s 4 % ID/g) and 3.4 fold increased Dox to the tumor from CTSL 
(2 v/s 6.8 %ID/g). The initial HT treatment was able to significantly increase (1.7 fold) 
Dox delivery to tumor from CTSL compared to TSL.  
 
 
Fig 1. Pharmacokinetics (A and B) and biodistribution (C and D) of Dox-TSL and Dox-
CTSL in B16BL6 tumor bearing mice upon NT or initial HT conditions. At NT 
condition (A and C), mice were injected with 3 mg/kg Dox and blood sampling was 
performed at the indicated time points and organs collected 24h after liposomes 
injection. At HT condition (B and D), tumors in mice were preheated for 1h at 41 °C 
and cooled down for 15min, in order to allow for liposome extravasation. Then, 
liposomes were injected at 3 mg/kg Dox and blood samples were collected up to 24h, 
after which the organs were removed. The Dox concentration in the blood and organs 
was analyzed by HPLC. *Mann-Whitney test, p-value ≤ 0.05. 
 
Tumor growth control and survival of mice with B16BL6 tumors 
 
The efficacy of either Dox-TSL or Dox-CTSL was followed in B16BL6 tumor 
bearing mice upon either NT or HT conditions (Fig 2A and B). HT itself showed a 
tremendous effect on tumor growth (A and B). HT effect on the tumor growth was 
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comparable to TSL without HT. Interestingly, HT added to CTSL decreased 
significantly tumor growth compared to their effect on the tumor growth without HT. 
HT applied to TSL did not add to inhibiting tumor progression. However, the 
combination of liposomes and HT showed the highest therapeutic effect. In the CTSL 
plus HT group, 4 out of 8 mice survived 12 days post-treatment whereas in the TSL plus 
HT group, 5 out of 6 mice survived 10 days post-treatment (C). In comparison, the 
group with CTSL without HT survived only 8 days post-treatment (4 out of 8 mice). 
Therefore, HT applied to mice treated with CTSL increased their survival by 4 days. HT 
added to TSL did not increase mice survival. HT added to PBS increased survival only 
with 1 day.  
 
 
Fig 2. Mice implanted with B16BL6 tumors were injected with 3mg/kg Dox-TSL or 
Dox-CTSL. In the HT group, liposomes were allowed to circulate for 5h, after which 
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HT at 42 °C for 1h was applied to trigger drug release. A. Individual tumor growth 
curves from all mice in all treatment groups. B. Efficacy of all treatments. C. Survival 
of mice upon different treatments. 
 
Tumor growth control and survival of mice with LLC tumors 
 
The efficacy of Dox-TSL and Dox-CTSL was followed in mice implanted with LLC 
tumor model based on two different treatment schedules: - preheating of the tumor for 
1h at 41 °C followed by cooling it down for 15 min, injection of liposomes, allowed to 
circulate for 5h and subsequently application of HT for 1h at 42 °C or: - the same 
treatment skipping the preheating phase (Fig 3). The preheating phase was used to 
induce extravasation of liposomes. Treatment with initial HT additionally to one HT 
treatment decreased significantly tumor growth and prolonged survival only in the case 
of Dox-CTSL (Fig 3A and B). Survival was increased with 8 days (from 10 to 18 days). 
The effect on tumor growth of Dox-TSL and Dox-CTSL with preheat were similar. 
Dox-CTSL with preheat increased the survival of mice with 2 days (from 16 to 18 days) 
compared to Dox- TSL with preheat. Preheating phase did not add to one HT treatment 
in inhibiting tumor growth or increasing survival when Dox-TSL or PBS alone were 
used.  
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Fig 3. Mice implanted with LLC tumors were either preheated for 1h at 41°C followed 
by 15 min of cooling down to body temperature or were not preheated. Then, they were 
injected with 3mg/kg Dox-TSL or Dox-CTSL, after which the liposomes were allowed 
to circulate for 5h at NT. After that, HT at 42 °C for 1h was applied to trigger drug 
release. A. Individual tumor growth curves from all mice in all treatment groups. B. 
Efficacy of all treatments. C. Survival of mice upon different treatments. 
 
Control on treatment toxicity in mice with B16BL6 tumors 
 
Dox-TSL and Dox-CTSL effect on mice regarding their toxicity was tested by 
measuring body weight every other day after treatment. In B16BL6 tumor model, PBS 
and PBS plus HT treatment did not show any toxicity on mice. All the other treatments 
with or without HT demonstrated toxicity only in the first two days after treatment 
shown by drop in body weight. However, after 2 days, body weight of all mice from all 
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treatment groups was recovered and remained stable until death (Fig 4A). Similarly, in 
LLC tumor model, there was an initial body weight loss in all the tratment groups, 
which was recovered in 2 to 4 days after treatment and remained stable until death of 
mice (Fig 4B). 
 
 
 
Fig 4. Body weight of the treated mice was followed every other days after treatment 
until death. A. Body weight of mice with B16BL6 tumors. B. Body weight of mice with 
LLC tumors. 
 
Intravital microscopy on liposome and Dox distribution in tumors 
 
In order to know which formulation of liposomes will be more effective in 
killing the tumor, we followed the retention of liposomes and Dox in tumor. Images of 
B16BL6 window chamber tumor bearing mice were taken up to 5 days after DiD 
labelled Dox-CTSL or Dox- Dox-TSL injection (Fig 5). Images show that the two 
formulations extravasated from circulation after 24h and can be found around the tumor 
vasculature or associated with it in the case of CTSL. Liposome and Dox clearance 
from the tumor progressed over time as can be concluded from decreased DiD and Dox 
fluorescent signal in the tumor. Remarkably, there was still an abundant amount of 
liposomes left in the tumor tissue even 120h after injection of the two formulations. The 
Dox clearance from the tissue was faster for TSL (B) than for CTSL (A) which is 
suggestive for higher retention of CTSL in tumors.  
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Fig 5. Doxorubicin and liposome retention in B16BL6 tumors implanted in window 
chamber bearing mice. Mice were injected with 5mg/kg Dox-CTSL (A) or Dox-TSL 
(B) labelled with DiD. Liposomes were allowed to circulate for 5h, after which HT was 
applied to the tumor for 1h. Mice were observed up to 120h in order to follow up the 
Dox and liposomes clearance from the tumor. 
 
IHC of tumor and normal tissues  
 
Dox-CTSL plus mild HT for 1h at 42 °C caused interstitial haemorrhage in s.c. 
murine B16BL6 melanoma. Oedema was also seen in this treatment group. No obvious 
pathology was obserbed in tumors from mice from the other groups.  None of the 
treatments showed any toxicity to the normal organs as concluded from the morphology 
of the spleen, kidneys and liver compared to the control PBS treatment. 
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Fig 6. H&E staining of s.c. murine B16BL6 melanoma tissues (A) in tumor rim or 
tumor center and in normal tissues (kidney, liver and spleen) (B) treated with PBS, Dox-
TSL or Dox-CTSL under HT. 
 
 
 
Discussion. 
 
Thermosensitive liposomes loaded with Dox in combination with HT have 
emerged as a promising treatment approach for cancer patients 39-41. The aim of this 
approach is to increase drug levels in the tumor, thus increasing therapeutic efficacy. 
Several TSL formulations have been developed in the last two decades differing in their 
serum stability, thermosensitivity and ligand targeting 7, 17, 20, 42-45. Liposome 
formulations having stability at 37 °C and fast release kinetics at HT will offer best 
results in the clinic. For optimal application, stability of liposomes at physiological 
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temperatures is very important in order to prevent premature drug release. Despite the 
many efforts made until now 42, 46, 47, the search for the best liposomal formulation is 
still ongoing. Reasons for this can be the limited tumor accumulation and specificity of 
liposomal nanoparticles, low drug bioavailability due to its stable entrapment and lack 
of control of drug release. Many novel approaches have been proposed in the past years 
to tackle these issues and thereby improve liposomal chemotherapy. We used two key 
approaches for improvement in this study being cell-specific targeting and temperature-
controlled drug release. On one hand, CTSL are positively charged and will recognize 
negatively charged anionic sites on the membranes of tumor endothelial cells and tumor 
cells. In this way they can target both tumor vasculature and tumor cells. Once in 
contact, the cationic lipids from CTSL will bind to the anionic molecules on the tumor 
or endothelial cells. This binding might evoke a receptor-mediated endocytosis, leading 
to CTSL internalization. On another hand, CTSL contain thermosensitive lipids in their 
bilayer and when HT is applied to trigger drug release, areas with increased 
permeability in the membrane of CTSL will be created, thus allowing the transport of 
the chemotherapeutic drug through them. This intracellularly released drug from the 
internalized CTSL will then be transported to the nucleus where it can exert its 
therapeutic effect. 
Although many studies focused on determination of Dox levels in tumors and 
blood and a comprehensive study by Al-Jamal et al. 37 described the pharmacokinetics 
and biodistribution of different TSL with or without HT, insight into biodistribution and 
pharmacokinetics of targeted TSL is still lacking. Therefore, this study focuses on 
understanding these together with the therapeutic efficacy of our CTSL.  
The pharmacokinetic behavior of Dox-TSL and Dox-CTSL was investigated 
with or without HT. In accordance with Al-Jamal et al. 37, local HT did not affect the 
blood kinetics of Dox from TSL and CTSL and it was cleared from circulation in a 
similar manner both under NT and HT conditions (Fig 1A and B). After 1h of liposome 
circulation under NT, ~50 % of the encapsulated Dox was cleared, after which its 
concentration gradually decreased. This pharmacokinetic profile of CTSL proves that 
targeting does not cause faster liposome and subsequently drug clearance from 
circulation and it is in accordance with Dicheva et al 7 showing by intravital microscopy 
that the concentration of fluorescently labelled CTSL and TSL in circulation was 
similar. Fig 5 confirms that targeting does not lead to faster liposomal clearance and 
shows that targeting contributes to a longer liposomal and drug retention in tumors. Dox 
from CTSL showed the only presence in circulation 4h after injection, whereas Dox 
from TSL was completely cleared. At later time points, Dox levels were below 
detection in any of the formulations for both NT and HT.  
Biodistribution studies showed that the highest uptake per gram of tissue of 
Dox-TSL and Dox-CTSL was in the spleen and the kidneys followed by the liver (Fig 
1B). This observation is also in accordance with Al-Jamal et al. 37 showing the highest 
uptake of their formulations in liver and spleen. The high spleen and liver uptake are 
due to the fact that these organs are part of the mononuclear phagocyte system (MPS), 
which is responsible for filtering out foreign particles from the blood circulation 48. 
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There was no explanation why kidneys had an increased Dox uptake at both NT and HT 
conditions. Interestingly, HT increased Dox from CTSL in spleen, kidneys and liver. As 
expected and in accordance with Al-Jamal et al.37, there was a little Dox uptake from 
the two formulations under NT and HT in heart and lungs and no uptake in brain and 
the leg muscle close to the heated tumor. The absence of Dox in the leg muscle shows 
that the heating was restricted only to the tumor. There was no difference in tumor 
uptake of Dox under NT from both formulations showing that targeting does not 
contribute to increased drug uptake at this condition. However, when initial HT for 1h at 
41 °C was applied, there was an increased Dox uptake in the tumor from both 
formulations, which is likely due to increased extravasation of liposomes upon HT and 
therefore their higher accumulation at the tumor site. Additionally, Dox concentration 
from CTSL in the tumor was significantly higher compared to TSL, which is most 
likely due to the targeting nature of CTSL causing a higher accumulation of the carrier 
in the tumor and subsequently increased drug delivery. 
In B16BL6 tumor model, HT itself had a tremendous effect in decreasing tumor 
growth (Fig 3) but also increased survival as compared to only PBS treatment. HT as an 
additive treatment to liposomes had a great effect on CTSL in reducing tumor 
progression compared to TSL. In this case, the survival was increased from 8 to 12 
days, whereas in the case of TSL the survival was not increased. There was not a 
significant difference in tumor growth inhibition between mice treated with Dox-TSL 
HT and Dox-CTSL HT, which shows that in this tumor model the targeting does not 
play a role in reducing the tumor volume compared with a non-targeted formulation. 
As the efficacy study with B16BL6 did not show the benefit of using targeted 
thermosensitive liposomes in inhibiting tumor growth, LLC tumor model was included 
in a pilot study where two HT treatments were used - an initial mild HT at 41°C for 1h 
to induce permeable tumor vasculature for liposome extravasation and; a second heat to 
trigger drug release 49. It was recently reported by Li et al. that a temperature of 41 °C 
for 1h can cause significant liposome extravasation in multiple murine and human 
tumor models 14. As seen in Fig 3, the two HT treatments led to reduced tumor growth 
by Dox-CTSL compared to one HT treatment. The two HT treatments were most 
efficacious for Dox-CTSL showing increased survival from 10 to 18 days. Preheating 
phase had no effect on TSL and PBS when compared to one HT treatment. 
Interestingly, histology demonstrated that only CTSL plus HT could cause 
hemorrhage and edema in the treated mice. This observation is in accordance with 
Dicheva et al. 7 demonstrating massive vessel destruction at 24h after liposomal 
injection when CTSL are used in combination with HT. In the treated tumor models, HT 
showed the highest effect in tumor suppression as an additive to Dox-CTSL compared 
to Dox-TSL. This might be a result of its higher stability in serum leading to an 
increased levels of released drug upon HT. Another factor contributing to it might be 
that HT increases CTSL binding to endothelial cells 44 leading to its higher retention and 
effectiveness in tumor growth inhibition. However, more comprehensive studies about 
liposome pharmacokinetics are necessary. Interestingly, two HT treatments might have 
a better treatment result with targeted liposomes than one HT treatment. While 
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intravascular release approach is considered to provide better results with non-targeted 
liposomes, the results presented here indicate a possible application for the so-called 
two step approach where HT is used to open up tumor vessels and to trigger release 
from targeted liposomes. 
 
 
 
Conclusion. 
 
Targeting of TSL did not lead to increased clearance of CTSL from circulation 
compared to TSL. Initial HT condition increased Dox uptake in tumors from CTSL 
compared to TSL. Efficacy study in B16BL6 tumor model demonstrated that HT had a 
significant effect on CTSL on tumor inhibition and prolonged survival. Efficacy study 
in LLC tumors showed that two HT treatments hold promises for successful therapeutic 
efficacy. 
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 Abstract. Introduction. Currently available chemotherapy is hampered by a lack in 
tumor specificity and resulting toxicity. Small and long-circulating liposomes can 
preferentially deliver chemotherapeutic drugs to tumors upon extravasation from tumor 
vasculature. Although clinically used liposomal formulations demonstrated significant 
reduction in toxicity, enhancement of therapeutic activity has not fully met expectations. 
Areas covered. Low drug bioavailability from liposomal formulations and limited 
tumor accumulation remain major challenges to further improve therapeutic activity of 
liposomal chemotherapy. The aim of this review is to highlight strategies addressing 
these challenges. A first strategy uses hyperthermia and thermosensitive liposomes to 
improve tumor accumulation and trigger liposomal drug bioavailability. Image-
guidance can aid online monitoring of heat and drug delivery and further personalize the 
treatment. A second strategy involves tumor-specific targeting to enhance drug delivery 
specificity and drug internalization. In addition, we review the potential of combinations 
of the two in one targeted thermosensitive triggered drug delivery system. Expert 
opinion. Heat-triggered drug delivery using thermosensitive liposomes as well as the 
use of tumor vasculature or tumor cell-targeted liposomes are both promising strategies 
to improve liposomal chemotherapy. Preclinical evidence has been encouraging and 
both strategies are currently undergoing clinical evaluation. A combination of both 
strategies rendering targeted thermosensitive liposomes (TTSL) may appear as a new 
and attractive approach promoting tumor drug delivery.  
 
Keywords: targeted thermosensitive liposomes, hyperthermia, triggered release, 
drug delivery 
 
1. Introduction. Cancer chemotherapy is an important treatment option for primary 
(non-resectable) or metastatic tumors. Administration of chemotherapeutic drugs 
usually occurs systemically, but its efficacy is greatly hampered by rapid drug clearance 
from circulation, lack of tumor specific delivery and activity and distribution of the drug 
throughout the body. The latter is responsible for toxicity to normal organs and tissues, 
usually limiting drug dosing. Due to these factors, only suboptimal levels of active drug 
will eventually reach the tumor limiting anti-tumor activity. In order to overcome these 
disadvantages of currently available chemotherapy, the encapsulation of drugs in a 
biocompatible nanoparticle such as a liposome, may lower systemic exposure and thus 
toxicity and on the other hand help to improve tumor-specific drug delivery. In this way 
liposomal chemotherapy will contribute to an increased therapeutic index, i.e. increased 
efficacy over a lower toxicity.  
Liposomes, self-assembling nanovesicles consisting of a lipid bilayer enclosing 
an aqueous phase, represent one of the best studied nanomedicines used in the treatment 
of cancer. Currently several liposomal products have obtained approval for clinical use 
such as: liposomes with doxorubicin – (Doxil/Caelyx, Myocet and Lipo-Dox) for 
treatment of Kaposi’s sarcoma, ovarian cancer, breast cancer and multiple myeloma, 
liposomes with daunorubicine (DaunoXome) for treatment of Kaposi’s sarcoma and 
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liposomes encapsulating vincristine – (Marqibo) for acute lymphoblastic leukemia 1. 
Many more liposomal drugs for cancer treatment have reached various stages of clinical 
trials, such as Endo-Tag-1 with paclitaxel as an active compound for treatment of 
pancreatic cancer and triple negative breast cancer; Brakiva loaded with topotecan for 
relapsed solid tumors; Lipoplatin with cisplatin as an active drug for non-small cell lung 
cancer 1. Liposomes have numerous advantages as drug carriers over the free drug. In 
their aqueous phase water soluble drugs can be entrapped, whereas the lipid bilayer can 
be used to incorporate lipophilic drugs. A drug that is encapsulated in pegylated 
liposomes, in which the liposome surface is coated with polyethylene glycol (PEG), has 
a greatly altered pharmacokinetic profile, including the area under the plasma 
concentration-time curve, the circulation half-life, the volume of distribution and 
clearance. These parameters greatly contribute to a limited drug distribution into healthy 
tissue while increasing it concentration at the tumor site 2. Anthracyclines are the best 
studied group of drugs which have been associated with liposomes. In preclinical 
models, Doxil/Caelyx produced remission and cure against many types of tumors 
including tumors of the breast, lung, ovaries, prostate, colon, bladder, and pancreas, as 
well as lymphoma, sarcoma and melanoma1. Whereas distribution of liposomal drug is 
mainly restricted to the vascular system, in tumors this is different. If liposomes are 
long-circulating and small enough they can pass through tumor capillaries characterized 
by increased permeability 3, 4. This process has been addressed as the enhanced 
permeability and retention effect 4. Tumor vessels are leakier due to ongoing 
angiogenesis and related basement membrane abnormalities and decreased numbers of 
pericytes lining the endothelium. Gap sizes in the discontinuous tumor endothelium can 
range from 100 to 400 nm depending on the tumor type and even within a tumor 3,5 . 
This is in contrast to the tight endothelial lining of normal vessels, preventing liposomal 
drug extravasation at those sites. Permeable tumor vessels allow extravasation of small 
liposomes into the interstitial space to reach tumor cells. However, this extravasation 
process is not a general phenomenon and appears relatively heterogeneous within a 
tumor and also highly variable between different tumor types 6. For instance, imaging 
radiolabeled liposomes as done by Harrington et al. clearly demonstrated that tumor 
accumulation of liposomes in cancer patients strongly depends on tumor type and size 7. 
In this study was shown that the levels of liposome uptake in tumors estimated from 
regions of interest on gamma camera images were approximately 0.5–3.5% of the 
injected dose at 72 h. The greatest concentration of liposomes (33% ID/kg) was found 
in head and neck tumors, followed by lung tumors (18.3% ID/kg) and breast tumors 
(5.3% ID/kg).  
Although liposomes can accumulate in tumors to some extent their non-tumor-
specific nature and high intrinsic stability hinders further drug bioavailability. Drug 
release from liposomes is usually gradual and inefficient, causing low drug uptake in 
tumor cells. Seynhaeve et al. demonstrated slow uptake of liposomal doxorubicin by 
tumor cells with evidence of nuclear delivery of bioavailable drugs only 2-3 days 
following systemic administration 8. The low drug bioavailability from liposomal 
formulations together with their limited accumulation in tumors in cancer patients are 
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thought to be the main reasons for the absence of major improvements in therapeutic 
outcome when applying liposomal doxorubicin 9.  
Summing up, liposomal formulations of chemotherapeutic drugs can lower 
toxicity to normal tissues, however improving their specific accumulation in tumors and 
promoting drug bioavailability to tumor cells remain important challenges to further 
improve their therapeutic activity. 
Liposomal drug bioavailability can be improved by several means including 
heat-triggered release from thermosensitive liposomes (TSL) or promoting cellular 
internalization by receptor-specific targeting.  
In the first approach heat is used to trigger drug release from thermosensitive 
liposomes (TSL) locally in tumors thereby improving drug bioavailability 10,11. TSL 
contain thermosensitive lipids in their bilayer undergoing a gel-to-liquid phase transition at the desired temperature (usually between 40 and 45 °C) causing release of entrapped hydrophilic drugs 12. The drug delivery approach using TSL primarily relies on release of the drug at the tumor site, after which the drug can enter tumor cells in free form. 
The second approach aims to improve liposomal drug bioavailability through the 
use of cell specific targeting ligands attached to the nanoparticles. First of all these 
targeting ligands can achieve (cell-) specific localization and retention of the liposomal 
drug in tumors e.g. on tumor cells or tumor vasculature. Second, these ligands can 
promote active cellular uptake of the drug-containing nanoparticles through binding to 
targeted internalizing receptors. By these means the drug is transported across the cell 
membrane, which normally forms a significant barrier for cellular drug uptake. 
Combining such targeting functions of ligands with the pharmacokinetic and drug 
delivery advantages of liposomes, targeted liposomes represent promising, tumor 
specific drug delivery nanoparticles 13-21.  
In this review we aim to highlight those two important approaches to improve 
liposomal chemotherapy that aim at increasing drug bioavailability through triggered 
drug release or by using tumor-specific targeting to enhance tumor specificity and 
promote drug internalization. In addition, we review the potential of a combination of 
those two approaches in one targeted thermosensitive triggered drug delivery system.  
 
2. Hyperthermia  
Mild hyperthermia, the application of temperatures a few degrees higher than 
physiological temperatures (40-44 °C) to tumor tissue, has become an attractive 
treatment strategy to enhance the efficacy of radio- or chemotherapy in the treatment of 
cancer patients.  
Initially, whole body hyperthermia was applied to the patient for homogeneous 
tissue temperature distribution. However, in this approach the high core temperature 
(>40 °C) was not very well tolerated by the patient 22. An improvement of the 
hyperthermia treatment involves the application of local hyperthermia by concentrating 
electromagnetic or ultrasound energy on the tumor coming from water-filled 
waveguides or ultrasound transducers, respectively 23. 
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Despite the achievements in hyperthermia treatment planning and local heat 
application, there are still obstacles concerning spatial accuracy and deep thermal 
response in solid tumors. Recent studies report on MRI-guided hyperthermia 24-26 and 
MRI-guided HIFU 27-29 (high intensity focused ultrasound), where MRI (magnetic 
resonance imaging) provides information on tissue anatomy for better treatment control 
and temperature mapping. MRI-guided hyperthermia helps to direct the heat to the 
desired region by online MR thermometry, thereby achieving higher treatment 
efficiency. Whereas electromagnetic hyperthermia has been used for both mild 
hyperthermia and tumor ablation, the most common application for HIFU is thermal 
ablation at temperatures >60 °C. More recently the application of HIFU for mild 
hyperthermia has also been demonstrated in preclinical studies in combination with TSL 
23, 27, 28. 
Hyperthermia (HT) plays a role as a potent radiosensitizer by increasing tumor 
perfusion and oxygenation causing enhanced radiosensitivity 30. Mild hyperthermia as 
an adjuvant therapy to radiotherapy or chemotherapy has become a standard clinical 
treatment option for various tumor types and has shown increased survival in several 
randomized clinical trials 31-36.  
The combination of HT and chemotherapy has also proven beneficial in various 
clinical trials 37, 38. Hyperthermia can cause cellular sensitization and thus cytotoxicity 
towards some chemotherapeutic drugs, especially platinum drugs 39-42 whilst 
doxorubicin has a temperature threshold beyond which its cytotoxicity can be increased 
41. al-Shabanah et al. stated that the application of HT at 43 °C for 30 min could 
enhance the cytotoxicity of doxorubicin to Ehrlich ascites carcinoma cells 40. A study by 
Urano et al. using spontaneous mouse fibrosarcoma cells compared the cytotoxicity of 
HT at 43 °C alone for 1h versus 1h of HT in combination with doxorubicin and found 
that in this period there was no difference in cytotoxicity. However, the prolonged 
treatment caused increased cytotoxicity in the combination group, which can suggest 
that doxorubicin cytotoxicity can be increased if tumors are subjected to the 
hyperthermia treatment for prolonged time or at elevated drug doses 42. However, most 
of those studies refer to thermal sensitization in vitro at elevated temperatures which are 
difficult to achieve in clinical settings. Furthermore, the thermal sensitization of a drug 
depends on the administration mode and dosage 41. An additional effect of HT 
combined with chemotherapy is the recently discovered effect on DNA-repair inhibition 
43-45. Radiation and chemotherapy action is often based on induction of DNA double 
strand breaks (DSB). Under normal circumstances, effective DNA repair mechanisms 
are executed to protect against abnormal DNA rearrangements. Two main mechanisms 
involved in DSB repair are homologous recombination (HR) and non-homologous end 
joining. HR was demonstrated to be inhibited by hyperthermia through degradation of 
BRCA2 43-45. As a result innately HR-proficient BRCA2-positive tumors became 
sensitive to PARP-1 inhibitors through hyperthermia. In this approach hyperthermia had 
no direct effect on DNA damage, but rather on the proteins involved in DNA repair, 
replication or chromosomal segregations 45. 
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Hyperthermia in combination with chemotherapy has proven to be an effective 
treatment option for patients with localized soft-tissue sarcoma as was shown recently in 
a large phase III clinical trial 38. This can be explained, not only by the cellular 
sensitizing effect of HT, but also by its effects on tumor pathophysiology. HT has been 
shown to increase tissue perfusion, oxygenation, blood flow velocity and microvessel 
permeability contributing to increased drug levels in tumors at clinically tolerated 
temperatures 46, 47. HT is also known to increase tumor vessel permeability to antibodies 
48 and ferritin 49 and even more interesting, to nanoparticles 4, 50-52. 
HT is able to induce changes in vessel morphology leading to increased 
endothelial cell gap size where the nanoparticles may extravasate efficiently from the 
circulation. Pioneering work by Dewhirst’s group reported on increased extravasation of 
liposomes when s.c. implanted human ovarian carcinoma were subjected to HT at 42 °C 
whereas they remained impermeable for liposomes at 34°C 49-51. Recently Li et al 52 
demonstrated that in contrast to NT, a temperature of 41 °C for 1h was able to increase 
vessel permeability to liposomes in 4 different tumor types (murine B16 melanoma, 
BFS-1 sarcoma, LLC Lewis Lung Carcinoma and human BLM melanoma), but not in 
normal vessels. Moreover, this study demonstrated that HT caused significant liposome 
penetration in tumor tissue up to at least 27 μm from the tumor vessels. Vascular 
hyperpermeability remained for several hours after HT of which the duration varied in 
the different studies between 6 h 51, 8 h 52 and 24 h 53. The work by Kong et al in human 
ovarian carcinoma implanted in skin-fold window chamber bearing nude mice reported 
on 2-4 fold increases in liposomal uptake in heated tumors than in non-heated 51,54. 
Moreover, studies in cats with soft-tissue sarcoma showed 2-16 fold increase of 
liposomal drug delivery due to hyperthermia 55. Hyperthermia also increased the 
extravasation of small molecule drugs leading to increased drug uptake 56 and 
nanoparticulate systems such as polymers 57. Interestingly in the latter study, heat 
cycling (repeated hyperthermia treatments followed by cooling) caused an even further 
increased macromolecular drug carrier accumulation in the FaDU (human squamous 
cell carcinoma) tumors compared to a single hyperthermia treatment 57. Additionally, 
HT applied to elastin-like polypeptides-Dox was able to completely inhibit tumor 
growth compared to the free drug 58. Moreover, in a recent study by Bidwell et al. was 
shown that temperature-responsive polypeptide, which is based on elastin-like 
polypeptide, was able to inhibit tumor growth in a mouse model of breast cancer 59. 
Local induction of hyperpermeability can induce tumor selective liposome extravasation 
which is an important advantage of combining hyperthermia and liposomal 
chemotherapy in cancer treatment. An additional advantage comes from the use of HT 
to trigger release from thermosensitive liposomes in the tumor as will be discussed in 
the next section. In summary, hyperthermia has shown a prominent effect when applied 
in combination with radio-or chemotherapy in a multifactorial manner and is now an 
established treatment modality for patients with various types of cancer enhancing the 
effectiveness of radio and/or chemotherapy with limited to no side-effects 34-38. Novel 
therapies involving nanoparticle-mediated drug delivery provide attractive options for 
combination with hyperthermia benefitting the drug delivery process.  
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3. Thermosensitive liposomes  
Besides the above discussed benefits on drug accumulation, increased cellular 
sensitivity and improved nanoparticle delivery, hyperthermia may also be used to 
trigger drug release from liposomes composed of thermosensitive lipids. The idea of 
using TSL and HT for drug delivery was proposed in 1978 by Yatvin and Weinstein, 
who designed liposomes consisting of the thermosensitive lipids DPPC and DSPC 
undergoing gel-to-liquid phase transition at temperature (Tm) around 44 °C 60. DPPC 
undergoes gel-to-liquid transition at 41.3°C, at which the passive permeability of ions is 
enhanced. To fine tune drug release temperature and/or drug release rate DPPC can be 
mixed for instance with defined quantities of for example Lyso-PC 11, DSPC 27,60-62, 
DPPGOG 63 or PEG2000-DSPE 62. Thus, upon heat areas with increased permeability 
will occur in the bilayers of these TSL, allowing release of encapsulated drug (figure 1).  
 
 
 
Fig 1. Release of an entrapped hydrophilic marker (CF) from cationic thermosensitive 
liposomes into the tumor tissue upon hyperthermia. At 37 °C thermosensitive liposomes 
are stable, not releasing their content. Once heated, they release the encapsulated marker 
(green) into the surrounding tumor tissue. 
 
The initially described TSL underwent additional modifications in order to be 
stabilized in blood circulation by adding additional membrane components, such as 
HSPC and cholesterol 64, 65. Although stability was increased, these adaptions either 
compromised the desired transition temperature applied by mild hyperthermia (41-43 
°C) (DSPC and HSPC) or led to formulations that were no longer responsive to 
temperature change (high cholesterol content) 65. Further improvements of 
thermosensitive liposomes were achieved by decorating them with polyethyleneglycol 
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or oligoglycerol moieties for prolonged circulation 62, 63 and incorporating additional 
lipids e.g. lysolipid 11 or oligoglycerol-PG 63 in their membrane to further increase their 
membrane permeability at the phase transition temperature. 
Low temperature sensitive liposomes, LTSL, is the first heat-triggered release 
formulation of the anthracycline doxorubicin that reached pharmaceutical development 
(ThermoDox ®, Celsion Corporation, Columbia, Maryland, USA) and clinical 
application, and was originally developed by Needham and Dewhirst’s groups 11,66. The 
bilayer of this formulation is composed of the synthetic phospholipids DPPC (1,2-
dipalmitoyl-sn-glycero-phosphatidylcholine), MSPC (monostearoyl-sn-glycero-
phosphatidylcholine), and DSPE-MPEG-2000 (1,2-distearoyl-sn-glycero-3-
phosphatidylethanolamine-N-[methoxy(polyethyleneglycol)-2000] where the presence 
of the lysolipid MSPC is thought to cause formation of pores in the liposomal bilayer at 
the transition from solid to liquid phase of the main bilayer lipid DPPC at 41.3 °C 11. 
Mild hyperthermia (41-42 °C) could trigger almost complete drug release from LTSL 
within 20-40s at the melting temperature of 41.3 °C 67. LTSL were proposed for 
application in a novel intravascular drug delivery approach in which liposomes are 
administered systemically while HT is being applied to the tumor, causing immediate 
drug release from the liposomes upon their arrival in the tumor area 68. Thermodox has 
been used in two clinical studies – a Phase II trial in combination with local mild 
hyperthermia for patients with recurrent breast cancer of the chest wall, and in a Phase 
III trial combined with thermal ablation in patients with hepatocellular carcinoma 69, 70. 
From these studies limited information is available yet, however adverse effects 
of LTSL and RFA in the treated patients were observed which resembled free drug side 
effects including; -neutropenia, leucopenia, lymphocytopenia, alopecia, fatigue, nausea, 
anorexia, fever. These toxicities are related to the heat-induced release in the tumor 
region in combination with the intrinsic instability of LTSL formulation causing large 
quantities of LTSL-released free drug in circulation 69-71. LTSL in combination with 
hyperthermia in an intravascular release approach seems to be an attractive therapeutic 
option to improve doxorubicin delivery to tumors, but also leaves a room for further 
improvement by achieving more stable TSL formulations with rapid heat-triggered 
release and little to no premature drug release and related systemic toxicity. 
Several other temperature sensitive liposomal formulations have been developed 
in the past decade that use different lipids and lipid compositions to increase drug 
release at elevated temperatures from intrinsically stable liposomes. Lindner et al. have 
incorporated phosphatidyl-oligoglycerols (DPPGOG) in their formulation (DPPG2-
TSL) that contributes to prolonged circulation as well as to the thermosensitivity of the 
liposomal bilayer 63. DPPGOG has a transition temperature of around 42 °C, which in 
combination with DPPC allows temperature controlled release of entrapped water-
soluble molecules 63. In presence of serum DPPG2-TSL proved more stable than LTSL 
69. Regarding release, different proteins in serum, such as albumin and immunoglobulin 
G, influenced liposome stability depending on lipid composition 69. Also particle size 
appeared an important factor affecting doxorubicin release, as demonstrated for LTSL, 
which showed increased doxorubicin release at 37 °C with decreasing particle size. This 
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phenomenon was less prominent for DPPG2-TSL 72. Another strategy to achieve 
improved stability with remaining high levels of content release from thermosensitive 
liposomes has been proposed by Li et al. 62. In this study, lysolipid were omitted from 
the TSL, which were then further optimized with regard to lipid composition and 
density of DSPE-PEG2000. Five mol% of DSPE-PEG2000 showed higher release kinetics 
than lower PEG-densities and this formulation released 60% of its content in 1 min at 
42°C and 100% in 1h. The addition of more than 5 mol% of DSPE-PEG2000 destabilized 
the liposomal bilayer causing increased instability at 37 °C and lower encapsulation 
efficiency. Recently, this optimized PEG-TSL formulation proved more efficacious in 
the intravascular drug release approach in comparison to LTSL in a human BLM 
melanoma model 73. Tagami et al. developed a LTSL related thermosensitive liposome 
formulation named HaT: Hyperthermia activated cytoToxic, in which the MSPC and 
DSPE-PEG2000 were replaced by with Brij78 (polyoxyethylene stearylether, 4 mol %) 
25, 74-76. The comparison between HaT and LTSL showed 1.2-2 fold faster release 
kinetics for HaT at 40-42 °C reaching 90-100% release in 2.5 min. In comparison with 
LTSL, HaT was able to deliver 1.4 fold higher levels of doxorubicin to the heated tumor 
(mouse mammary carcinoma). Additionally, the combination of HaT with HT 
significantly improved antitumor efficacy when compared to LTSL 74. 
Although LTSL are at the forefront of pharmaceutical development and clinical 
application, and their application in the novel intravascular release approach holds 
promise, the intrinsic instability of this formulation and related risks for side effects are 
of concern. Novel formulations, lacking the lysolipid and with optimized densities of 
PEG-lipids, or other synthetic lipids such as DPPGOG or Brij-surfactants focus on 
further tailoring increased TSL stability in combination with (fast) heat-triggered 
release. 
 
4. Intravascular and interstitial drug release. 
When applying combinations of hyperthermia and TSL two different approaches 
can be followed. In the first one HT treatment is used to trigger interstitial drug release 
from liposomes that have accumulated in tumor tissue. The second approach triggers 
drug release intravascular from TSL that pass the heated tumor area. 
Whereas the interstitial drug release approach relies on traditional EPR mediated 
accumulation of nanoparticles in the tumor area, the novel intravascular release 
approach is not dependent on this process of liposome extravasation 68. Therefore, in the 
intravascular approach, heterogeneity in vessel permeability and nanoparticle 
penetration 7, 52, 77 is no longer an obstacle. Intravascular release of drugs from 
liposomes provides a continuous supply of drug to the tumor as long as the tumor is 
heated and drug-loaded liposomes pass the area. The established high intravascular drug 
concentrations in combination with hyperthermia increased interstitial fluid flow create 
drug gradients penetrating deeply into tumor tissue 68, 73. An additional advantage is that 
in this approach the drug is readily bioavailable for both tumor and endothelial cells 68, 
73, 78. 
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However, the intravascular drug release approach may suffer from drawbacks such as 
wash out of free drug from the tumor and related systemic side effects and requires 
precise heating of only the tumor area, which remains a challenge also in clinical 
practice. Therefore, although the intravascular release approach provides an efficacious 
delivery approach for drugs that are rapidly absorbed by tumor tissue in combination 
with precise tumor heating, the interstitial release approach, which relies on the content 
release from extravasated liposomes, can still be of significant value. 
In that approach, hyperthermia can also be used prior to liposome injection to 
first increase tumor vascular permeability and subsequent liposome accumulation at the 
tumor. Several studies have shown that hyperthermia increased extravasation of 
liposomes in various mouse tumor models and in feline sarcoma patients 51, 52, 54, 55. 
Alternatives to increase liposomal nanoparticle extravasation may also be used 
including the manipulation of tumor vasculature with biological agents increasing 
vascular permeability, e.g. TNF, IL-2 and Histamine causing more homogeneous 
nanoparticle and drug delivery 8, 79. Upon achieving optimal liposome levels within the 
tumor interstitium, a next heat trigger can be applied to induce drug release in close 
proximity to tumor cells, facilitating intracellular drug delivery. In order to better 
understand which treatment option could ultimately be used clinically, additional 
studies are required evaluating both approaches. In such evaluation the tumor type, the 
possibility for precise local heating, and the type of drug used are important parameters 
that should be taken into consideration.  
Image-guided drug delivery may provide an important tool in these studies and 
ultimately also in the clinic to monitor the localization of liposomes in tumors and their 
behavior.  
 
5. Image-guided drug delivery  
The possibility to monitor the intratumoral accumulation of liposomes during 
hyperthermia and subsequently their drug release would ultimately add significant 
benefit to the therapeutic outcome in the individual patient. Therefore, the development 
of non-invasive imaging techniques and imageable thermosensitive liposomes is of 
great clinical importance. Image–guided clinical intervention techniques using MRI, 
ultrasound or nuclear imaging such as X-ray computed tomography (CT), positron 
emission tomography (PET) and single-photon emission computed tomography 
(SPECT) are well established. PET and SPECT imaging are often used for visualization 
of liposome localization into certain types of tumors. For these purposes, liposomes can 
be labeled with radionuclides, from which the most often used are Tc-99m, In-111, Tl-
201, F-18, I-123 and 131 and Ga-67 2, 7, 55. For the application of image-guidance in 
TSL-hyperthermia mediated drug delivery MRI has great potential. First of all it 
provides a good soft tissue signal and thus morphological/anatomical information and 
second MR thermometry could evaluate temperature alterations in different dimensions 
within the heated tissue 23, 27. Thirdly, the hyperthermia-induced release of content can 
be monitored indirectly by co-release of an MRI contrast agent from the TSL. When 
inside the liposome, these contrast agents are not visualized due to the limited water 
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exchange across the bilayer. However, upon raising the temperature to the phase 
transition temperature of the bilayer, water exchange is increased and/or contrast agent 
is released from the liposomes thereby shortening the 1H MR relaxation time of the 
surrounding tissue 23. Co-encapsulating both chemotherapeutic drugs and MR imaging 
agents in one carrier was demonstrated to provide a valid tool for image-guided 
temperature-induced drug release. Viglianti et al. and Ponce et al. e.g. have used 
doxorubicin and manganese as MRI contrast agent in one carrier. With this approach, in 
preclinical studies the concept of “dose painting” was demonstrated by MRI 26, 80. 
However, manganese toxicity will limit the applicability of this approach 26, 80. An 
improvement of this concept was achieved by Lindner et al. who used the clinically 
approved MR contrast agent Omniscan in DPPGOG-containing TSL and proved that, 
when HT is applied, the contrast agent is released and could be successfully monitored 
by MRI 24. A similar approach was published by de Smet et al., who used the clinically 
approved MRI contrast agent Prohance co-entrapped with doxorubicin in traditional 
thermosensitive liposomes 27, 61. They demonstrated the feasibility of this approach in 
HIFU mediated mild hyperthermia in a HIFU-MRI system 27. The co-encapsulation of 
Prohance did not influence doxorubicin encapsulation or its release kinetics, whereas 
Prohance release at the transition temperature of the liposomes occurred simultaneously 
with doxorubicin 61. Moreover, this contrast agent did not display any cellular toxicity. 
Recently, several studies have reported on MRI guided HIFU-mediated mild 
hyperthermia together with TSL in murine, rat and rabbit tumor models 25, 27, 28, 81. In 
these studies, the combination of TSL with MRI guided HIFU hyperthermia resulted in 
higher doxorubicin concentrations delivered to the tumor when compared to TSL alone 
and free doxorubicin. Interestingly, the combination of LTSL with MR-HIFU 
hyperthermia in a rabbit tumor model showed increased doxorubicin delivery to the 
tumor core compared to LTSL alone and free doxorubicin treatment groups, of which 
drug delivery was limited to the tumor periphery 28. Normally, drug delivery to the 
center of the tumor, an area with decreased perfusion and increased interstitial pressure, 
is limited. An explanation for this phenomenon is that the combination of LTSL and 
MRI guided HIFU caused increased perfusion, convection and vascular permeability in 
the tumor. All these findings demonstrate the feasibility of imaging-guided drug 
delivery as a useful approach for online monitoring the delivery of heat to the tumor and 
subsequent drug release from TSL and intratumoral accumulation, which helps to refine 
the treatment. As it has been shown that drug delivery efficiency depends on the tumor 
type and morphological characteristics such as vascularization, necrosis and 
permeability, image-guided drug delivery may serve as a powerful tool to personalize 
hyperthermia-mediated TSL-chemotherapy for cancer.  
 
6. Targeted liposomes  
A second approach to improve drug bioavailability in combination with a further 
improvement in tumor (cell) selective intracellular drug delivery may come from active 
targeting of liposomes to the tumor. This can be achieved by decorating liposomes with 
targeting ligands specific for receptors uniquely or overexpressed on the target cells. By 
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doing so, this may result in higher levels of retention of liposomes at the tumor site, cell 
specific binding and drug delivery 2, 82-84. In addition, upon targeting an internalizing 
antigen, the ligand can induce receptor-mediated endocytosis of the liposomal 
nanocarrier, which upon intracellular processing may release the entrapped drugs 2, 83. 
Intracellularly released drug will be prevented from rapid diffusion from the tumor area 
and will be delivered across the cell membrane barrier close to its active site, which for 
most chemotherapeutic drugs is intracellular; in the cytosol or the nucleus. Via these 
ways targeting of liposomes may contribute to increased therapeutic efficacy.  
Regarding the targeting ligand, a careful selection is required, concerning its 
selective expression or overexpression on the target cell, possible shedding of the 
targeting ligand and its capacity for receptor-mediated endocytosis 85-89. Several 
targeting ligands have been studied for development of targeted liposomes, including 
antibodies and their fragments, peptides, vitamins, carbohydrates, nucleic acids and 
charged lipids. It is important that liposomal attachment of targeting ligands does not 
interfere with normal physicochemical characteristics of the liposomes and the targeting 
moiety such as size, stability, drug retention and receptor-binding affinity nor affects 
liposome pharmacokinetics, biodistribution and tumor accumulation 2, 83, 90, 91. 
Antibody targeting is the most commonly used and extensively studied means of 
targeting liposomes with encapsulated chemotherapeutic drugs. This is related to the 
usually high affinity of antibodies for their targets. Additionally, several monoclonal 
antibodies that have reached clinical application display therapeutic activity by 
themselves which can contribute to increased therapeutic activity, e.g. trastuzumab 
(Herceptin) targeting HER2 receptors overexpressed on some types of breast cancer 92, 
bevacizumab specific for the VEGF receptor which is in use as an inhibitor of 
angiogenesis 84, 92. 
For liposome targeting, basically two main approaches can be followed that are 
distinguished based on the target cell type; 1. vascular targeting, 2. tumor cell targeting. 
Vascular targeting does not rely on nanoparticle extravasation and has the advantage 
that circulating liposomes have direct access to tumor endothelial cells. Vasculature-
targeted liposomes often utilize proteins overexpressed on angiogenic endothelial cell 
membranes, such as integrins, adhesion molecules or growth factor receptors 93. Binding 
through these receptors may lead to liposome internalization by endothelial cells and 
subsequent drug release, which can thereafter induce endothelial cell death, vascular 
damage and subsequent massive tumor cell death. 
The second approach of tumor cell targeting relies on liposome extravasation 
into the tumor interstitium, where the targeting ligand can specifically recognize and 
bind the target receptor. Upon tumor cell binding, targeted liposomal chemotherapeutics 
have been demonstrated to improve therapeutic efficacy over non-targeted liposomes 94-
96.  
 
6.1. Tumor vasculature targeting.  
Angiogenesis, the formation of new blood vessels from preexisting ones is a 
crucial process in tumor growth and metastasis. Targeting of tumor vasculature to 
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interrupt this process has become an attractive approach to suppress tumor growth 
because of the important role tumor vessels play in tumor pathophysiology by providing 
nutrients and oxygen to the proliferating tumor cells. Hence, destroying endothelial cells 
in tumor vessels may affect a multitude of tumor cells. Tumor vasculature targeting can 
be achieved by the cell surface expression of angiogenesis-related receptors on the 
endothelial cells and their direct accessibility for circulating targeted liposomal 
therapeutics 97. Therefore, in contrast to tumor-cell targeted liposomes, they do not need 
to cross the endothelial cell layer and are not hampered by the relatively high 
intratumoral fluid pressure, which may prevent deep tumor penetration 98. Specific 
targets on tumor vasculature include αvß3 integrins 99, receptors for angiogenic growth 
factors (such as VEGFR, EGFR) 84, aminopeptidase N (e.g. CD13) 100 and the 
overexpression of negatively charged molecules 98.  
An extensively studied target for tumor vasculature-targeted liposomes is the 
VEGF receptor. VEGFR2 has been found upregulated on angiogenic endothelial cells 92 
and bevacizumab therapy has been developed for blocking VEGFR receptor function 
and thus angiogenesis. Although antibody therapy alone is efficacious in cancer 
treatment 92, their attachment to liposomes offers additional advantages. 
Immunoliposomes having both a specific antibody for tumor vasculature and a 
chemotherapeutic drug, which may have an additive or synergistic effect, may 
eventually have an increased therapeutic potential 101. Wicki et al. have shown that anti-
VEGFR2 immunoliposomes loaded with doxorubicin had an increased therapeutic 
efficacy when compared to antibodies alone in a Rip1Tag2 mouse model for 
insulinoma, in MMTV-PyMT mouse model for breast cancer, and in a HT-29 human 
colon cancer xenograft transplantation model 84. Additionally, anti-VEGFR2 
immunoliposomes were much more effective in reducing tumor growth compared to 
non-targeted pegylated liposomal doxorubicin 84. Several tumor vasculature specific 
peptides have been used for liposome targeting. The NGR peptide has been proven to 
interact selectively with aminopeptidase N (APN) isoforms (CD13) overexpressed on 
tumor vasculature and not on normal vasculature 100. Pastorino et al supported the idea 
that due to the internalizing properties of NGR epitope, liposomes after binding and 
internalization are degraded by lysosomal or endosomal enzymes, causing intracellular 
drug release and cytotoxicity. NGR targeted liposomes proved effective in reducing 
tumor vascularization and tumor growth as shown in an orthotopic neuroblastoma 
mouse model 100. More recently Loi et al. have shown that mice injected with 
aminopeptidase A (APA)-targeted Dox-containing liposomes, targeting perivascular 
cells, had a prolonged life span than control mice but shorter than mice treated with 
APN targeted Dox liposomes. However, the combination therapy of APN- and APA-
targeted Dox-containing liposomes led to the largest increase in life span compared to 
each of the individual treatments. Moreover, the combination treatment was able to 
cause massive destruction of tumor vasculature with depletion of endothelial cells and 
the pericytes 102. Another study by Moura et al. demonstrated that the F3-peptide 
targeted liposomes (binding to NH2 terminal domain of nuclein) were able to target 
both tumor and endothelial cells in human orthotopic tumors, implanted in the 
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mammary fat pad of nude mice 103. RGD-targeted liposomes represent another 
interesting vasculature-targeted liposome formulation directed to αvß3 integrins 
overexpressed on angiogenic tumor vasculature. In several studies it has been 
demonstrated that RGD-targeted liposomes are specific for proliferating tumor 
vasculature and are able to decrease tumor growth in comparison with non-targeted 
formulations 99, 104, 105. An alternative way of targeting tumor vasculature involves the 
use of cationic lipids incorporated in the liposomal bilayer for specific interaction with 
anionic molecules overexpressed on angiogenic endothelial cell membranes 106, 107. 
These anionic molecules are part of the glycocalyx of the endothelial lining: 
glycoproteins, glycolipids, proteoglycans whose distribution on blood vessels is patchy 
and heterogeneous. In addition, the sluggish and irregular blood flow in tumors 
facilitates the selective targeting of cationic liposomes to angiogenic endothelial cells. 
Alternatively, Ho et al. have shown that cationic liposomes can be opsonized by yet 
unidentified proteins inducing specific binding to angiogenic endothelial cells . Images 
in figure 2 represent an example of tumor vasculature targeting of cationic liposomes 
described in Dicheva et al. 2013 . In this study vasculature was visualized in green by 
the constitutive expression of green fluorescent protein (GFP) in endothelial cells. 
Cationic liposomes (in red) can be seen as immobile patchy fluorescent hotspots 
attached to the vessel wall. In several studies it was shown that cationic liposomes 
loaded with chemotherapeutic drugs were able to diminish tumor growth and prolong 
survival when compared to control non-cationic formulations 107, 110-112. 
 
 
 
Fig 2. Binding of cationic thermosensitive liposomes to angiogenic tumor vasculature of 
B16BL6 window chamber bearing mice 24h after liposome injection. Liposomes were 
injected at a concentration of 5 μmol lipid and were labeled with rhodamine-PE (red). 
Tumor vasculature is visualized in green due to the expression of GFP protein in the 
endothelial cells. Unpublished observation from a study by Dicheva et al 19. 
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In conclusion, the use of liposomal therapeutics targeted to tumor vasculature 
represents a promising approach in cancer therapy. The angiogenic tumor endothelium 
offers easy access and opportunities for specific recognition for circulating vasculature-
targeted liposomes. The direct attack on tumor vasculature and induction of vascular 
damage will affect tumor cells that strongly depend on the supply of oxygen and 
nutrients. In this way the cytotoxic action targeted towards endothelial cells will induce 
death of a multitude of underlying tumor cells. 
 
6.2. Tumor cell targeting. 
Next to vascular targeting, liposomes can be designed for tumor cell targeting. 
An important requirement for this approach is extravasation of nanoparticles through 
the angiogenic tumor endothelium, a process which requires small size and prolonged 
presence of liposomes in systemic circulation. Upon extravasation, liposomes come in 
close proximity of tumor cells allowing the targeting ligand to bind to tumor cell 
specific receptors. The binding will increase the retention of the nanoparticle in the 
tumor and prevent wash out of liposomes from the tumor to the circulation. Ligand-
specific binding may also promote internalization. Strategies for tumor cell targeting 
have been developed involving both antibodies and peptides specific for tumor cell 
surface markers. For instance, targeting of HER2 overexpressing breast cancer has been 
achieved using anti-HER2 immunoliposomes. A study by Park et al. demonstrated that 
anti-HER2 immunoliposomes displayed significant therapeutic efficacy in four different 
HER2 overexpressing breast xenograft models. Anti-HER2 immunoliposomes were 
much more efficient in reducing tumor growth than free doxorubicin, non-targeted 
liposomal doxorubicin or anti-HER2 MAb (trastuzumab) 13. This study demonstrated 
that conjugation of a drug-loaded liposome to a therapeutic antibody can exert dual 
antitumor activity. Another potential receptor for targeted liposomes, which is 
overexpressed on tumor cells, is the EGF receptor. Mamot et al. developed EGFR-
targeted immunoliposomes and reported higher cellular toxicity of the encapsulated 
drugs by EGFR-targeted immunoliposomes compared to non-targeted liposomal drug in 
EGFR-overexpressing cancer cells, thereby demonstrating the importance of active 
intracellular drug delivery 113. In addition, superior tumor growth inhibition was 
demonstrated for these immunoliposomes when compared to non-targeted liposomes or 
free drug 114. An important development is the clinical application of EGFR-targeted 
doxorubicin liposomes in a phase 1 trial. Results from this study demonstrated the 
treatment was tolerable and warrants further testing of this targeted liposomal 
nanomedicine in a phase II trial 115. It is important for tumor cell targeting that the 
targeting ligands do not interfere with liposome pharmacokinetics and biodistribution 
and in that sense promote optimal liposome extravasation similar to non-targeted 
liposomes. When using whole antibodies, exposure of the Fc-domain may interfere with 
liposome circulation and thus tumor accumulation 90, 91. In order to diminish fast 
clearance, limited antibody density should be chosen or the Fc-domain should be 
abandoned completely by using antibody fragments (Fab’2, Fab’, scFv, or single 
domain variable fragments) attached to the liposomes. Griffiths et al. have shown a 
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superior amount of doxorubicin delivered to tumor cells by Fab-targeted liposomes in 
comparison with non-targeted liposomes and these liposomes hold promise for in vivo 
application 116. In another study by Pastorino et al., mice with neuroblastoma, treated 
with doxorubicin-liposomes targeted with Fab’ specific for disialoganglioside GD2 
overexpressed on these tumors, exhibited prolonged survival over mice treated with 
non-targeted Dox-liposomes or free doxorubicin 117. Allen et al. demonstrated that 
internalization of targeted liposomal chemotherapy is of crucial importance for efficacy, 
by showing that doxorubicin loaded internalizing anti-CD19-targeted liposomes caused 
improved survival in lymphoma bearing mice compared to those injected with non-
targeted or anti-CD20-targeted non-internalizing liposomes 89. In addition to vasculature 
targeting, tumor cell targeting can provide a powerful tool to increase the efficacy of 
chemotherapy due to the specific uptake of liposomes in tumor cells. However, unlike 
vascular targeting, tumor cell targeting may require various specific antibodies and 
liposomal conjugates for different tumor types and even tumor type subclasses as they 
will greatly differ in the expression of biomarkers. This will limit the development of a 
general antibody targeted treatment approach for large groups of tumors, but will 
require the availability of a multitude of targeted formulations and also screening of 
patients for biomarker expression. An additional disadvantage could be the so-called 
binding site barrier phenomenon as described for monoclonal antibodies by Weinstein 
et al. 118. Tumor cell targeted immunoliposomes upon extravasation may bind 
immediately to the first receptorpositive tumor cells encountered, being those located 
perivascularly, thereby preventing liposomes and drug from further penetration into the 
tumor tissue. The use of whole antibodies in this respect may, also upon extravasation in 
the tumor, promote Fc-receptor mediated uptake by tumor associated macrophages, 
preventing efficient tumor cell drug delivery 90,91. Therefore, the use of antibody 
fragments may not only prevent rapid uptake of liposomes by tissue macrophages in 
liver and spleen, but also aid to escape Fc-receptor mediated endocytosis by 
macrophages present in perivascular tumor regions and promote tumor cell specificity 
116, 117. 
Tumor cell targeted liposomal chemotherapeutics have demonstrated potential to 
improve tumor specific drug delivery and improved bioavailability in preclinical 
studies. Further studies will now have to demonstrate clinical benefit. It is encouraging 
that such studies were initiated recently. Despite the specific delivery and the higher 
uptake of liposomes in tumor cells due to internalization, there is still room for 
improvement of this targeted drug delivery concept. Usually liposomes are slowly 
degraded by tumor cells resulting in suboptimal bioavailable drug concentrations 8. 
Therefore, application of an external trigger, e.g. heat, can be an important means to 
achieve intracellularly triggered drug release to improve and control drug bioavailability 
from targeted liposomes 62, 63. Such a heat trigger will in addition also improve 
extravasation of tumor cell targeted nanoparticles 73. Therefore, the combination of heat 
with liposomes that are targeted and thermosensitive may help to further improve 
liposomal chemotherapy. 
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7. Targeted thermosensitive liposomes. 
Despite the various approaches developed to improve tumor drug delivery and 
drug bioavailability such as improving nanoparticle extravasation, triggered release and 
cell specific targeting, still further improvement could be achieved, for instance from 
smart combinations of these individual approaches. Therefore, recent progress in the 
development of targeted liposomes with heat-induced delivery and drug release 
properties will be reviewed in this section. Such targeted and triggerable systems can 
improve tumor retention through interactions with cells, target the nanoparticles 
specifically and can be triggered for drug release upon intracellular arrival, all 
contributing to improved drug bioavailability and thus efficacy. From the point of view 
of the TSL, a combination with targeting can help to improve TSL tumor retention, 
provide cell specific drug delivery and intracellular drug distribution upon heat. From 
the point of view of the targeted liposomes, designing them with a thermosensitive 
bilayer and apply them with a heat trigger may enhance tumor accumulation and trigger 
intracellular drug release close to their molecular targets. Although several different 
strategies can be applied to improve drug bioavailability from targeted and internalized 
liposomal nanocarriers, e.g. using pH dependent fusogenic peptides 119 or lipids 120, 
light-sensitive probes enhancing endolysosomal escape 14, we here focus on the use of 
heat and thermosensitive liposomal bilayers in combination with cell-specific targeting. 
Targeted TSL (TTSL) will require the attachment of specific ligands like 
peptides and antibodies to the liposome or the incorporation of cationic lipids in their 
bilayer (figure 3).  
 
 
 
Fig 3. Schematic representation of three different approaches to target thermosensitive 
liposomes. Peptides attached to PEG (right), antibody conjugated to PEG (bottom) and 
cationic lipids in the lipid bilayer (left). 
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When TSL are targeted to the tumor vasculature, the intravascular release approach may 
be exploited more optimal for delivery of high quantity of chemotherapeutic drugs in 
the tumor area. For example, the current approach for intravascular drug release requires 
ultra-fast releasing TSL formulations, which unfortunately are characterized by intrinsic 
instability and risks for increased free drug toxicity. As an alternative, more stable 
TTSL could be targeted to tumor vasculature from which heat- triggered release may 
render control over drug release and in combination with the improved stability cause 
less premature drug release. In such an approach one needs to determine the optimal 
sequence of hyperthermia and nanoparticle administration to achieve maximal tumor 
accumulation, either at the vasculature, or after extravasation at the level of the tumor 
cells and efficient HT triggered drug release. Tumor vasculature targeted TSL will be 
bound to or internalized by angiogenic endothelial cells from where a heat trigger can 
release the drug extra-or intracellularly (figure 4).  
 
 
 
Fig 4. Schematic representation of targeted thermosensitive liposomes bound to tumor cells 
and endothelial cells (A), triggered release (B) and nuclear drug uptake (C). 
 
From these intravascular or intracellular release sites drug may effect endothelium and 
upon penetration into tumor tissue, also tumor cells. TTSL may have additional benefit 
by targeting yet unidentified micrometastases. In comparison with non-targeted 
liposomes, TTSL, due to their high affinity for tumor vasculature or tumor cells may 
reach and specifically accumulate into these micrometastastic nodules and in a targeted 
way deliver their drug contents passively into these tumors. Upon equipping these 
TTSL with contrast agents, they may aid visualization of metastatic loci and subsequent 
local heating, e.g. by using HIFU to trigger drug release.  
Although literature on targeted thermosensitive liposomes is limited, several 
groups have started to explore this novel strategy of targeted temperature-triggered drug 
delivery (Table 1).  
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Table 1. Overview of targeted thermosensitive liposomes applied with external 
hyperthermia.  
 
 
 
In 2002, Gaber et al. described the first TTSL formulation in a paper on folate-
targeted TSL15. These TTSL loaded with doxorubicin were able to circumvent 
multidrug resistance through folate receptor mediated liposome internalization and 
hyperthermia triggered intracellular drug release. More recently, Puri et al. and Smith et 
al. developed affibody-conjugated thermosensitive liposomes specific for HER2 
positive tumor cells 18, 111. They demonstrated 10-fold increased specificity of these TSL 
in vitro in comparison with non-targeted liposomes in HER2 positive cells and a lack of 
binding to HER2 negative cells. Additionally, hyperthermia at 45 °C for 20 min caused 
substantial release of a liposome encapsulated marker in the cytosol. Similar TTSL, 
loaded with doxorubicin were able to deliver 2-3 fold more doxorubicin into HER2 
positive cells in comparison with non-targeted TSL. Therefore, these liposomes 
combining both targeting and triggered release properties in one carrier hold promise for 
improved efficacy in breast cancer treatment 111. A drawback of targeted liposomes may 
be their eventual uptake by acidic compartments in cytosol (endosomes, lysosomes) 
where the low pH may hinder the escape of the heat- released drug from these 
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organelles. Kullberg et al. indeed demonstrated the problem of endo/lysosomal escape 
of TSL released contents 16. However, they also presented a potential solution for this 
problem by proposing the use of a pore-forming molecule. TTSL were equipped with 
lysteriolysin O, which is able to create pores in the endosomal membrane, thus allowing 
the released liposomal content in the endosomes to reach the cytosol 17. In this study, 
TTSL targeted to HER2 overexpressing mammary epithelial cells were able to deliver 
22-fold higher amount of the encapsulated liposome marker (calcein) into HER2 
positive cells than to HER2 negative ones. In vivo studies accessing efficacy and 
possible toxicity to normal cells of this advanced drug delivery approach is not yet 
available. 
Besides tumor cell targeting some groups also addressed tumor vasculature 
targeting of TSL. Dreher et al. have designed thermosensitive liposomes targeted to 
tumor vasculature through cyclic NGR peptides exposed on the liposomal surface 20. 
These liposomes showed a potential for improving chemotherapy due to their high 
specificity for CD13+ cells in vitro and demonstrated clear temperature-release kinetics 
when hyperthermia was applied. Recently, we developed another novel targeted 
thermosensitive liposome formulation containing cationic lipids in their bilayer 19. 
Similar to Dreher’s approach, our cationic TSL displayed specific binding to angiogenic 
endothelial cells, but in addition also to tumor cells in vitro and in vivo. Moreover, these 
dual-targeted liposomes were stable at physiological conditions and released their 
content extra-and intracellularly under hyperthermia both in vitro and in vivo 19. 
In a related field of magnetic targeting and alternating magnetic field (AMF)-
induced hyperthermia several additional examples of triggering content release from 
targeted liposomes are available. The difference here is that the development of heat 
occurs in the liposome itself through interaction of the AMF with the entrapped 
magnetic nanoparticles causing heat 121. Pradhan et al. reported on the development of 
both biologically (by a folate ligand) and physically (by a magnet) targeted TSL 122. 
These liposomes yielded an increase in doxorubicin uptake as compared to Doxil or 
non-magnetic folate targeted liposomes in cells overexpressing a folate receptor. 
Additionally, magnetic hyperthermia was able to increase cellular toxicity of these 
liposomes. Kikumori et al. targeted in vivo magnetoliposomes to HER2-positive breast 
cancer cells and proved a significant tumor regression in the AMF-hyperthermia treated 
group 123. Therefore, targeted magnetoliposomes in combination with AMF-induced 
hyperthermia may also provide a powerful tool in cancer treatment. 
In conclusion, the field of TTSL in combination with HT triggered drug release 
is underexplored thus far, however promising achievements are emerging. Yet, firm in 
vivo proof of efficacy of this approach proving the benefits of TTSL is scarce and 
should be a focus for near future studies. Especially in combination with imageable 
TTSL this approach could be further optimized by image-guidance through 
visualization of tumor specific targeting and identification of possible micrometastases 
which could next be heated to achieve rapid and maximal drug delivery. 
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 Conclusion. The application of targeting and of heat-triggered drug release 
from thermosensitive liposomes represent further improvements of conventional 
liposomal chemotherapy. Targeted liposomes benefit from high specificity for tumor 
cells and/or tumor vasculature, which will increase their retention in tumors and 
promote liposome internalization and intracellular drug delivery. Thermosensitive 
nanoparticles combined with  hyperthermia can also help to overcome the low drug 
bioavailability of conventional liposomes by improved tumor accumulation and 
triggered drug release from the nanoparticles. When combining the increased liposome 
specificity from targeted liposomes with temperature sensitive bilayers and 
hyperthermia, further improvement of intracellular drug delivery can be achieved. To 
achieve this, various tools are available, that should be applied in an optimal way to 
guarantee efficient drug delivery. Such combinations together with image-guided drug 
delivery have potential to improve the therapeutic outcome of liposomal chemotherapy 
for cancer and warrants further personalization of cancer chemotherapy. 
 
Expert opinion. Liposomal encapsulation has improved cancer chemotherapy in the 
past decade. Stable drug entrapment in small (<100 nm) long-circulating liposomes has 
contributed significantly to improved treatment of cancer patients. Up to now clinical 
outcome demonstrates major benefit of this approach to decrease toxicity of 
chemotherapy. Although therapeutic activity has been clearly observed in various tumor 
types, in general no strong improvement was observed compared to free drug treatment. 
This can be explained by several factors including limited tumor accumulation and 
specificity of liposomal nanoparticles, low bioavailability of drug contents due to (too) 
stable entrapment and lack of control of drug release. Many novel approaches have been 
proposed in the past years to tackle these issues and thereby improve liposomal 
chemotherapy. Two key approaches for improvement are the subject of this review 
being cell-specific targeting and temperature-controlled drug release.  
Cell specific targeting of liposomal nanoparticles can benefit tumor specificity 
of drug delivery by recognition of cell surface moieties that distinguish tumor 
vasculature or tumor cells from normal tissues. Targeting tumor vasculature overcomes 
the important hurdle of nanoparticle extravasation into tumor tissue and can potentially 
affect a multitude of tumor cells upon drug delivery to and damaging of single tumor 
vessels. Important requirements are the targeting of tumor vasculature specifically, 
using angiogenesis-specific receptors, and delivery of drugs able to effectively impinge 
on endothelial cells. Tumor cell targeted nanoparticles require extravasation across the 
tumor vascular endothelium in order to access tumor cell specific receptors for binding. 
Such nanoparticles in principle do not promote increased total tumor drug delivery 
levels, but rather the precision and intracellular localization of the chemotherapy. 
Specific ligands are available as well as conjugation strategies for nanoparticle 
assembly to allow for the targeted approach and preclinical studies have demonstrated 
therapeutic benefit. Yet, clinical application employing targeted liposomal 
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chemotherapy has been initiated and will hopefully demonstrate therapeutic benefit of 
the targeting.  
Hyperthermia to improve tumor accumulation of nanoparticles and control drug 
release from thermosensitive liposomes provides an attractive therapeutic option to 
improve liposomal chemotherapy by overcoming the tumor vascular barrier and 
providing control of intratumoral delivery of bioavailable drug  from the nanoparticles. 
Several thermosensitive liposomal formulations demonstrated improved therapeutic 
activity compared to doxorubicin or non-thermosensitive doxorubicin liposomes in 
preclinical setting. Triggered drug bioavailability can be achieved by two different 
strategies; interstitial and intravascular drug release. The interstitial release approach 
relies on hyperthermia-enhanced liposome extravasation and tumor accumulation 
followed by triggered interstitial drug release in close proximity of the tumor cells. The 
novel intravascular drug delivery approach uses tumor specific heating to trigger drug 
release from circulating thermosensitive liposomes in the tumor vasculature, thereby 
inducing tumor drug influx along the created drug gradient from the high concentration 
in tumor vasculature into the tumor tissue. This promising approach requires very 
precise heating of the tumor and fast release from the nanoparticle in combination with 
drugs that are rapidly taken up by tumor vasculature and/or tumor cells. The application 
of lyso-PC based thermosensitive liposomal doxorubicin with hyperthermia or 
radiofrequency ablation is currently being evaluated in clinical trials, which is an 
important development. Although conclusions on the outcome of these studies are not 
available yet, improvements on thermosensitive liposome design have been proposed to 
improve liposomal drug retention in circulation in combination with effective and 
intratumorally triggered drug release. In addition, the application of imaging and 
liposomal encapsulation of contrast agents has been developed to allow for online 
monitoring of tumor delivery of both heat and drugs through image-guidance and will 
benefit further personalization of chemotherapy delivery.  
Combinations of both the targeted and temperature triggered drug delivery 
approaches have been described and can help to further improve tumor specific 
chemotherapy delivery by several means. In case of intravascular drug release from 
thermosensitive liposomes an increased retention or prolonged presence of the 
nanoparticles in tumor vasculature through promoting tumor vascular interaction, could 
ensure improved and more specific tumor drug delivery. Next, hyperthermia can 
increase tumor vascular permeability and promote extravasation of tumor cell targeted 
nanoparticles and their interaction with tumor target cells. A temperature shock may 
further promote drug bioavailability from tumor cell targeted liposomes either extra- or 
intracellularly. Moreover, targeted systems may aid identification of distant metastases 
and promote heat triggered drug delivery at these sites upon image- guidance.  
Up to now only a limited number of studies focused on the targeted 
thermosensitive drug delivery approach. Near future in vivo studies will have to 
demonstrate the therapeutic potential of this novel strategy. 
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Discussion  
 
One of the crucial problems with current cancer chemotherapy is related to a 
small therapeutic window because of its toxicity to vital organs such as bone marrow, 
heart, liver, kidney and mucosal surfaces. This toxicity in general does not allow for 
optimal dosing to obtain important tumor responses. Moreover certain pathophysiologic 
characteristics of tumors further impede sufficient intratumoral drug delivery. The 
research described in this thesis was dedicated towards improving chemotherapy. This 
can be a reason for relapse of the tumor and the appearance of drug resistance 1. The 
medical research community has searched for therapies which target specifically tumor 
cells while sparing normal cells. Although remarkable progress has been made in cancer 
therapy, many cancers are still little or nonresponsive to these conventional therapies. 
Therefore, new modalities to improve chemotherapy, that can increase therapeutic 
efficacy, need to be investigated. In this thesis, liposomes were chosen as a means to 
increase therapeutic indexes of anticancer drugs. The aim was to locally deliver 
chemotherapeutic drugs, such as doxorubicin to the tumor in order to increase efficacy 
and to reduce side effect to normal tissues (Fig 1). Although liposomes have been 
proven successful in several tumor types, their efficacy is often not better to the free 
drug. Progression-free survival and overall survival of patients treated with pegylated 
liposomal doxorubicin (PLD) and free doxorubicin remain similar 2. However the 
benefits are associated with a decrease of toxicities: PLD decreases cardiotoxicity, 
myelosuppression, alopecia and vomiting. Reasons for the lack of strong improvement 
of liposomal chemotherapy 2-4 is the non-specific nature of liposomes leading to limited 
tumor accumulation 5 and their high intrinsic stability 6-8 causing low drug 
bioavailability. Liposomes have to circulate for days in order to reach the tumor in high 
concentrations 9. Liposome accumulation in the tumor tissue competes with their 
accumulation in liver and spleen and only 10% or less of the injected dose will 
eventually reach the tumor 5. Doxil has long circulation due to its stability and ability to 
escape clearance by the RES. However, due to its stability the doxorubicin 
bioavailability is low 8. Seynhaeve et al. demonstrated that Doxil is taken up 
intracellularly in lysosomes, where it is retained intact for a relatively long period, 
which impairs delivery of doxorubicin to the nucleus 10. Therefore, a drug delivery 
system which possesses specific affinity for the tumor and ability to release its drug 
payload at the tumor site, is needed. For this purpose, we created targeted 
thermosensitive liposomes (TTSL), which incorporate both the targeting and triggered 
functions of a liposome in one carrier. In this way, both low tumor retention and low 
drug bioavailability can be circumvented. 
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Fig 1. Theoretic distribution of a free drug (A) and liposomal drug (B) 
throughout the body, emphasizing the difference in volume of distribution. 
 
Liposome formulations  
In order to increase liposomes retention in the tumor and drug bioavailability, 
the liposomes used in the presented work were both targeted and thermosensitive. They 
contained in their lipid bilayer thermosensitive lipids, which upon HT were able to 
translocate and create permeable areas in the liposomal membrane for transition of the 
entrapped drugs through it. Thus, HT applied locally to the tumors actively triggered 
drug release from TSL. Once released in the tumor area, the free drug can cross the cell 
membranes and reach its site of action, the nucleus. Additionally, to further improve 
drug delivery, our liposomes were targeted. When liposomes are targeted, they can 
recognize specific receptors either on tumor or endothelial cells, which can promote 
receptor-mediated endocytosis. Thereafter, the endocytosed liposomes may release 
intracellularly the encapsulated drug, favoring transport to the nucleus. Cellular 
targeting is due to the specific affinity of liposomes decorated with molecules 
recognizing cell surface moieties distinguishing tumor cells from normal cells. Using 
these improvements of liposomes, we aimed at increasing therapeutic efficacy of 
liposomal chemotherapy. In the studies described we followed two main ways of 
liposome targeting based on different cell types: tumor cell targeting and vascular 
endothelial cell targeting. Endothelial cell targeting has the advantage that liposomes do 
not need to extravasate through tumor vasculature and endothelial cells are easily 
accessed by liposomes. This targeting can contribute to killing of millions of tumor cells 
relying on oxygen and nutrients derived from tumor vasculature. On another hand, 
tumor cell targeting relies on extravasation of small and long circulating liposomes that 
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will eventually reach tumor cells. The close localization of liposomes to tumor cells will 
allow binding between the targeting ligand and cell-specific receptors. This specific 
binding prevents the liposomes from wash out from the tumor to the circulation. In 
comparison to vascular targeting, tumor cell targeting involves the use of different 
targeting ligands specific for tumor cell receptors in the different tumor types expressing 
different biomarkers. Therefore, this targeting approach cannot depend on a unique 
molecule attached to the liposome, which limits its application. Another disadvantage of 
tumor cell targeting is the so-called binding site barrier phenomenon 11. Tumor cell 
targeted immunoliposomes may bind immediately to the first receptor-positive tumor 
cells encountered upon extravasation, being those located perivascularly, thereby 
preventing liposomes and drug from further penetration into the tumor tissue. The use of 
whole antibodies in this respect may, also upon extravasation in the tumor, promote Fc-
receptor mediated uptake by tumor associated macrophages, preventing efficient tumor 
cell drug delivery 12, 13. Therefore, the use of antibody fragments may not only prevent 
rapid uptake of liposomes by tissue macrophages in liver and spleen, but also aid to 
escape Fc-receptor mediated endocytosis by macrophages present in perivascular tumor 
regions and promote tumor cell specificity 14, 15. Anti-HER2 immunoliposomes have 
demonstrated significant antitumor efficacy in several tumor models when compared to 
nontargeted immunoliposomes 16. Mamot et al. have reported on a significant tumor 
growth inhibition by EGFR-expressing immunoliposomes compared to nontargeted 
immunoliposomes 17. Tumor cell targeting has achieved promising results in cancer 
treatment but there is still a room for improvement. Despite its advantages, this 
targeting suffers from the fact that once liposomes reach and bind specifically to tumor 
cells, drug release is slow and inefficient, which limits its therapeutic efficacy. 
Therefore, the combination of targeted and triggered release features of liposomes in 
one carrier may help to overcome some of the drawbacks of currently available 
liposomal chemotherapy. This recently emerging field of targeted thermosensitive 
liposomes (TTSL) in cancer chemotherapy will benefit from the increased tumor 
retention of the carrier together with triggering drug release upon its arrival in the 
tumor. Several approaches are available for enhancing drug bioavailability. In the 
presented work, we focus on the use of HT and thermosensitive liposomes in 
combination with cell-specific targeting. Although the field of TTSL has already 
showed promising results, there is still more to be done concerning its therapeutic 
efficacy 18-26 . In this thesis, two targeted thermosensitive liposome formulations were 
investigated; cationic thermosensitive liposomes (CTSL in Chapter 2 and 3) and RGD-
targeted thermosensitive liposomes (RGD-TSL in Chapter 4). These two formulations 
differed in the targeting ligands. In the case of CTSL, cationic molecules were 
incorporated in the liposome bilayer for specific binding to overexpressed anionic sites 
on the endothelial or tumor cell membranes. RGD-TSL made use of RGD peptides 
attached to the lipid bilayers for recognition of αvβ3 integrins overexpressed on 
endothelial cells and some types of tumor cells. Both formulations showed stability at 
physiological temperatures of 37 °C and slightly started to release their drug payload at 
39 °C. The observed release kinetics are in accordance with non-targeted 
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thermosensitive liposomes proven successful for in vitro and in vivo heat-triggered 
content release 27 . Maximum drug release of our TTSL occurred at temperatures 
between 41-43 °C, which are clinically tolerable temperatures locoregionally and in 1h 
they released almost 100% of their content, time for heating which can be applied in 
clinics. Besides their temperature sensitive properties, both CTSL and RGD-TSL could 
bind specifically to tumor and endothelial cells. Upon binding, the targeted liposomes 
were internalized into the acidic cellular organelles. Using lysotracker as a lysosomal 
marker, we could prove that a big part of both CTSL and RGD-TSL are internalized 
into the lysosomes (Chapter 3 and 4). The applied HT triggered drug release into 
lysosomes. The released Dox there could have difficulties to escape the lysosomes 
because of the low pH in these organelles, which may cause precipitation of the drug 28. 
An interesting way to stimulate Dox release from acidic compartments in cytosol might 
be the use of pH-sensitive functions that affect endo-lysosomal membrane stability at 
low pH. This approach caused faster nuclear Dox accumulation compared to non-pH 
sensitive liposomes 29-31. Triggered intracellular Dox release in vitro from CTSL and 
RGD-TSL accumulated in cytoplasmic vesicles was visualized by live cell confocal 
microscopy as intracytoplasmic fluorescent nanobursts. The released Dox into 
lysosomes upon HT resulted in its translocation to the nucleus in the tested tumor cell 
lines and remained predominantly cytoplasmic in the endothelial cells. Reason for this 
can be slower lysosomal release of Dox from endothelial cells compared to tumor cells. 
As a consequence of Dox retention in acidic compartments, we speculate that we could 
not see improved cytotoxicity with neither CTSL or RGD-TSL when HT was applied. 
However, when normothermia (NT) was applied, Dox-CTSL were more toxic to all the 
tested tumor cell lines and endothelial cells than TSL, which again confirms their 
targeting nature. In accordance with in vitro results, in vivo intravital imaging has 
shown binding of CTSL and RGD-TSL to tumor vasculature, something which was not 
observed with TSL. In accordance with Thurston et al. 32 , in both cases binding started 
approximately 20 min after injection and increased up to 24h. Intravital imaging 
techniques showed also that although the concentration of both formulations in 
circulation decreased up to 5h after injection, they were still present in circulation in this 
time frame that was used for liposomes binding to tumor vasculature. Additionally, the 
applied HT in vivo could increase liposome extravasation, which was demonstrated by 
increased fluorescence signal and quantification of images. Besides increased 
extravasation, HT in vivo triggered massive drug release from both CTSL and RGDTSL 
(Chapter 3 and 4). The amount of the released drug delivered to the tumor was higher 
for CTSL compared to TSL, which is due to the targeting nature of this formulation 
contributing to increased tumor retention and therefore increased drug delivery. The 
amount of delivered Dox to the tumor from TSL and RGD-TSL was not significantly 
different. Additionally, both targeted formulations showed stability in vivo in the 5h 
targeting phase, which was demonstrated by no premature Dox release. Moreover, in 
the case of Dox-CTSL, a massive vessel destruction could be observed already 24h after 
liposome injection and was not observed when Dox-TSL were applied, which again 
proves the specificity of the targeted liposomes for tumor vasculature. This is in 
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accordance with studies from other groups using non-temperature sensitive 33,34, 
cationic formulations. The performed pharmacokinetic studies with Dox-CTSL show 
that despite the targeting nature of liposomes, they were not cleared faster from 
circulation than TSL (Chapter 6). This is in agreement with the intravital image 
analysis. Biodistribution studies using initial HT treatment demonstrated that due to the 
binding features of CTSL, which might be increased upon HT, and HT-induced 
extravasation, CTSL delivered more Dox to the tumors than TSL. Efficacy studies in 
B16BL6 melanoma show that HT had a significant effect on CTSL concerning tumor 
growth inhibition and prolonged survival. However, the efficacy study in B16BL6 did 
not show a therapeutic effect of the targeted formulation and they did not perform better 
than non-targeted formulation. Reasons for the lack of suppression in tumor growth as 
well as prolonged survival could be that the used tumors were too small, the tumor 
model was fast growing or that we should use a different treatment schedule. Efficacy 
study in LLC Lewis lung carcinoma with preheat treatment for increased extravasation, 
demonstrated that two HT treatments show slightly higher tumor inhibition than one HT 
treatment. A preheating phase for opening up the tumor vasculature for passive 
accumulation of TSL has already been reported by Li et al 35. When tumors were 
preheated for 1h at 41 °C, long-lasting gaps between the tumor vascular endothelial 
cells were created, thus allowing liposome penetration into the tumor tissue to at least 
27.5 μm in radius from tumor vasculature 36. Therefore, it might be useful to continue 
performing efficacy study by using two HT treatments in this tumor model including 
more mice or testing another tumor model with the use of bigger tumors. Therefore, 
there is still a room for improvement in order to reach an optimal formulation showing 
optimal therapeutic results.  
 
Hyperthermia treatment scheduling  
Hyperthermia is used in these studies as a mean to increase liposome 
accumulation in the tumor and to trigger drug release. There are two different 
approaches for triggering drug release: intravascularly or interstitially. Each release 
approach requires adaptation of the liposomal carrier. Intravascular release approach 
was suggested by Manzoor et al. 37 and is characterized by HT treatment, which is 
applied to circulating liposomes thus creating gradient for drug transfer from the high 
drug concentration in the tumor vasculature towards tumor tissue. This release approach 
led to a significant increase in penetration depth of doxorubicin into the tumor tissue 
compared to animals treated with free doxorubicin or Doxil 37. In this case, fast 
releasing liposomes that are stable at body temperatures and rapidly release their content 
at mild temperature, are needed. This treatment schedule also relies on a precise tumor 
heating. Intravascular release approach has the advantage that here the heterogeneity in 
tumor vascular permeability and liposome penetration do not play a role 5, 9, 35. Besides 
all these, chemotherapeutic drugs with high cellular binding capacity are necessary in 
order to prevent drug washout. In this approach, there is a continuous drug supply to 
tumor and endothelial cells as long as heat is applied to the tumor and drug 
encapsulating liposomes pass the heated area. Additionally, the released drug is easily 
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available for both tumor and vascular endothelial cells 37-39. However, the intravascular 
drug release approach suffers from the possible wash out of the released drug which can 
cause side effects. Limmer et al. extended the use of intravascular release approach to 
more hydrophilic drugs, such as gemcitabine 40. 
In the current work, we used interstitial release strategy (Chapter 2,3,4 and 5). In 
this approach, liposomes had to first extravasate through tumor vasculature in order to 
reach tumor cells. Only after they reach tumor cells, HT trigger is applied for drug 
release. In this approach, liposome stability and long half-life is even more important. 
Liposomal size also plays a crucial role for optimal extravasation. Large liposomes have 
limited penetration depth, preventing drug uptake by tumor cells at a large distance from 
the vasculature 41, 42. In order to guarantee a high concentration of delivered drug to the 
tumor, liposomes must be stable at body temperature. Here, fast drug release and precise 
tumor heating is not of importance. In this approach, HT can be applied prior to 
liposome injection in order to increase liposome extravasation and subsequently 
liposomal drug accumulation. HT is known to increase extravasation is several mouse 
tumor models and feline sarcoma patients 35, 41, 43, 44. Since HT can also increase 
extravasation, the combination between the two approaches might result in even higher 
concentrations of bioavailable drug. In this case, HT can be used to both trigger drug 
release intravascularly and increase extravasation, after which the injected liposomes 
can extravasate through the leaky tumor vasculature. When reaching the tumor cells, 
second heat treatment can be applied to trigger drug release. 
All these treatment schedules seem promising, however, in order to understand 
which treatment provides best results more studies are needed concerning the possibility 
of precise heating, the types of used drug and tumor. 
 
 
 
Fig 2. Heating approaches for drug delivery using TSL. A. Interstitial release approach, 
B. Intravascular release approach. Figures are adapted from Koning et al. 45 
 
Image-guided drug delivery. Image-guided drug delivery is used in liposomal 
chemotherapy for monitoring of liposome localization, drug release and/or efficacy of 
the drug. Therefore, the development of non-invasive imaging techniques monitoring 
TSL and the release of encapsulated drugs, play a potentially important role in cancer 
treatment. Nuclear imaging of radiolabelled drugs is one of the most commonly used 
 
 
155 
 
ways to image the localization of the drug-encapsulating carrier in tumors 5, 46. 
However, this imaging approach cannot be used to image drug release, because the 
contrast enhancing characteristics of the radioactive agents are the same for the released 
and the encapsulated drug. Therefore, for this purpose MRI is best used to image both 
the liposome carrier and the released drug when MRI contrast agent is co-encapsulated 
with the drug 47-49. More recently, de Smet et al. have used in their studies the MRI 
contrast agent Prohance co-encapsulated with doxorubicin in traditional thermosensitive 
liposomes 50, 51. They used this approach in HIFU-mediated mild hyperthermia in a 
HIFU-MRI mediated system. In several studies in a rat, murine and a rabbit tumor 
models, the combination of TSL with MRI-guided HIFU mediated mild hyperthermia 
led to increase of doxorubicin concentrations in the tumor when compared to TSL alone 
and free doxorubicin 50, 52-54. As the chemotherapeutic efficacy depends on the tumor 
type and its morphological characteristics, such as vascular permeability and necrosis, 
image-guided drug delivery might be a powerful tool for personalization of 
hyperthermia-mediated drug delivery from TSL. 
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Summary 
 
In this thesis, temperature-sensitive liposomes and hyperthermia (HT) were used as a 
tool to increase the efficacy in cancer chemotherapy. Additionally, TSL were targeted 
for increased specificity to tumors. 
 
Chapter 1 provides a feedback on the study by introducing several topics involved in 
the thesis. Chapter 2 is dedicated on the production of novel cationic thermosensitive 
liposomes (CTSL) encapsulating carboxyfluorescein (CF) as a drug marker. These 
liposomes proved to be stable at physiological conditions (37 °C) and rapidly released 
their content when mild HT of 42 °C was applied. They showed higher binding to- and 
internalization by tumor and endothelial cells than TSL. HT used in vitro was able to 
cause both extra- and intracellular CF release. In vivo, CTSL bound to tumor and 
endothelial cells and the applied HT at 43 °C caused a massive CF release. 
Chapter 3 focuses on optimization of CTSL containing Dox with regards to drug 
encapsulation, stability and targeting functions. A CTSL formulation containing 7.5 mol 
% of the cationic lipid DPTAP proved to be the best for in vitro and in vivo 
applications. The optimized CTSL showed both targeted and triggered functions. They 
were able to target both in vitro and in vivo endothelial and tumor cells. In vitro, using 
confocal microscopy we demonstrated that CTSL are internalized in lysosomes. The 
performed cytotoxicity assays showed that Dox-CTSL were more toxic to all the tested 
tumor and endothelial cells than TSL. Additionally, CTSL showed temperature-
triggered drug release in vitro and in vivo. In vivo, they were stable at body temperature 
and abundantly released their drug payload upon heat. Moreover, Dox-CTSL caused 
massive vessel destruction 24h after injection. 
Chapter 4 investigates the development of a novel cRGD-anchoring TSL entrapping 
Dox. In vitro, these liposomes specifically bound to melanoma and endothelial cells due 
to their overexpression of αvβ3 integrins. Moreover, the delivered Dox to tumor and 
endothelial cells was higher for RGD-TSL than TSL. RGD-TSL were internalized into 
lysosomes. When tumor and endothelial cells were subjected to HT, there was an 
intracellular burst of the internalized liposomes resulting in drug release into acidic 
cellular organelles. Some of the released drug could translocate to cellular nuclei. In 
vivo, RGD-TSL bound to tumor vasculature and the applied HT triggered drug release 
resulting in drug uptake by tumor and endothelial cells. 
Chapter 5 studies the pharmacokinetics, biodistribution and efficacy of Dox-CTSL. 
The pharmacokinetics shows that targeting of liposomes does not decrease their blood 
circulation. Dox-CTSL delivered more Dox to the tumor than TSL. Efficacy in B16BL6 
murine melanoma shows that HT had a significant effect on CTSL in tumor suppression 
and prolonged survival. Efficacy in LLC Lewis lung carcinoma tumor model 
demonstrates that two HT treatments hold promises for a successful treatment option. 
Chapter 6 reviews the literature on thermosensitive and targeted liposomes and 
proposes the recently developed combination of both in one carrier as a promising way 
of treating cancer. 
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Chapter 7 discusses the results presented in this thesis in relation to the currently 
available liposome formulations and treatment options and proposes possible 
improvements in these targeted and triggered drug delivery nanocarriers. 
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Samenvatting 
 
In deze thesis werden zogenaamde temperatuur-gevoelige liposomen gebruikt in 
combinatie met milde hyperthermie voor de behandeling van solide tumoren. Door 
gebruik te maken van deze liposomen wordt getracht meer van de actieve stof, een 
chemotherapeuticum, in de tumor te krijgen.  Daarnaast werd getracht deze liposomen 
specifiek naar de tumor te richten. 
 
Hoofdstuk 1 beschrijft de achtergrond van het onderzoek en geeft een inleiding. 
Hoofdstuk 2 is toegewijd aan de productie van een nieuw kationisch thermosensitieve 
liposoom (KTSL). Als model chemotherapeuticum werd carboxyfluorescein (CF) 
gebruikt. KTSL bleken stabiel onder fysiologische omstandigheden (37°C), terwijl CF 
zeer snel werd afgegeven indien de liposomen werden blootgesteld aan milde 
hyperthermie (HT) van 42°C. Deze liposomen bleken tevens beter te binden aan en 
sneller opgenomen door tumor- en endotheelcellen dan normale TSL. Indien HT werd 
toegepast gaven de liposomen intra en extracellulair de inhoud af. Ook in vivo werd een 
verhoogde binding van KTSL aan tumor- en endotheelcellen gezien en veroorzaakte HT 
een sterke afgifte van CF.  
Hoofdstuk 3 beschrijft de optimalisatie van doxorubicine bevattende KTSL met 
betrekking tot inkapseling, stabiliteit en binding aan de target. Een KTSL formulering 
waarin 7.5 mol % van het kationische lipid DPTAP bleek het best voor in vitro en in 
vivo toepassing. Deze liposomen binden in vitro en in vivo gericht aan tumor- en 
endotheelcellen. We toonde aan met confocale microscopie dat deze liposomen effectief 
worden opgenomen en belanden in lysosomen. In vitro bleken KTSL met doxorubicine 
meer actief en beter in staat tumor- en endotheelcellen te doden dan normale TSL. 
Tijdens bloostelling aan HT geven de liposomen zowel in vitro als in vivo goed 
doxorubicine af. Tevens bleken deze liposomen in vivo stabiel bij 37°C. Behandeling 
met KTSL en HT resulteerde een ernstige vaatschade 24 uur na injectie. 
Hoofdstuk 4 beschrijft de ontwikkeling van een ander gericht liposoom. Hier wordt 
circulair RGD (cRGD) gebruikt om TSL met doxorubicine te richten. Deze liposomen 
binden specifiek aan endotheelcellen maar ook de onderzochte melanoomcellen, 
aangezien deze cellen αvβ3 integrine tot expressie brengen. Door de aanwezigheid van 
cRGD op de liposomen konden we meer doxorubicine afleveren in de cellen, 
waarschijnlijk in de lysosomen. We zagen dat HT resulteerde in snelle afgifte van  
doxorubicine in organellen in de cel met een relatief lage pH. Van daar uit kon een 
gedeelte de celkern bereiken. In het proefdier zagen we RGD-TSL gebonden aan de 
tumorvaatwand en na toepassing van HT een snelle afgifte van doxorubicine wat 
resulteerde in opname hiervan door zowel tumor- als endotheelcellen. 
Hoofdstuk 5 beschrijft de pharmacokinetiek, biodistributie en effectiviteit van KTSL 
met doxorubicine (DOX-KTSL). Doelgericht maken van het liposoom had geen effect 
op de circulatietijd, terwijl injectie van DOX-TSL resulteerde in een hoger DOX niveau  
in de tumor in vergelijking met normale TSL. Studies in muizen met een B16BL6 
 
 
164 
 
muizen melanoom laten zien dat HT in combinatie met DOX-KTSL een significant 
effect heeft op de tumor wat resulteerde in een verlengde overleving. De verkregen 
resultaten in een LLC Lewis lung carcinoma tumor model laten zien dat vooral het 
geven van twee HT behandelingen een succesvolle toepassing zou kunnen zijn.  
Hoofdstuk 6 geeft een overzicht van de literatuur op het gebied van thermosensitieve 
en gerichte  liposomen. Tevens wordt de recent ontwikkelde combinatie van beide in 
één liposoom geïntroduceerd als een veelbelovende mogelijkheid voor de behandeling 
van tumoren. 
In Hoofdstuk 7 worden de resultaten gepresenteerd in deze thesis bediscussieerd in 
relatie tot de liposomale formulering die momenteel beschikbaar zijn en de toepassingen 
waarvoor ze gebruikt worden. Tevens worden voorstellen gedaan op welke wijze 
mogelijk verbeteringen kunnen worden aangebracht bij deze gerichte en manipuleerbare 
nanodeeltjes voor chemotherapie. 
 
by T.L.M. ten Hagen 
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drug delivery to endothelial and tumor 
cells 
 
Imagination 2009, Nijmegen, NL. Oral 
presentation: Thermosensitive cationic 
liposomes and hyperthermia for drug 
delivery to endothelial and tumor cells 
 
Liposome Advances: Progress in Drug and 
Vaccine Delivery, London, UK. Poster 
presentation: Cationic thermosensitive 
liposomes for drug delivery to 
endothelial and tumor cells 
 
Surgery Staffdag, Rotterdam, NL. Oral 
presentation: Cationic thermosensitive 
liposomes as a candidate to improve drug 
delivery to solid tumors. 
 
26th Annual Meeting of the European 
Society of Hyperthermic Oncology, 
Rotterdam, NL. Oral presentation: 
Cationic thermosensitive liposomes in 
combination with hyperthermia for 
improved drug delivery to endothelial 
and tumor cells 
 
2011 Annual Meeting of the Society of 
Thermal Medicine, New Orleans, 
Louisiana. Oral presentation: Cationic 
thermosensitive liposomes - a novel 
heat-triggered drug delivery approach 
for endothelial and tumor cells 
 
The 27th Annual Meeting of the Society 
for Hyperthermic Oncology and the 7th 
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09.11.2011 
 
 
 
 
15.11-16.11.2011 
 
 
 
 
09.12.2011 
 
 
 
28.08-31.08.2012 
 
 
 
 
 
 
 
17-21.04.2013 
 
 
 
 
26-28.05.2013 
 
 
 
 
 
 
 
19-22.06.2013 
ESHO Educational Day, Aarhus, Denmark. 
Poster presentation: Cationic 
thermosensitive liposomes - a novel 
heat-triggered drug delivery approach 
for endothelial and tumor cells 
 
Spinoza conference, Amsterdam, NL. Oral 
presentation: Cationic thermosensitive 
liposomes for improved drug delivery to 
tumors. 
 
Micronano conference, Ede, NL. Oral 
presentation: Cationic thermosensitive 
liposomes for improved drug delivery to 
tumors. 
 
Surgery Staffdag, Rotterdam, NL. 
Improving drug delivery to tumors by 
using cationic thermosensitive liposomes 
 
11th International Congress of 
Hyperthermic Oncology (ICHO) & 29th 
Japanese Congress of Thermal Medicine 
(JCTM).Poster with short oral 
presentation: Novel cationic 
thermosensitive liposomes for 
doxorubicin delivery to solid tumors.  
 
30th Annual STM meeting 2013, Aruba. 
Oral presentation: Improved doxorubicin 
delivery to tumors by cationic 
thermosensitive liposomes. 
 
COST and EMIM meeting 2013, Torino, 
Italy. Oral presentation: Dual targeted 
cationic thermosensitive liposomes for 
improved drug delivery to tumors. Poster 
presentation: Cationic thermosensitive 
liposomes to increase doxorubicin 
delivery to tumors. 
 
ESHO, Munich, Germany. Oral 
presentation: Cationic thermosensitive 
liposomes improve drug uptake in solid 
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tumors. 
 
Laboratory 
skills: 
cell culture, TLC, western blotting, gel 
electrophoresis, PCR, biofermentation 
and work with bioreactors, basic 
microbiology procedures, ELISA, confocal 
and fluorescent microscopy, FACS, animal 
experiments, immunohistochemistry, 
liposomes, nanotechnology procedures       
Courses: 
 
27-32.10.2008 
 
14.09-02.10.2009 
03.02-05-02.2010 
11.10-15.10.2010 
01.11-05.11.2010 
01.02-02.02.2011 
10.2010-01.2011 
12.09-14.09.2011 
22.09/06.10.2011 
16.11.2011 
 
21.11-25.11.2011 
12.12-16.12.2011 
 
08.03-16.03.2012 
31.01.2012 
10.12 
06-12.11.12 
 
 
In vivo imaging ”From Molecule to 
Organism” 
Laboratory Animal Science 
The 4th Animal Imaging Workshop by AMIE 
Biomedical Research Techniques   
Basic and Translational Oncology 
Molecular Medicine 
Scientific Writing in English for 
Publication 
SPSS 
Research management for phd students 
Microscopic image analysis: From Theory 
to Practice 
Advanced drug delivery and Drug 
targeting 
Introduction into clinical and 
fundamental oncology  
Advanced course “ Molecular immunology’’  
Photoshop & Illustrator CS5 Workshop 
Imaging data analysis 
Advanced course on Radiation safety, 
level 5B 
03.2013 
 
Additional 
Skills:  
 
InDesign CS5 Workshop 
Foreign 
languages: 
English  
Italian 
Basic Portuguese 
Basic Dutch 
Computer Windows, Microsoft Office, Photoshop, 
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literacy: 
 
Awards: 
 
Illustrator, InDesign, Prism, Internet 
  
1. ESHO-Magforce student award for 
biology, Rotterdam, NL, 2010. 
2. Young Investigator Award at the 11th 
International Congress of Hyperthermic 
Oncology & the 29th Japanese Congress of 
Thermal Medicine, Kyoto, Japan, 2012. 
3. ESHO-Rosner Award Winner for biology, 
2012.  
4. New Investigator Travel Award at STM 
(Society for Thermal Medicine)in Aruba, 
2013. 
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